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ABSTRACT 
Coronary artery disease is highly prevalent in the end stage renal disease population. For the 
general population, there are guidelines for managing coronary artery disease, however there are 
no clear consensus guidelines for patients with end stage renal disease.  Renal transplantation is 
superior to dialysis in terms of both patient survival and quality of life.  A significant proportion 
of potential renal transplant candidates are at high risk of coronary artery disease; they need to be 
scrutinized and aggressively treated for risk factors in order to maintain the graft and survival 
benefit that has been created by organ donation.   In addition, clinicians also need to consider the 
risk of cardiovascular disease for dialysis patients not undergoing transplantation. 
In terms of pathophysiological processes, there is growing evidence of a varied and significant 
effect of chemokines on cardiovascular disease; of particular interest are MCP-1, CCL15 and 
CCL18. There also exists established data demonstrating that the non-invasive investigation of 
measuring carotid intimal media thickness appears to be predictive of cardiovascular mortality in 
patients with end stage renal disease.  Whilst coronary angiography is considered the gold 
standard investigation for diagnosing and treating coronary artery disease, it is an invasive 
procedure and therefore not without complication and is an expensive resource. 
This work examines the effect of elective coronary angiography on glomerular filtration rate in 
patients with advanced chronic kidney disease and has demonstrated that coronary angiography 
performed in a timely fashion did not accelerate the decline in renal function. In addition this 
work examines the cardiac survival of potential transplant patients undergoing coronary 
angiography and intervention and has demonstrated that a thorough approach to diagnosing and 
intervening on angiographically significant coronary artery disease was associated with a low 
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incidence of cardiac mortality and morbidity. Finally, this work has demonstrated higher 
chemokine levels in patients with progressive coronary artery disease compared to patients 
without progressive coronary artery disease, and shows that a significant proportion of patients 
with normal coronary angiograms at initial screening have no evidence of angiographically 
progressive disease over a 3 year period. 
These results can be applied when performing cardiac risk stratification in an end stage renal 
failure population. In addition this work provides some evidence to support chemokines as 
appealing targets for novel therapies in the future. 
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1 INTRODUCTION 
It is well established that cardiovascular disease is the major cause of mortality and morbidity in 
patients with end stage renal disease [ESRD], and that the disease process differs from that seen 
in patients with normal renal function (Sarnak, 1999). For the general population there are 
guidelines for managing coronary artery disease [CAD] (Hamm, 2011); unfortunately there are 
no clear consensus guidelines for the ESRD population. Hence there is continuing need for 
therapeutic strategies or interventions that reduce cardiovascular events for patients with renal 
disease. 
Cardiovascular events occur significantly more often in patients with all degree of renal 
impairment compared to the general population (Jardine, 2001).  Those at greatest risk are 
patients with ESRD on dialysis; their risk of dying from a cardiovascular cause is up to 20 times 
higher compared with an age-matched patient with normal renal function (Jardine, 2001).  
Furthermore, the burden of cardiac disease in the ESRD population is set to increase; national 
data has shown that our greatest uptake of patients being treated with ESRD has occurred in a 
group with the highest risk for cardiovascular disease, namely older patients and patients with 
diabetic nephropathy.   
Despite the protective benefits of renal transplantation, cardiovascular disease remains the 
principal cause of death in patients with a functioning graft (Lindholm, 1995). Following 
transplantation, cardiac event rates have been shown to peak during the first 3 months and 
decrease subsequently by transplant vintage, with a late peak as graft dysfunction occurs when 
patients behave in a similar way to any other patient with chronic kidney disease
 
(Meier-
Kriesche, 2004; Baigent, 2000).   
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It is clear that most immunosuppressive drugs affect cardiovascular risk factors (Kasiske, 2003, 
Midvedt, 2000, Fellström, 2000 and Jindal, 2000). However, the pathogenesis of cardiovascular 
disease in transplant patients is not just related to immunosuppressive drugs; cardiovascular 
disease present prior to transplantation as well as traditional and non-traditional risk factors in 
transplant recipients are likely to be contributory. 
There are a number of features of cardiovascular disease that are unique to patients with chronic 
kidney disease [CKD]. The conventional cardiovascular risk factors that are highly prevalent in 
the CKD population include hypertension, diabetes and dyslipidaemia (O’Donnell, 2008).  There 
also exist some risk factors that are associated exclusively with renal disease and include 
hyperparathyroidism, hyperphosphataemia and left ventricular hypertrophy [LVH] as a 
consequence of anaemia (Wang, 2003; Cannella, 1991).   Other novel risk factors include 
enhanced platelet activity, oxidative stress, chronic inflammation, hypercoagulability and 
endothelial dysfunction, which are considered responsible for accelerated atherosclerosis 
(Prichard, 2003).   
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1.1 Coronary Artery Anatomy and Physiology 
The coronary arteries are responsible for ensuring sufficient oxygenation of the myocardium is 
sustained at all levels of cardiac activity. There are two main vessels the right coronary artery 
[RCA] and left coronary artery [LCA]. Figure 1 illustrates the anatomy of the coronary 
circulation.  The left main coronary artery [LMCA], divides into the left anterior descending 
[LAD] and left circumflex [LCx] branches.  The LCA and the RCA arise from the respective 
coronary sinuses, which are situated behind the aortic valve leaflets at the base of the aorta.  The 
distal and smaller coronary branches make up the microvascular network.  
 
Figure 1: Frontal view of the relevant cardiac vessels  
Reproduced with permission from Boston Scientific Corporation ©2012 
Each coronary artery supplies a different anatomical cardiac region. The American Heart 
Association [AHA] recommends division of the left ventricle into a number of segments, 
referred to as the 17 segment model (Cerqueira, 2002). The left ventricle is divided into basal, 
mid-cavity and apical slices. The basal and mid cavity sections are then divided into 6 segments 
each, and the apical section has four segments and an apical cap. 
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The arterial supply to the segments is illustrated in Figure 2, for example when dominant the 
RCA supplies the inferior and posterior regions, the LAD vessel supplies the antero-septal and 
antero-apical regions, and the Cx supplies the antero-lateral region.  
 
Figure 2: 17 Segments of the heart. Adapted from the American Society of Nuclear Cardiology. J Nucl 
Cardiol.1999; 6:G47-G84 and reproduced with permission from ©2010 Astellas Pharma US, Inc. 
The 12-lead ECG can often identify a specific region of ischaemia or infarction that can then be 
linked to a diseased coronary artery. However the 12 lead ECG is a blunt diagnostic tool.  
Considerable individual variability occurs in coronary artery anatomy, which means the 17 
segmental model is not a one size fits all concept (Pereztol-Valdes, 2005; Ortiz Perez, 2008).  In 
order to establish the vessel involvement, and attempt revascularization, a coronary angiogram is 
required. 
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1.1.1 Vascular Endothelium 
Endothelium is a single-cell lining covering the internal surface of blood vessels, cardiac valves, 
and numerous body cavities (Verma, 2002). The role of the vascular endothelium in regulation 
of smooth muscle function was first reported in the 1970s (Gimbrone, 1974).  Over the last 
decade, the role of endothelium in regulating vascular homeostasis and its other mechanisms of 
action, including inhibition and stimulation of smooth muscle cell proliferation and migration, 
thrombogenesis and fibrinolysis (Lüscher, 1997; Kinlay, 2001) have all become apparent.   
Various dilator and constrictor substances are involved in maintaining vascular tone in healthy 
endothelium.  Initially, the vasodilatory substance that was found to be released by endothelium 
was named the Endothelium-Derived Relaxing Factor [EDRF]; it is now known that this is nitric 
oxide [NO] (Ignarro, 1987).  However this is not the only endothelial derived vasodilatory 
substance; bradykinin and prostacyclin both play key roles in promoting vasodilatation (Drexler, 
1998). Nitric oxide and prostacyclin have a synergistic effect on inhibition of platelet 
aggregation (Lüscher, 1997).  Bradykinin not only stimulates the release of NO, but also 
prostacyclin and stimulates the production of tissue plasminogen activator [t-PA], an essential 
component of fibrinolysis.  Mediators of vasoconstriction include endothelin and angiotensin II.  
Endothelin is the most potent endogenous vasoconstrictor identified (Davignon, 2004) and 
angiotensin II is a pro-oxidant that stimulates the production of endothelin and has a direct 
vasoconstrictor action (Sowers, 2002).   
When the endothelial surface is disturbed, the resultant imbalance of vasoconstriction and 
vasodilatation causes a cascade of events that promote or exacerbate atherosclerosis including 
increased endothelial permeability, platelet aggregation, leukocyte adhesion, and generation of 
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cytokines (Ross, 1999).  It has been shown that a single dialysis session can adversely affect 
endothelial function (Errakonda, 2011).  Research has confirmed that endothelial dysfunction is 
present in the early stages of atherosclerosis (Ludmer, 1986), and endothelial dysfunction of the 
microvasculature is associated with exercise induced myocardial ischaemia in the absence of 
significant stenotic major epicardial lesions (Zeiher, 1995).   
 
1.1.2 Coronary Blood flow 
The human heart has two main chambers, the atrium and the ventricle, separated by the atrio-
ventricular valve to prevent regurgitation of blood between the chambers. The right side of the 
heart receives blood from the systemic circulation via the inferior and superior vena cava and 
pumps blood into the pulmonary circulation.  Oxygenated blood is then returned to the left side 
of the heart via the pulmonary veins and is subsequently pumped via the aorta into the systemic 
circulation. The ventricle wall contracts during systole and relaxes during diastole, when the 
ventricle fills with blood from the atria.   There are a variety of cardiac conditions that influence 
cardiac function, but in this research the main focus is on myocardial perfusion problems in the 
setting of compromised coronary blood flow due to CAD. 
The heart has a high demand for oxygen and therefore high oxygen consumption; it needs 
oxygen in order to regenerate ATP that is used by membrane transport mechanisms.  Oxygen is 
also necessary to maintain myocyte contraction and relaxation.  MVO2 is a measure of 
myocardial oxygen consumption.  Compared to the resting state, strenuous exertion causes a 
significant increase in the MVO2. 
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Organ 
 
MVO2 (ml O2/min/100g) 
Heart – Resting 8 
Heart - Strenuous exercise 70 
Kidney 5 
Muscle – Resting 1 
Muscle - Strenuous exercise 50 
Table 1: MVO2 (ml O2/min/100g) values for various organs 
Skeletal muscle also has a range of values for MVO2 depending the level of activity.  However, 
compared to all other organs, the MVO2 for the heart is the highest (Table 1).  In the arrested 
heart there is still a measurable MVO2 (2ml 02/min/100g) due to basal ATP utilization (Klabunde 
RE, 2011).  The heart must obtain oxygen from arterial blood to supply the myocardium.  There 
is an established relationship between coronary blood flow [CBF], the extraction of oxygen from 
the blood (which is the difference between arterial and venous oxygen, or CaO2-CvO2), and 
MVO2: 
MVO2 = CBF × (CaO2 − CvO2) 
 
At rest, blood flow is controlled by the process of autoregulation.  The system of autoregulation 
occurs in the resistance vessels of the myocardium and maintains constant blood flow over a 
range of aortic pressures (Bourdarias 1995; Hoffman 1984; Klocke, 1987).  At rest, the total 
coronary blood flow is about 200 ml/min (Guyton, 1996), and in the main epicardial arteries it 
can vary between 20 and 80 ml/min (Dorsaz, 1997). 
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1.1.3 Cardiac Innervation 
 
Figure 3: Cardiac Innervation.  
Reproduced with permission from Klabunde, R on behalf of Lippincott Williams & Wilkins (2011) 
 
Coronary blood flow is regulated to a large extent through the direct activation of adrenergic 
receptors and indirectly by changes in metabolic autoregulation and endothelial function (Di 
Carli, 1997).  In the hypothalamus a complex neural system receives afferent inputs from 
different areas of the brain and modulates the cardiovascular response to different stimuli 
(Figure 3).  Sympathetic activation allows increased coronary flow due to increased contractility 
and heart rate.  Parasympathetic activation via the vagus nerve causes acetylcholine release that 
has a direct action on the coronary vessels and causes coronary vasodilatation. When the heart 
rate drops, parasympathetic activation results in decreased myocardial oxygen demand, which 
triggers intrinsic metabolic mechanisms to increase coronary vascular resistance.   
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1.2 Inflammation & Atherosclerosis 
The essential role of inflammation in the pathophysiological process of atherosclerosis has been 
extensively investigated. Immune cells dominate early atherosclerotic lesions and their effector 
molecules accelerate the progression of the lesions (Hansson, 2005). The subsequent production 
of pro-coagulant and pro-thrombotic factors results in thrombus formation that presents clinically 
with acute coronary syndromes (Hansson, 2005).  Clinical studies have demonstrated the 
association of circulatory markers of inflammation and acute coronary syndrome (Berk, 1990; 
Liuzzo, 1994; Toss, 1997; Morrow, 2000; Ridker, 2000).  It seems that circulating acute phase 
reactants are not only markers of risk for cardiovascular events, but in many cases they 
contribute to their pathogenesis (Libby, 2002). 
This new insight provided important information on the link between risk factors and the 
mechanisms of atherogenesis, as well as prognostic information of considerable clinical 
relevance (Libby, 2002).  At present inflammation and markers of the process, are not yet used in 
the clinical setting for risk stratification. It is hoped that future novel anti-inflammatory 
therapeutics will become available.  In Sections 1.2.1 to 1.2.5 I describe the pathophysiological 
stages of atherosclerosis from fatty streak to ruptured plaque, how this impacts in the clinical 
setting and the role of cytokines in atherosclerosis. 
 
1.2.1 Pathophysiology of atherosclerosis 
The innermost layer a normal blood vessel is the intima (Figure 4).  In the earliest stages of 
atherosclerotic lesions, a fatty streak packed with macrophages and T cells, becomes evident in 
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the intimal layer.  These lesions can occur in young people, often without any pathological 
significance (Libby, 2002). It is only when the deposition of cells, connective-tissue elements, 
lipids and debris occurs at the site of the fatty streak that the atheromatous lesion becomes 
established (Stary, 1995).  
 
Figure 4: Life history of an atheromatous lesion 
Reproduced with permission from Libby, P on behalf of ©2012 Nature Publishing Group. 
On analysis of diseased coronary arteries, foam cells and extracellular lipid droplets have been 
found in the centre of the atheromata (Jonasson, 1986). This accumulation of cells becomes 
surrounded by a cap of smooth muscle cells and collagen rich matrix (Hansson, 2005). The 
atheroma is not only infiltrated by T-cells and macrophages but also mast cells and many of 
these immune cells are responsible for producing inflammatory cytokines (Frostegard, 1999). A 
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stable plaque can transform into a vulnerable lesion and rupture as a result of inflammatory 
molecules and proteolytic enzymes that weaken the cap and activate cells in the atheromata core 
(Hansson, 2005).  An acute coronary syndrome will occur as a result of the thrombus that forms 
from the ruptured plaque (Libby, 2002).   
 
1.2.2 Atherosclerotic plaque rupture  
It was previously thought that myocardial infarction occurred as a consequence of the lumen of 
the coronary artery progressively narrowing due to atherosclerosis, with resultant reduced blood 
flow to the myocardium and infarction of the segment of the heart supplied by the culprit vessel.  
However, angiographic studies have identified culprit lesions that have not been caused by a 
marked stenosis (Hackett, 1988), and it is now evident that plaque activation followed by rupture 
or endothelial erosion and subsequent thrombus formation on the surface of the plaque (Davies, 
1996), can precipitate ischaemia or infarction.  Coronary vasospasm may also account for some 
myocardial ischaemia or infarction in the absence of a significant coronary vessel stenosis 
(Hansson, 2005). 
Coronary thrombosis can result from plaque rupture or endothelial erosion and in 60-70% of 
cases of coronary thrombosis plaque rupture is identified (Falk, 1995).  Ruptures occur most 
frequently at the site where the fibrous cap is thin and partly destroyed (der Wal, 1994).  
Activated immune cells accumulate at the site of the damaged fibrous cap and release proteolytic 
enzymes (metalloproteinases and cysteine proteases) that directly attack collagen and other 
components of the tissue matrix (Hansson, 2005). As the plaque ruptures circulating blood is 
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exposed to pro-thrombotic material from the centre of the plaque including phospholipids, 
platelet-adhesive matrix molecules and tissue factors (der Wal, 1994).  
In a mouse model, targeted deletion of the gene for apolipoprotein E [Apo-E] causes severe 
hypercholesterolaemia and spontaneous atherosclerosis (Hansson, 2005). In addition, mice 
lacking low-density lipoprotein [LDL] receptors also develop atherosclerosis, especially if fed a 
fatty diet (Hansson, 2005). These two mice models have been used to examine the relationship 
between atherosclerosis and hypercholesterolaemia, and to assess the effects of genes and gene 
products on these conditions. Furthermore, by mating these mice with mice lacking immuno-
regulatory genes, the role of immunological mechanism in atherosclerosis has been studied. 
 
1.2.3 Coronary Artery Disease 
The process of atherosclerosis has already been outlined.  When the vessel wall becomes 
narrowed as a result of atherosclerosis, the structure and function of the vessel is altered and 
CAD is said to exist, causing blood flow to the heart to be compromised.  Not only does this 
cause angina (due to tissue hypoxia), and infarction (due to tissue anoxia), but it also can result 
in cardiac conduction abnormality and impairment of mechanical activity of the heart, causing 
heart failure and arrhythmias (Felker, 2002; Ghuran, 2001).  In situations such as these, stenting 
of the vessel can be performed angiographically to ensure the vessel remains open, and coronary 
artery bypass surgery can be used to circumvent the diseased vessel with a graft.  Other 
therapeutic strategies include the administration of thrombolytic agents, if thrombosis is 
contributing to the near vessel occlusion, while anti-platelet treatments may be used to prevent 
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recurrence of the thrombosis.  Coronary vasodilators can be used if the reduced flow is due to 
vasospasm. 
Above is a basic description of CAD; in reality CAD is far more complex and challenging to 
treat, particularly in the ESRD population. Disorders of perfusion can occur in the setting of non-
atherosclerotic small vessel disease, or as a result of an underlying cardiomyopathy, neither of 
which is amenable to revascularization procedures.  The first demonstration of myocardial 
ischaemia during dialysis was in the late 1980s (Zuber, 1989) and subsequently a dozen or more 
studies have demonstrated silent ST segment depression during dialysis with 15-40% of the 
dialysis population affected (Abe, 1996; Cice 2008; Mohi-ud-din, 2005). Following on from 
electrocardiographic evidence of ischemia were perfusion studies.  One study demonstrated up to 
70% of patients had evidence of perfusion defects during dialysis sessions (Singh, 1994). 
 
1.2.4 Inflammatory biomarkers 
The most convincing data linking inflammation to the development of vascular events are from 
large population based studies.  It has been demonstrated in normal healthy humans undergoing 
population screening that elevated inflammatory mediators have been predictive of future 
vascular events (Koenig, 1999). ESRD is a pro-inflammatory state and patients on dialysis show 
serological markers of an activated inflammatory response (Stenvinkel, 2005). 
There is compelling outcome data that IL-6 (Bologa, 1998; Rao, 2005), IL-18 (Chiang, 2006), 
cell adhesion molecules such as soluble ICAM-1 (Suliman, 2006), and acute phase reactants 
including CRP (Zimmermann, 1999), fibrinogen (Zoccali, 2003) and serum amyloid A (Ridker, 
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2000) all have prognostic implications in terms of cardiovascular morbidity and mortality in the 
ESRD population.  Although research has suggested that IL-6 has a greater predictive value, in 
terms of morbidity for patients with CKD compared to CRP (Panichi, 2004), it is not a biomarker 
that is readily available in day-to-day practice. CRP in the setting of CKD is said to provide 
additional prognostic information beyond the traditional Framingham risk factors (Albert, 2003).   
Therapeutic options aimed at reducing inflammation are limited, with statin therapy being seen 
as the first line of attack (Nissen, 2005; Ridker, 2005).   Although a reduction in CRP with 
statins may be associated with improved cardiovascular outcomes, in vitro studies have 
implicated other biomarkers as mediators of inflammation, and suggest CRP has indirect 
involvement (Menon, 2005). Aside from statins, in the dialysis population various manipulations 
of dialysis treatment have been shown to reduce inflammatory burden, for example short daily 
dialysis versus 3x/wk dialysis (Ayus, 2005). 
Finally, of note is the well-established relationship between raised troponin and patients on 
dialysis, which is predictive of mortality (Ooi, 1998; Dierkes, 2000; Deegan, 2001). A well-
designed study by Apple et al looked at 733 ESRD patients without cardiac symptoms and 
measured cardiac Troponin T [cTnT] and cardiac Troponin I [cTnI] and then followed patients 
for two years.  The authors demonstrated a two- to five-fold increase in mortality in patients with 
raised baseline troponin levels, with two year mortality figures of 30% for a cTnI <0.1mcg/L and 
52% for patients with a cTnI of >0.1mcg/L (Apple, 2002).  
A generalised overview of the role of cytokines in atherosclerosis is described in the following 
section. The chemokines MCP-1, CCL15 and CCL18 that are examined in this study are 
described in greater detail in Sections 1.3.1, 1.3.2 and 1.3.3. 
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1.2.5 Cytokines in atherosclerosis 
Cytokines have been grouped into several classes including interleukins, tumor necrosis factors, 
interferons, colony stimulating factors, transforming growth factors, and chemokines (Tedgui, 
2006). Cytokines are produced by cells of the innate immune system (monocytes, neutrophils, 
and natural killer T cells) in response to microbial infection, toxic reagents, trauma, antibodies, 
or immune complexes (Nathan, 2002).  Cytokines have an important role in regulating 
inflammatory and immune responses and in controlling both innate and adaptive immunity 
(Tedgui, 2006).  
Cytokines are seen as secondary mediators of inflammation and not the primary triggers (Tedgui, 
2006). The association with the chlamydia TWAR strain with acute myocardial infarction and 
chronic coronary disease was reported in 1988 (Saikku, 1988). Since then an infectious 
aetiological role in atherosclerosis has been extensively reviewed (Libby, 1997). However, a 
number of clinical trials including, Azithromycin in Acute Coronary Syndrome (AZACS) and 
Azithromycin and Coronary Events Study (ACES) that assessed the potential benefits of 
antibiotic therapy targeted at Chlamydia pneumoniae, showed no effect of treatment in patients 
with CAD (Grayston, 2005; Cercek, 2003). 
The process of atherosclerosis from the earliest visible lesion to plaque rupture in association 
with its clinical implications has been described already, and the role of inflammation alluded to. 
In a step-by-step breakdown of the various stages of atherosclerosis, inflammation has been 
implicated in the formation of early fatty streaks when endothelium is activated.  It then 
expresses the chemokines MCP-1and IL-8 as well as the adhesion molecules ICAM-1, VCAM-1, 
E- and P-selectin, that leads to monocyte and lymphocyte recruitment and infiltration into the 
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subendothelium (Hansson, 1991).  Inflammation also has a key role leading up to the time of 
plaque rupture, when activated cells within the plaque secrete matrix proteases that degrade 
extracellular matrix proteins and render the fibrous cap fragile resulting in rupture and thrombus 
formation (Libby, 2005).  Macrophage apoptosis may contribute to enlargement of the lipid core, 
whereas plaque smooth muscle cell apoptosis may induce a thinning in the fibrous cap, favouring 
its rupture (Kockx, 2000). The balance between pro- and anti-inflammatory cytokines has 
emerged as a major determinant of plaque stability (Tedgui, 2006).  
In summary, the biological effects of cytokines are extensive and include activation of adhesion 
molecules and chemokine expression, mobilization of vascular progenitor cells, regulation of 
neovascularization, induction of apoptosis, modulation of pro-coagulant activity and fibrinolysis 
(Tedgui, 2006). 
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1.3 Chemokines  
The chemokines are a group of chemotactic cytokines that are responsible for the up-regulation 
of leucocytes at sites of vascular inflammation (Gerard, 2001). Chemokines are involved in 
various processes including angiogenesis, haematopoiesis, tumour growth and metastasis 
(Schutyser, 2005). 
 There are about 50 human chemokines that have been divided into 4 families according to their 
structure and function.  The largest family is known as the CC chemokine family because the 
first 2 of the 4 conserved cysteine residues are adjacent to each other (Charo, 2004).  The CXC 
family of chemokines attract polymorphonuclear leukocytes and consist of a single amino acid 
residue between the first and the second canonical cysteines (Charo, 2004).  The CX3C family 
only has one identifiable member (Fractalkine) that can exist as a soluble or immobilised protein, 
and can function as either a cell-adhesion receptor or as a chemoattractant (Charo, 2004).  The 
final family is the C Chemokine family, which lack two (the first and third) of the four conserved 
cysteine residues (Charo, 2004). 
As discussed earlier, atherosclerosis is increasingly seen as a dyslipidaemic disorder with a 
strong inflammatory overlay (Hansson, 2005).  The inflammatory processes are to some extent 
orchestrated by chemokines that participate in the process of inflammation by mediating 
monocyte recruitment to the site of injury (Kraaijeveld, 2007).  This promotes the proliferation 
of vascular smooth muscle cells and the process of angiogenesis, and causes platelet activation 
(Charo, 2004; Weber, 2005; Kraaijeveld, 2007).  It has also been reported that ischaemia leads to 
the induced expression of chemokines in the myocardium with recruitment of leukocyte subsets 
and progenitor cells to the injury zone, which then contribute to injury repair (Dewald, 2003).  
 36 
With the growing evidence of a varied and significant effect of chemokines on cardiovascular 
disease, not only might the chemokines serve as biomarkers of atherosclerosis and plaque 
disruption, but they may also represent appealing targets for novel therapies in the future. 
 
1.3.1 MCP-1 
As discussed in Section 1.2.1, the earliest stage in the formation of atheromata, are fatty streaks 
that are composed of lipid-laden macrophages.  Studies in non-human primates and swine have 
indicated that circulating monocytes are the precursors to foam cells (Gerrity, 1980; Faggitto, 
1984), and there is supporting evidence to show that MCP-1 is crucial for recruiting monocytes 
in fatty streaks (Nelken, 1991).  Furthermore, it has emerged that MCP-1 is a possible molecular 
link between oxidized low-density lipoproteins (LDL) and foam cell recruitment to the vessel 
wall (Cushing, 1990). 
MCP-1 is the most characterised of all the CC chemokines, and is also known as CCL2.  CCR2 
is an established functional receptor for MCP-1 on hematopoietic cells (Boring, 1998).  When 
CCR2 is deleted in apoE deficient mice, the mice gain significant protection from both 
macrophage accumulation and atherosclerotic formation (Boring, 1998), further implicating the 
importance of MCP-1 in the process of atheromata formation.  The role of MCP-1 in the 
advanced stages of atherosclerotic lesions, such as plaque rupture, is not fully established. 
However, one mechanism in which MCP-1 may be involved in plaque rupture is via its ability to 
activate tissue factor and contribute to plaque thrombosis (Charo, 2004). 
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The role of MCP-1 in ischaemic heart disease has been studied (de Lemos, 2003).  This study 
examined plasma MCP-1 levels in healthy volunteers and patients with acute coronary 
syndrome.  There was considerable overlap in MCP-1 levels between the two groups, however, 
high levels of MCP-1 did correlate with poorer outcomes in terms of both further myocardial 
infarction and death (de Lemos, 2003). 
Chemokines are important therapeutic targets, and most of the work so far has been in the 
development of chemokine receptor antagonists.  So far the traditional inflammatory disease 
processes such as rheumatoid arthritis have been targeted, and as yet not aimed at 
arteriosclerosis.  A monoclonal antibody that prevents MCP-1 from binding to CCR2 has been 
used in phase II trials for the treatment of rheumatoid arthritis, but not ischaemic heart disease 
(Charo, 2004). 
 
1.3.2 CCL-15 
CC Chemokine Ligand 15 [CCL-15] is also called Leukotactin-1 [Lkn-1], MIP-1δ, MIP-5, HCC-
2 and NCC-3.  Mature CCL-15 is composed of predicted 92 amino acid residues and has long 
amino acid residues preceding the first cysteine at the NH2 terminus (Youn, 1997; Pardigol, 
1998).  Several forms of CCL15 have been studied in order to characterise the biological activity 
of this chemokine (Youn, 1997; Lee, 2002; Zhang, 1999). Both intact CCL15 (1-92) and 
truncated forms of CCL15 (25-92) bind to CCR1 and CCR3 receptors (Youn, 1997).  The major 
role of CCL15 is to induce chemotaxis and calcium flux (Youn, 1997).  In addition to this, 
CCL15 has a role in leukocyte trafficking and activation.  It has also been demonstrated that 
CCL15, along with other members of the CC chemokine family including CCL1, CCL2 [MCP-
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1], CCL11, MIF and CCL16 have a regulatory role in angiogenesis (Bernardini, 2003; Salcedo, 
2000; Strasly, 2004; Hwang, 2004).   
The mechanism of action of CCL15 in regulating angiogenesis has been examined in vitro and in 
vivo (Hwang, 2004).  CCL15 appears to induce endothelial cell migration, with the truncated 
CCL15 (25-92) showing greater effect (Hwang, 2004). Amino-terminal truncation of 
chemokines often results in either enhancement or loss of activity, as well as causing the 
appearance of an antagonist effect, or change in chemokine receptor specificity (Forssmann, 
2001).  The involvement of leukocyte infiltration in both physiologic and pathologic 
angiogenesis has attracted a great deal of attention (Bernardini, 2003).  CCL15 as a novel 
mediator of atherosclerosis and progression of vascular disease is still to be established (Lee, 
2002). 
 
1.3.3 CCL18 
CC Chemokine ligand 18 [CCL18] is produced by monocytes and macrophages and is 
chemotactic for both naive and activated T cells, but not for granulocytes or monocytes (Adema, 
1997).  CCL 18 has been linked to various disease processes.  For example, CCL18 is thought to 
have a potential tumour suppressor role in relation to ovarian and gastric carcinoma (Curiel, 
2004; Leung, 2004).  Also CCL18 has been found in high levels in synovial fluid in patients with 
active arthritis, particularly rheumatoid and septic arthritis rather than osteoarthritis (Schutyser, 
2001).  And finally, CCL18 has been found in consistently high levels within lungs affected by 
hypersensitivity pneumonitis or idiopathic pulmonary fibrosis in comparison with control lung 
tissue (Pardo, 2001).   
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Evidence of the exact role of CCL18 in cardiovascular disease is not entirely conclusive; there is 
a relative paucity of data, with a handful of studies demonstrating CCL18 expression in 
atherosclerotic plaques, particularly at the site of reduced stability (Papaspyridonos, 2006; 
Reape, 1999).  CCL18 has not been studied in patients with both atherosclerosis and CKD.  One 
convincing study examining a panel of chemokines in the setting of unstable angina 
demonstrated elevated plasma levels of CCL18 in patients with unstable angina (Kraaijeveld, 
2007).  Patients with refractory coronary artery disease had the highest levels of CCL18 
(Kraaijeveld, 2007).  Vulnerable plaques releasing CCL18 is a plausible theory for the elevated 
plasma levels detected in the setting of unstable angina (Reape, 1999).  In addition to assessing 
the role of CCL18 in patients with unstable and refractory angina, Kraaijeveld et al also 
examined its diagnostic potential and reported a PPV of 78.5% for the combined analysis of 
CCL5 and CCL18 (Kraaijeveld, 2007).  Of note, the addition of CRP levels to the analysis did 
not yield any further increases in sensitivity, specificity, or predictive value (Kraaijeveld, 2007). 
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1.4 Myocardial dysfunction 
An estimated 25% of patients starting dialysis will have a normal echocardiogram, with 
myocardial dysfunction occurring well before the need for renal replacement therapy [RRT] 
(Parfrey, 1988). CAD and hypertension are important causes of myocardial dysfunction in the 
renal failure population (Foley, 1995).  Once ESRD is reached, it is hypothesized that LV 
overload, which leads to maladaptive myocyte changes and myocyte death, in combination with 
malnutrition, uraemia and hyperparathyroidism will predispose patients to LV dilatation and 
ultimately systolic dysfunction (Lamiere, 2000). In addition myocardial fibrosis occurs, which 
significantly reduces cardiac compliance and intensifies the hypertrophic response to pressure 
overload (Lamiere, 2000). 
Earlier I have described how the restoration of flow in a vessel can be achieved via 
revascularization procedures.  It is important to understand that even after restoration of blood 
flow; recovery of cardiac function will depend on the viability of the myocardial tissue affected 
by the culprit vessel (Kaul, 2000). In patients with CAD transient myocardial ischemia may lead 
to LV dysfunction that can persist after the return of normal perfusion (McIntyre, 2009). This 
prolonged LV dysfunction is known as myocardial stunning, a term first described in humans in 
the 1980s (Braunwald, 1982). Myocardial stunning is well recognized as a cause of heart failure 
in the non-dialysis patient population (Barnes, 2002). Repetitive myocardial ischaemia may lead 
to a spectrum of disease from myocardial stunning through to myocardial hibernation and 
ultimately irreversible loss of contractile function due to myocardial remodeling and scarring 
(McIntyre, 2009).  The “smart heart” hypothesis describes hibernation as a functional adaptation 
to chronic hypoperfusion that can be reversed with the restoration of myocardial blood flow 
(Braunwald, 1986). 
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The mechanisms underlying myocardial stunning and hibernation are not fully understood, but 
the two dominant theories are that it relates to a direct effect of oxygen free radicals, and that the 
disturbance of cellular calcium homeostasis plays a role (Boli, 1999).  
In the next section I describe some of the latest data on myocardial stunning and myocardial 
fibrosis, and focus on data specific to the renal population.  Reperfusion injury, vascular 
remodeling and preconditioning are beyond the remit of this study. 
 
1.4.1 Myocardial Stunning 
In patients with normal GFR who have proven CAD a transient episode of myocardial 
ischaemia, whether solitary or repetitive, can lead to LV dysfunction that remains even after 
reperfusion is achieved (McIntyre, 2009).  This process is referred to as myocardial stunning 
(Braunwald, 1982).  Conventional haemodialysis three times a week is often considered a 
cardiac stress test in itself due to the haemodynamic disturbances that occur during each 
treatment session (Henrich, 1986). 
  It has been proven that dialysis is capable of inducing myocardial ischaemia (McIntyre, 2009). 
Unfortunately patients on dialysis are particularly vulnerable because they often have underlying 
vascular and cardiac structural abnormalities as a consequence of years of CKD, and ultimately 
chronic LV dysfunction may prevail.  
Echocardiographic studies have also demonstrated that dialysis related ischaemia causes LV 
regional wall motion abnormalities that return to baseline after the haemodynamic changes 
during dialysis are complete (Selby, 2006).  Myocardial stunning can be determined from the 
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degree of change in LV segmental shortening fraction [SF] and the number of cardiac segments 
involved on two-dimensional echocardiography (Hothi, 2009). Echocardiography has been 
performed serially on patients during dialysis and the presence of myocardial stunning in both 
the adult and paediatric population has been demonstrated (Hothi, 2009; Selby, 2006).  
McIntyre et al examined myocardial blood flow [MBF] in dialysis patients with no 
angiographically significant CAD, using H2
15
O positron emission tomography [PET] (McIntyre, 
2008).  This study provided evidence to show that haemodialysis precipitates a reduction in MBF 
to levels which are consistent with myocardial ischaemia during the peak of dialysis, and 
reported rates of myocardial stunning in 60% of the dialysis patients examined (McIntyre, 2008). 
As a result of the poor prognosis associated with the sequelae of myocardial stunning, further 
studies have examined how to reduce its occurrence.  Such studies include reduction of intra-
dialytic hypotension [IDH] either with biofeedback dialysis or reduced temperature dialysis and 
findings so far would suggest that any improvement in MBF is related to maintenance of intra-
dialytic blood pressure (Selby, 2006).  
 
1.4.2 Myocardial fibrosis 
Findings of diffuse inter-myocardiocyte fibrosis on autopsy in patients with CKD were not found 
in a matched group of patients with hypertension but no CKD, and thus appear to be unique to 
the CKD patients (Aoki, 2005).  In recent years there have been significant developments in the 
field of myocardial fibrosis in dialysis patients. Greater understanding and insight into the 
biological mechanisms involved in the role of fibrosis in the spectrum of cardiovascular disease 
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in the dialysis population have propelled this subject forward and exposed future therapeutics 
themes. 
As already discussed, myocardial hypertrophy occurs in dialysis patients as a consequence of the 
haemodynamic shifts during each dialysis. Myocardial hypertrophy results in increased myocyte 
mass that eventually outstrips the vascular supply and causes myocardial ischaemia. This leads to 
the activation of cellular apoptotic and autophagic signals, as well as activation of other 
pathways that cause extracellular matrix production, with intermyocardial cell fibrosis as the 
final outcome (Gross, 2008; Dorn, 2009). As a consequence of the fibrosis, myocardial 
relaxation is impaired and LV compliance is reduced (Burlew, 2002).  As the LV is less 
compliant, a higher filling pressure is required to complete LV filling; this is the definition of 
diastolic dysfunction that in turn can lead to overt heart failure (Redfield, 2003). Research 
suggests that heart failure is not the only complication of diastolic dysfunction in the ESRD 
population and it has been shown to be associated with IDH, which can contribute to LV 
remodelling (de Simone, 2003).  In addition, intermyocardial fibrosis can also result in disruption 
of the cardiac conduction pathway (Gross, 2008).  Ventricular fibrillation, as a result of a high 
resistance pathway for ventricular electrical conductance, and enhancement of re-entry pathways 
can prove fatal (Ritz, 2008).  These arrythmogenic mechanisms are thought to be responsible for 
a significant proportion of sudden cardiac deaths in the dialysis population (Ritz, 2008). 
The hypothesis that the mammalian target of rapamycin [mTOR] pathway is involved at a 
cellular level has been examined (Ritz, 2009) and supported further by observational data on 
LVH regression in post transplant patients who were switched to Sirolimus (a partial mTOR 
inhibitor) from a calcineurin inhibitor [CNI] based regimen (Paoletti, 2008).  However, a number 
of complex mechanisms are involved and not just a single pathway.  For example, cytokine 
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release (including TNF-alpha, IL-1 and IL-6) causes activation of the sympathetic nervous 
system, and excessive endothelin-1 production may also be involved in the promotion of LVH 
(Ritz, 2009). Other promoters of myocardial fibrosis include persistent hyperaldosteronaemia 
resulting in increased TNF-beta, which has pro-fibrotic properties (Steigerwalt, 2007), and 
deficiency states such as anaemia and vitamin D deficiency (Sakurabayashi, 2008; Strozecki, 
2001).  Arterio-venous fistulas [AVFs] have also been implicated, on the basis that CAPD 
patients have less LVH (Tian, 2008), and other potential targets for reducing fibrosis include 
treating hyperparathyroidism (Koleganova, 2009). 
As myocardial fibrosis and increased LV mass carries such a poor prognosis Glassock et al have 
begun to address how increased LV mass may be reversed or prevented (Glassock, 2009). More 
frequent episodes of dialysis or lengthened hours of dialysis per week may help in reducing 
LVH; the frequent haemodialysis network trial is currently underway to examine this in a 
randomised controlled trial [RCT] designed study (Suri, 2007). Optimal anaemia, 
hyperparathyroidism and hypertension treatment, and closure of AVF after transplantation are all 
theoretical targets that have been examined clinically to varying degrees (Parfrey, 2009; 
Achinger, 2005; Mattioli, 2004; Cridlig, 2008).  Future potential therapeutic strategies include 
Sirolimus (Paoletti, 2008), and possibly aldosterone antagonists (Covic, 2006), but these are not 
yet established. 
In order to reduce the occurrence of sudden cardiac death from fatal dysrrhymias in patients with 
ESRD, the use of implantable cardiac defibrilators [ICD] appears plausible.  However, recent 
meta-analysis data looking at patients with ESRD and ICDs reported that patients receiving 
dialysis had a 2.7-fold higher mortality compared with those not receiving dialysis (Sakhuja, 
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2009). Addressing the problem early, in a “prevention is better than cure” approach is almost 
certainly the best method of intervention. 
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1.5 Assessment of coronary artery disease 
Silent CAD is common in patients with ESRD, and in particular in those patients with 
concomitant diabetes with a reported prevalence of 88% in potential transplant recipients over 
the age of 45 with type 1 diabetes mellitus (Manske, 1992).  The prevalence of CAD in patients 
with ESRD at the initiation of RRT is reported to be 38-45% (Stack, 2001). 
Historically, patients were screened for CAD on the basis of their symptoms. This approach 
proved to be unreliable because of the poor correlation between clinical signs and significant 
coronary disease in individuals with renal failure (Rostand, 1984).  In the dialysis population 
volume status obfuscates the detection of myocardial ischemia, and in patients with diabetes 
cardiac symptoms are a poor indicator of ischemia.  The development
 
of an autonomic 
neuropathy has been postulated
 
as the mechanism responsible for the defective anginal warning 
system (Caracciolo, 1996).  
The question of whether all dialysis patients should be screened for CAD is highly controversial 
- more controversial than the question of screening for CAD prior to renal transplantation. The 
Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, recommend all dialysis 
patients should be screened for CAD, but they do not recommend a standardized screening tool 
(National Kidney Foundation, 2005). The 2005 K/DOQI guidelines also specify frequency of 
repeat investigation for “silent” disease, with the recommendation that renal transplant 
candidates should be rescreened every 1 to 3 years, diabetic transplant candidates every 1 year, 
non-diabetic high risk patients every 2 years and non-diabetic low risk patients every 3 years. 
The statistics in the first paragraph on prevalence of CAD are compelling; in theory the majority 
of dialysis patients will have no cardiac symptoms and a significant number will have 
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undiagnosed angiographically significant coronary artery lesions. Currently any form of 
evidence base addressing whether intervention is beneficial to asymptomatic dialysis patient is 
lacking.  In an attempt to address this during this study I have analysed retrospectively a cohort 
of patients who had screening coronary angiograms prior to activation on the transplant waiting 
list. 
Leaving aside the question of who and who not to screen, Sections 1.5.1 to 1.5.6  focus on the 
options for diagnosing CAD. This includes dobutamine stress echocardiography [DSE], 
myocardial scintigraphy and exercise stress test [EST] that assess for the functional 
consequences due to the presence of CAD, and coronary computed tomography angiography 
[CCTA], coronary magnetic resonance angiography [cMRA] and conventional angiography 
coronary angiography [CA] that assess for the anatomical presence of CAD. Although there are 
additional myocardial perfusion imaging [MPI] options other than DSE and myocardial 
scintigraphy (for example stress first-pass contrast-enhanced myocardial perfusion MRI) as 
imaging modalities their use is restricted either due to resources or lack of validation in CKD 
patients. I have therefore focused my discussion on the modalities commonly used by 
nephrologists. 
 
1.5.1 Exercise Stress Test [EST] 
During exercise coronary blood flow must increase
 
to meet the higher metabolic demands of the 
myocardium. Limiting
 
the coronary blood flow may result in electrocardiographic changes.  
Exercise stress tests are often used to identify patients at risk of cardiovascular events when they 
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have presented with an acute coronary syndrome, without electrocardiographic or biochemical 
evidence of myocardial infarction. 
The resting ECG in dialysis patients is often difficult to interpret due to the presence of LVH and 
pathologic Q waves at baseline, as well the presence of ST segment abnormalities in many 
patients without clinically evident myocardial ischemia (Zuber, 1989, Kasiske, 1995, Murphy 
1996). It has also been reported that ST elevation in the context of a MI is 50% less frequent in 
dialysis patients versus non-dialysis patients (Surana, 2009). The presence of baseline ECG 
abnormalities and the fact that patients with ESRD are often unable to exercise to a predictive 
capacity limits the usefulness of EST in diagnosing CAD in this population.  
There are few studies formally examining this modality of screening in the renal failure 
population mainly due to the reduced exercise capacity of patients with ESRD. In a study of 
renal transplant candidates the exercise ECG had a sensitivity of only 35% in predicting CAD 
(Sharma, 2005).   Despite the poor predictive value of EST, it has been shown to have prognostic 
value in the ESRD population where a significantly reduced survival is reported in patients 
unable to complete >6 mins of an EST (Patel, 2008). 
 
1.5.2 Dobutamine Stress Echocardiography 
DSE is based on the principle that during stress-induced ischaemia, the decrement in contractile 
function of the myocardium is directly related to the decrease in regional sub-endocardial blood 
flow (Gallagher, 1983). For technical reasons pharmacologic stress produced by positive 
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inotropic drugs such as dobutamine are preferable to exercise in the ESRD population, due to the 
restricted exercise capacity in these patients already alluded to. 
In contrast to an EST that assesses actual functional capacity, a DSE assesses simulated 
functional capacity. The wall-motion analysis during a DSE is a subjective, semi-quantitative 
analysis, and it is therefore dependent on the observer's expertise (Barasch, 1994). However with 
improvements in imaging technology and expertise, DSE is now performed with a high level of 
accuracy. Although it is considered a relatively safe procedure, side effects of dobutamine 
administration must be considered. 
DSE was reported to have a sensitivity of 52% and a specificity of 74% in one relatively small 
study, when prospectively compared with coronary angiographic detection of CAD (>50% vessel 
stenosis) in potential renal transplant candidates (Herzog, 1999).  DSE is therefore considered a 
useful, but imperfect screening test for angiographically defined CAD in renal transplant 
candidates.   
In a further study of over 2000 patients subdivided according to level of renal function, with 
categories of normal renal function, mild and moderate renal impairment, an abnormal DSE 
predicted adverse cardiac outcomes in all groups (Karagiannas, 2008). Other studies have 
reported similar findings of DSE having an important prognostic role.  Bergeron et al showed 
that echocardiographic evidence of stress-induced ischaemia was a powerful independent 
predictor of mortality, even among patients who subsequently underwent renal transplantation 
(Bergeron, 2007). The findings are concordant with meta-analysis data that reported similar 
adverse outcomes for patients with ESRD who either had fixed defects or inducible ischaemia on 
DSE (Rabbat, 2003).   
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1.5.3 Myocardial Perfusion Scan [MPS] 
A myocardial perfusion scan is another non-invasive test of cardiac function, used primarily to 
diagnose ishcaemic heart disease.  A cardiac specific radioisotope is administered i.e.
99m
Tc-
tetrofosmin, 
99m
Tc-sestamibi or 
201
Thallium, then either with exercise or by pharmacological 
means the heart rate is increased to induce myocardial stress.  The distribution of these tracers is 
measured with single-photon emission computed tomography [SPECT]. A MPS is conducted 
both at rest and after a cardiac stress to reveal flow heterogeneity induced by a 
haemodynamically significant coronary stenosis (de Vriese, 2012). 
In the general population, the accuracy of MPS is comparable with other non-invasive tests for 
ischemic heart disease and has a sensitivity of 85%, a specificity of 72% and overall accuracy of 
83% (Elhendy, 2002). Elhendy et al, pooled together 13 studies including 1208 patients in order 
to calculate the sensitivity, specificity and accuracy results but unfortunately there was some 
variability in defining the severity of CAD, with some studies using a 50% stenosis as significant 
versus 70% stenosis in others.  
Author Year N %Stenosis Sensitivity Specificity Accuracy 
Elhendy 2002 1208 50-70% 85% 72% 83% 
Vandenberg 1996 41 70% 62% 76% 71% 
Dahan 1998 60 70% 92% 89% 90% 
Schmidt 2001 55 70% 80% 37% 59% 
De Vriese 2009 62 70% 62% 54% 58% 
Table 2: Studies comparing MPS (Dipyridamole) with Coronary Angiography. 
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MPS with exercise has the same limitations as EST in the ESRD population, related to the 
inadequate exercise performance and chronotropic incompetence of the patients (deVriese, 
2012), and dipyridamole is primarily the cardiac stressor of choice. A summary of some of the 
studies in the ESRD population is cane be seen in Table 2. With the exception of one study 
(Dahan, 1998), correlation between CAD on angiography and abnormalities on MPS were less 
convincing in the ESRD population (de Vriese, 2009; Vandenberg, 1996; Schmidt, 2001; Dahan, 
1998). One potential explanation for the low sensitivity is the presence of balanced ischaemia in 
patients with ESRD, a term that refers to the situation when flow is equally diminished in all 
myocardial areas (de Vriese, 2012). As MPS measures relative rather than absolute perfusion, the 
sensitivity of the test in the setting of balanced ischaemia may be reduced. An impaired 
vasodilatory response to adenosine in the dialysis population is another potential explanation for 
the low sensitivities in these studies (de Vriese, 2012). 
The most recent publication relating to MPS in the ESRD populations was an evaluation of MPS 
as a tool for CV risk stratification and the authors found that myocardial stress testing was useful 
only in patients with just one risk factor (de Lima, 2012).  
 
1.5.4 Coronary Artery Magnetic Resonance Angiography  
Magnetic Resonance Imaging [MRI] techniques used to image the heart, can assess coronary 
arteries with angiography and also provide information on cardiac morphology, acquired 
diseases of the great vessels, and cardiac function at rest and under stress (Nagel, 1999). 
Visualisation of the coronary arteries with Magnetic Resonance Angiography [MRA] was first 
reported by Paulin et al in 1987. 
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The major problem of early cMRA was related to cardiac contractions and the motion of the 
diaphragm limiting the quality of images gained, however different techniques have been 
employed to overcome these limitations (Foo, 2000, Danias, 1998).  Other technical restrictions 
relate to accurate visualization of relatively small coronary arteries with diameters less than 3.5 
mm and vessels that follow a tortuous course or have surrounding epicardial fat (Dharwan, 
2004). Also, the interpretation of the imaging of a left circumflex coronary artery in cMRA is 
limited by difficulty in distinguishing the artery from parallel running cardiac veins (Danias, 
1998). 
A decade ago MRA was not practical other than for diagnosing left main stem disease and 3-
vessel disease [3VD], as demonstrated in a multi-centred study (Kim, 2001).  In the current era 
technical advances have allowed different MR methods to image the coronary arteries.  One 
technique is known as steady state free precession [SSFP] whole heart cMRA (Weber, 2003). 
This allows better image acquisition without the need for contrast, because of an intrinsic high 
blood signal intensity (Finn, 2006), and less motion artefact due to motion adapted respiratory 
gating (Plein, 2003).  Images can be achieved in less than 20 mins (Kato, 2010), compared to the 
lengthy scanning techniques from a few years ago which could take up to 70 mins (Kim, 2001). 
Whole heart cMRA using 32-channel cardiac coils and a high parallel imaging factor to reduce 
length of scan further is under evaluation (Yang, 2009). 
The latest multi-centred study utilising these more sophisticated processes has shown a 
sensitivity of 88%, specificity of 72%, a positive predictive value [PPV] of 71% and a negative 
predictive value [NPV] of 88% in detecting significant coronary artery stenosis of any major 
epicardial vessel (Kato, 2010). This recent analysis has also reported cMRA is particularly 
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accurate when diagnosing LMS or 3VD, with a high NPV of 99% (Kato, 2010).  However, 
imaging coronary anatomy with cMRA remains a research tool only. 
 
1.5.5 Cardiac CT Angiography 
Cardiac CT angiography [CCTA] is performed following the administration of intravenous 
contrast and requires multi-slice CT techniques to produce images of the coronary arteries. The 
technology has been improved over the years by increasing the number of slices that can be 
acquired simultaneously. Original studies used a 4-slice detector, and image acquisition was 
limited. With the introduction of a 64-slice detector scanning was reduced to ten seconds, which 
most patients manage as a breath-hold (AHTA, 2006). Now current best practice is with a single 
source 256-slice detector CT, and in the future a single slice 320-slice CT may be the next step to 
improving this non-invasive imaging modality (Hsiao, 2010).  
Although some of the imaging acquisition constraints of CCTA have been overcome with the 
technical advances described, a number of issues relevant to the CKD population exist.  The first 
issue is surrounding ECG-gating in patients with high heart rates and atrial fibrillation due to 
reported image inaccuracy (Herzog, 2006; Leschka, 2006).  The second issue is related to 
calcification that is well recognised as a complication of CKD (Goodman, 2000; Haydar, 2004; 
Russo, 2004) and impairs image quality (Ong, 2006). These factors should be taken into 
consideration, as the outcome data (described below) is from a non-CKD population. 
Like cMRA, CCTA has a high negative predictive value. With the exception of the CORE 64 
(Coronary Evaluation Using Multi-detector Spiral Computed Tomography Angiography using 
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64 Detectors) prospective multi-centred trial, which had a NPV of 83% (Miller, 2008), meta-
analysis data reported a NPV of 100% when compared to conventional coronary angiography 
(Mowatt, 2008). In the meta-analysis the sensitivity was highest in the LMCA, and lowest (85%) 
in the Cx (Mowatt, 2008).  The ACCURACY (Assessment by Coronary Computed Tomographic 
Angiography of Individuals undergoing Invasive Coronary Angiography) multi-centred trial 
concluded that CCTA had comparable specificity but superior sensitivity and NPV to the 
established non-invasive modality of stress echocardiography (Budoff, 2008). 
The radiation dose with CCTA is often a raised as concerning, with quoted risks of cancer as a 
result of the scan of 1 in 270 women and 1 in 600 men undergoing CCTA at the age of 40 
(Smith-Bindman, 2009).  However there is a variety of techniques that can be employed to 
reduce radiation dose (Hausleiter, 2008), and in reality conventional coronary angiography is not 
without its own radiation risk.  Both CCTA and conventional CA require the administration or 
intravenous contrast and contrast nephropathy is discussed in Section 1.5.5. In an attempt to 
avoid contrast nephropathy cMRA may be a more attractive option. However the use of 
Gadolinium can precipitate Nephrogenic Sclerosing Dermopathy in patients with advanced CKD 
and ESRD (Cowper, 2001) and also needs careful consideration.   
In conclusion, CCTA may be considered as a useful non-invasive evaluation tool in specific 
circumstances and protects the patient from the potential complications of CA. The AHA 
recommends the use of CCTA over cMRA, because comparatively the cMRA images and 
diagnostic accuracy are considered inferior, but list the specific indications for its use (Hendel, 
2006).  
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1.5.6 Coronary angiography 
Coronary angiography is the gold standard investigation in diagnosing CAD, and has been 
extensively performed for over 60 years.  It allows visualisation of the epicardial coronary 
anatomy including the distal vessels.  In a small study of 126 renal transplant candidates, CA was 
the best modality to detect CAD, compared to single photon emission computed tomography 
[SPECT], DSE and clinical risk stratification (de Lima, 2003).  It is also the only diagnostic 
method whereby therapeutic intervention can be performed concomitantly.   On the down side it 
is expensive with small but not insignificant risks of complications, and a considerable number 
of patients undergoing CA will turn out to have normal coronary arteries (Kato, 2010). 
There exists a degree of reluctance to perform coronary angiography on patients with CKD and 
ESRD (Chertow, 2004; Charyton, 2006).  This has been partly attributed to the fact that most of 
the evidence-based guidelines for managing CAD are based on clinical trials performed in 
patients without CKD (Charyton, 2006), and partly due to increased risk of procedural 
complications in the setting of uraemia.  The Renal Association states “CKD and dialysis 
patients should have unimpeded access to a full range of cardiac investigations including 
exercise and stress echocardiography, radio-isotopic cardiac scans and coronary angiography” 
(Holt, 2010).   
The risk of suffering myocardial infarction approaches 75% after a patient has been on dialysis 
for 3 or more years (USRDS, 2007). Recently, an opposing view has surfaced attributing the 
majority of cardiovascular deaths to arrhythmias, possibly related to uraemic cardiomyopathy 
(Patel, 2008) or abnormalities in myocardial ultra structure (Herzog, 2008).  This opinion states 
that CAD is a relatively minor component of the accelerated cardiovascular disease that affects 
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end stage renal failure patients, despite the high incidence of myocardial infarction reported from 
USRDS data (USRDS, 2007). This has led to nephrologists questioning the rationale for 
performing cardiovascular assessments and coronary intervention and further compounds 
reluctance to perform coronary intervention on patients with ESRD.  Silent disease can only be 
diagnosed with a screening tool and in such situations coronary angiography provides vital 
information about the condition of coronary arteries that non-invasive “functional” screening 
tools may not detect. 
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1.6  Coronary Angiographic Diagnostics  
Accurate assessment of the severity of CAD is vital as it determines the selection of the most 
appropriate treatment for the patient. Inaccuracy can result in risk to the patient in terms of health 
burden, and financially to the health service for the same reason. 
The majority of coronary angiographic diagnostics is based on visual inspection and therefore 
dependant on user experience. CA alone provides an outline of a contrast filled lumen, but does 
not provide any information on the vessel wall itself. However CA has become more 
sophisticated over the years with various technical advances such as automated analysis 
programmes and physiological measures of flow.  Quantitative Coronary Angiography [QCA] 
was introduced in the late 1970s (Brown, 1977), but intravascular Doppler ultrasound [IVUS] 
was not fully established until the 1990s (Kern, 1993, Di Mario 1995).  Both these methods have 
proven reliable, and will be discussed in this section in more detail. The combination of IVUS 
images with biplane acquisitions (Molina, 1998) has enabled cardiologists to assess the 
haemodynamic severity of a coronary lesion with greater accuracy.  In assessing how much of an 
effect a coronary artery lesion has on myocardial perfusion, the Fraction Flow Reserve [FFR] 
can be measured. FFR is determined at the time of angiography by introducing a 0.014-inch 
pressure monitoring guidewire, which does not interfere with coronary blood flow.  There is a 
general consensus that determining the severity of a stenosis and its effect on the cardiovascular 
systems is challenging, particularly when trying to quantify the severity in a single measure 
(Gould, 1990; Marcus 1988), which becomes relevant to this study in the methods section.   
Finally in Section 1.6.5, I have included a discussion on the recognised complication of contrast 
on renal function, which is of relevance to patients enrolled in this study. 
 58 
1.6.1 Quantitative Coronary Angiography [QCA] 
Before IVUS was established QCA was the reference method of choice when assessing the 
severity of CAD, and was also considered a useful comparator when examining for the 
progression of a lesion (Brown, 1977). Its use in various trials has undoubtedly impacted on the 
practice of interventional cardiology (Keane, 1995).  The limitations of QCA soon became 
apparent and prompted validation studies to be carried out.  
 
Figure 5: Quantitative coronary angiography. Edge detection in demonstrated in yellow and vessel reference is 
demonstrated in red. 
Many computer applications are available which allow quantification of a coronary stenosis 
(Reiber, 1984), however their accuracy is variable (Keane, 1995). In principle, an angiographic 
image is selected, magnified and the diseased portion of a vessel is measured both in terms of 
length of stenosis and degree of vessel narrowing using QCA-specific software (Figure 5).  
Keane et al examined 10 QCA systems in North America and Europe and found that QCA 
overestimated the minimal luminal diameter, and underestimated the gain in diameter following 
stent insertion; there was also significant random error (Keane, 1995).   The clinical implications 
were considerable and where this method was used the calculation of a study power and sample 
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size may have been inaccurately generated.  The findings of the validation study (Keane, 1995) 
were taken on board by the producers of the QCA systems and refined algorithms were 
incorporated.  
Finally, the other major disadvantage of QCA is that it does not provide any information of 
plaque severity or morphology and is therefore not felt to be as informative as other methods of 
assessing CAD severity (Athanasiadis, 1998).  Some arteries with seemingly near-normal lumen 
contours
 
can often be extensively involved with plaque (Glagov, 1987; Kragel, 1989), and this 
would not be detected with QCA.  It is therefore possible that cardiovascular events may not be 
predicted by anatomical measurements of luminal narrowing. 
However, despite these negative findings, QCA should not be looked at as entirely unfavourable; 
its application in scientific research has provided a better understanding of CAD and has 
lessened the subjectivity and variability of visual assessments (Zir, 1976; Goldberg, 1990).    
 
1.6.2 Intravascular Ultrasound [IVUS] 
IVUS emerged in the 1990s as a far more sensitive tool for assessing plaque morphology and 
disease severity (De Scheerder, 1994; Takazawa, 1997; Yamagishi, 2002). The technique 
involves the introduction of a miniaturized Doppler probe attached to the distal end of a fine 
catheter that visualises the vessel wall allowing determination of the extent of plaque disease. It 
is particularly useful for regions within the coronary arterial system that angiography is not 
entirely reliable; for example in areas where multiple arterial segments overlap and the 
angiographic images are obscured (Zafari, 2004). When first introduced IVUS, like QCA could 
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not reliably identify characteristics of
 
the plaque that render it vulnerable (Herd, 1997) which 
includes the presence of macrophage clusters, the large core lipid pool, or
 
the dangerously thin 
fibrous cap (Davies, 1993). However with the introduction of Virtual Histology IVUS [VH-
IVUS], the technique is now more refined.   Based on advanced radiofrequency analysis of 
reflected ultrasound signals in a frequency domain analysis, a reconstructed colour-coded map of 
plaque composition superimposed on cross-sectional images of the coronary artery obtained by 
grayscale IVUS is created (Nair, 2006), allowing some insight into plaque morphology. 
IVUS has allowed researchers to gain greater insight into why some stenoses that appeared on 
angiographic images to be significant turned out not to be.  One of the most significant findings 
with the use of IVUS was that the re-stenosis which was reported after angioplasty was not a true 
problem of re-stenosis, but remodeling of the atheromatous plaque resulting in images on 
angiography appearing as re-stenosis (Potkin, 1992; Mintz, 1996).  Therapeutically it has 
enabled the examination of plaque burden and vessel stenosis in studies of therapies including 
landmark stent and statin studies (Serruys, 2002; Nissen, 2006). 
The major disadvantages of IVUS are the expense, the additional time to complete the procedure 
and that anatomically the procedure is limited to the proximal segments of vessels.  It is also 
worth noting that the use of IVUS with all coronary angiograms performed does not impact on 
outcome (Schiele, 1998), however, in selected cases it can provide greater insight into the 
disease severity and plaque burden in questionable lesions. 
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1.6.3 Fractional Flow Reserve  
During cardiac catheterisation it is possible to measure the pressure differences across a stenotic 
lesion by introducing a transducer attached to the end of a very thin wire. During maximal blood 
flow (induced by adenosine) measurements of pressure distal to a lesion relative to the pressure 
proximal to the lesion are calculated to produce the FFR (Pijls, 1993).  FFR is an index that 
represents the fraction of normal maximal myocardial flow that can be achieved despite the 
vessel stenosis (Pijls, 1996).  
As highlighted earlier non-invasive tests of functional significance have been shown to be of 
limited value or inconclusive in ESRD patients (Section 1.5).  One of the most attractive features 
of FFR is that it provides quantitative information on whether a lesion is functionally important 
which neither CT angiography, IVUS or QCA will do.  
The DEFER study examined patients with single vessel disease undergoing stenting and found 
that those patients with a FFR >0.75 did not have any prognostic benefit from stenting, compared 
with those patients with a FFR of >0.75 who did not undergo stenting (Pijls, 2007).  Although 
DEFER used a FFR of 0.75 as significant, for a number of clinical trials a FFR of 0.8 was 
interpreted as significant. One such landmark study was FFR v Angiography for Multi-vessel 
Evaluation (FAME) study that looked at multi-vessel disease (Tonino, 2009). This multi-centred 
study across 2 continents randomised patients to intervention with a drug eluting stent based on 
angiography or angiography with FFR.  In the angiography alone patients group, intervention 
occurred on the basis of visual inspection while in the angiography with FFR group patients were 
only stented if the FFR was <0.8. The results suggested many aspects of benefit to patients, i.e. 
less stent utilisation, lower rates of death, non-fatal MI and repeat revascularisation, and shorter 
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hospital stays in the FFR group.  Although it is generally viewed as a procedure that prolongs 
angiography time, FAME reported this not to be the case (Tonino, 2009)  
 
1.6.4  Scoring systems 
As discussed, QCA, IVUS and FFR have proven useful in assessing the severity and progression 
of CAD in many clinical trials, and alleviates some of the inter-observer variability (DeRouen, 
1977, Zir 1976) associated with visual inspection alone. Of greater importance is their use in 
guiding whether revascularisation should be carried out or not.  Scoring systems have also been 
widely utilised, and provide yet another option for assessing disease severity in clinical trials. 
One of the most widely recognised scoring systems to emerge over the last few years is the 
Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery 
[SYNTAX] score (Sianos 2005). This score combined a number of previously validated 
angiographic classifications that graded the coronary anatomy with respect to number of lesions, 
the location of the lesions and the functional impact and complexity of the lesions (Siannas, 
2005).  The SYNTAX score has been validated from a prognostic point of view in patients with 
3-vessel disease as well as in patients with LMS disease that underwent PCI or CABG 
(Capudanno, 2009).  Its usefulness as a score to select patients for treatment has also been 
demonstrated for patients with LMCA disease and selection for CABG surgery (Capudanno, 
2009). 
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Further description of SYNTAX score calculations and interpretation are described in the 
Material & Methods section, as this was the assessment of choice for angiographic progression 
in this study. 
 
1.6.5 Contrast induced Nephropathy 
The renal dysfunction associated with contrast-induced nephropathy [CIN] peaks at 3-5 days 
following the administration of contrast and improves in 1 to 3 weeks (Berns, 1989).  In those 
patients in whom renal insufficiency persists >3 weeks, cholesterol embolisation syndrome may 
be a contributory factor (Saklayen, 1997). 
CIN results from a combination of pathophysiologic processes. Hypertonic contrast media causes 
the production of oxygen-free radicals leading to apoptosis in renal tubular cells (Katholi, 1998). 
Aside from direct tubular injury, contrast media also has effects on the metabolism of certain 
vasoconstrictors including adenosine and endothelin, causing disturbances to renal 
haemodynamics (Russo, 1995).  Cholesterol embolization syndrome occurs when disruption to a 
vascular plaque releases cholesterol crystals into the bloodstream, resulting in localized 
inflammation and fibrosis, most commonly seen in the skin, digits, kidneys, and eyes and often 
persisting for weeks. The initial event may be either due to spontaneous plaque rupture, or as a 
secondary phenomenon following the administration of thrombolytics or following vascular 
endothelial trauma (Bashore, 2003). One prospective study, evaluating patients undergoing 
coronary angiography found that no patients had dermatological manifestations of cholesterol 
embolization syndrome, but a persistently elevated creatinine at three weeks was reported to 
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occur in 2% of patients studied, which was attributed to cholesterol embolization to the kidneys 
(Saklayen, 1997). 
There has been a tendency to delay coronary angiography in potential transplant recipients until 
they have been established on renal replacement therapy due to the concerns that contrast 
induced nephropathy [CIN] and cholesterol embolisation syndrome may precipitate the need for 
chronic dialysis (McCullough, 2006). The reported incidence of CIN following coronary 
angiography ranges from 3.3%-37%, with pre-existing renal disease being the greatest 
independent predictor (Rihal, 2002; Fung, 2004; Gami 2004). The need for dialysis treatment in 
the setting of CIN has been reported to occur in 7.1% patients in the short term, and 0.9% in the 
long term (Pichard, 2000).  In addition, there is a reported increased in-hospital mortality in 
patients requiring acute dialysis following the administration contrast during percutaneous 
coronary intervention (McCullough, 1997).  
Various preventative measures have improved the safety profile of coronary angiography in the 
modern era.  Such measures include the use of adequate hydration, N-Acetyl cysteine, smaller 
volumes of non-ionic contrasts, biplane imaging techniques, staged procedures in cases requiring 
intervention, and careful post angiography monitoring (Pucelikova, 2008).  Of note however, a 
recent RCT that randomised 2,308 patients to N-Acetyl cysteine 1200mg bd for 2 days pre-
procedure and 2 days post-procedure, or placebo, showed identical (12.7% versus 12.7%) 
incidence of acute kidney injury [AKI] (Berwanger, 2011). The use of continuous veno-venous 
hemofiltration, initiated before exposure to contrast and continued for 18 to 24 h after the 
procedure, has been reported to result in a significant reduction in the degree of renal injury in a 
cohort of patients known to be at considerable risk (mean baseline creatinine 265.2 μmol/L) 
(Marenzi, 2003). This approach obviously has significant implications in terms of resources. 
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In this study I examine the effect of contrast on rate of decline of GFR in patients with advanced 
CKD who underwent standard pre-procedure preventative measures according to local practice 
at the time. 
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1.7 Modifiable and non-modifiable cardiac risk factors 
The burden of cardiovascular disease in terms of both morbidity and mortality for patients with 
CKD has already been highlighted in earlier sections. As renal function deteriorates, the rates of 
cardiovascular events and mortality increase (Go, 2004).  The relationship between risk factors 
and cardiovascular outcomes is often different in patients with CKD when compared to the 
general population (Jun, 2011).  
The classical risk factors for cardiovascular disease, which include hypertension, diabetes, 
obesity and lipid abnormalities, occur more frequently in patients with CKD, than in those 
patients with normal renal function (Rucker 2009, Tozawa 2007, Fox 2004, Muntner 2000). It 
has been observed that the logarithmic-linear relationship between cardiac risk factors and 
cardiac outcome that is seen in the general population is not applicable to patients with CKD 
(Jun, 2011). Specifically, hypertension (Alborzi, 2007), high cholesterol (Liu, 2004), and obesity 
(Mafra, 2008) that in the general population are predictors of cardiac disease, are associated with 
a different pattern of risk in the CKD population.  What has been observed is an inverse 
relationship, where patients with low blood pressure, low cholesterol and low BMI have the 
worst outcome. This is often referred to as “reverse causality”, and theories to explain this 
occurrence include confounding factors such as inflammation and malnutrition at a 
pathophysiological level, and survival bias in observational data at a statistical level (Kopple, 
2005).  It has also been observed that patients with CKD and ESRD are less likely to receive 
aspirin, beta blockers, RAS blockade or statins, than non-CKD patients (Winkelmayer, 2006; 
Anavekar, 2004; Berger, 2003). 
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Data from subgroup analysis of clinical trials, have demonstrated different outcomes of risk 
factor intervention in patients with CKD.  This has led to some degree of uncertainty around the 
patho-physiological mechanisms and the validity of applying data from general population 
studies to the CKD population.  In addition, it is well recognised that there is a paucity of 
randomised control trials in the CKD population, and where they do exist they are often small 
and underpowered. Further studies of how to optimize the management of CAD risk factors in 
the dialysis population should be a clinical priority.  In this section the best current evidence for 
cardiac risk factor management in the CKD and dialysis population is discussed.   
 
1.7.1 Hypertension 
The rationale for controlling hypertension in patients with CKD is two-fold. Firstly, to reduce 
cardiovascular risk and secondly, to slow down the progression of CKD.  The evidence for the 
latter is best demonstrated with greatest effect in patients with co-existing proteinuria (Appel, 
2010; Sarnak, 2005; Jafar, 2003; Peterson, 1995). Landmark RCTs examining various renin 
angiotensin system [RAS] blockade treatments measured renal outcome with hard end points 
including reaching ESRD or doubling of serum creatinine.  Specifically the REIN (Ramipril 
Efficacy in Nephropathy) and AIPRI (Angiotensin-Converting Enzyme Inhibition in Progressive 
Renal Insufficiency) studies that looked at non-diabetics with proteinuria demonstrated that RAS 
blockade treatment slowed the progression of CKD when compared to standard antihypertensive 
therapy (GISEN group, 1997; Maschio, 1999).  The RENAAL (Reduction of Endpoints in 
NIDDM with the Angiotensin II Antagonist Losartan) study that examined type 2 diabetics with 
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proteinuria demonstrated significant renal benefit, although had no effect on mortality (Brenner, 
2001).    
In terms of the benefit of blood pressure reduction on cardiovascular end points in patients with 
CKD, the data is more limited and comes mainly from subgroup analyses of large RCTs such as 
the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR 
Controlled Evaluation), PROGRESS (Perindopril Protection against Recurrent Stroke Study), 
HOPE (Heart Outcomes Prevention Evaluation) and EUROPA (European Trial on Reduction of 
cardiac events with Perindopril in stable coronary artery disease) studies (ADVANCE 
collaborative group, 2008; Perkovic 2007; Mann, 2001; Brugts, 2007).  Collectively these trials 
have included thousands of patients with CKD, and found that treatment with an ACEi reduces 
the risk of major cardiac events by 13-35% (Jun, 2011). Of note the benefits would seem to be 
similar to those in the non-CKD population (Jun, 2011).   
With regards to the dialysis population a recent meta-analysis of 8 RCTs, which included 1679 
patients on dialysis, has shown that the dialysis population do benefit from lowering blood 
pressure, with a reduction of 36% (95% CI 65-57%) for cardiac events, and a reduction of 20% 
(95% CI 4-34%) for all cause mortality (Heerspink, 2009).  However, it is widely acknowledged 
that there are inherent difficulties in accurately interpreting blood pressure readings in dialysis 
patients, in whom BP is so variable.   
Renal association guidelines suggest a target driven approach to BP management, aiming for BP 
of 130/80 or 125/75. The advantage and disadvantages of target-centered BP treatment, over 
administration of fixed dose treatments have been explored (Kaplan, 2007). In a trial of over 
11000 patients with diabetes, patients were administrated either a fixed dose ACEi based 
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treatment or target driven treatments, and there was a reduction in cardiovascular events 
regardless of baseline blood pressure (Heerspink, 2010). Similarly, the recently completed 
ACCORD study demonstrated that for people with type 2 diabetes, a systolic blood pressure 
target of less than 120 mmHg, compared with less than 140 mmHg, did not reduce the overall 
rate of fatal and non-fatal major cardiovascular events, although the risk of stroke was reduced 
(ACCORD Study Group, 2010). People with impaired kidney function were included although 
subgroup analyses are not yet available. 
 
1.7.2  Dyslipidaemia 
In the Framingham study, the risk of myocardial re-infarction was increased by about nine times 
in women and three times in men with a total cholesterol >270 mg/dL when compared with 
individuals with total cholesterol <190 mg/dl (Wong, 1991). This epidemiological data provided 
convincing evidence that hyperlipidaemia is a modifiable cardiac risk factor in the general 
population. 
The much anticipated results from the SHARP (Study of Heart and Renal Protection) study have 
supported the use of aggressive lipid lowering treatment in patients with all degrees of CKD 
including those on dialysis (Baigent, 2011).  The end points measured included non-
haemorrhagic CVA, arterial revascularisation procedures, non-fatal myocardial infarction and 
death from coronary artery disease.  The SHARP study demonstrated a reduction in all these 
outcome measures in the group randomized to a combination of Simvastatin and Ezetimibe, 
however the non-fatal myocardial infarction and death from coronary artery disease rates were 
not significantly reduced (Baigent, 2011). 
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Prior to the SHARP study, evidence for lipid lowering treatment was equivocal.  The 2 most 
frequently quoted studies were the Deutsche Diabetes Dialyse Studie - 4D (Wanner, 2005) and 
the AURORA (Fellstrom, 2009) trials involving 4028 patients on dialysis.  Neither reported any 
significant effect of lipid-lowering treatment on cardiovascular events or all-cause mortality.  A 
systematic review of 50 studies involving 30,144 participants (Strippoli, 2008) also showed no 
significant effect on all-cause mortality (RR 0.92, 95% CI 0.82 to 1.03).  However unlike the 
SHARP, 4D and AURORA studies, this systematic review (Strippoli, 2008) reported statins did 
have a significant impact on preventing fatal (RR 0.81, 95% CI 0.73 to 0.90) and non-fatal 
cardiovascular events (RR 0.78, 95% CI 0.73 to 0.84).  It is worth noting that there were major 
differences in the patient populations with this systematic review involving mainly early stage 
CKD (Strippoli, 2008), unlike the SHARP study that included 3023 dialysis patients.  
Furthermore, the data in the systematic review by Strippoli et al may have been skewed by some 
of the methodology used in a number of the studies included for analysis (Strippoli, 2008; Jun, 
2011). 
 
1.7.3 Obesity and malnutrition 
The global obesity epidemic is a major public health issue.  Epidemiological studies have 
demonstrated an association between obesity, cardiovascular disease and mortality in the general 
population (Byers, 1995). However in the 1980s a unique relationship between decreasing 
mortality with increasing body mass index [BMI] in dialysis patients surfaced (Degoulet, 1982). 
This French data had significant limitations, but the numerous studies that followed did not 
refute this relationship, and only served to strengthen the data supporting this concept of obese 
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dialysis patients having improved survival when compared with underweight dialysis patients 
(Kopple, 1997; Port, 2002; Fleischmann, 1999). This lead to general acceptance of obesity being 
protective for dialysis patients. Now it seems that we must be cautious in accepting this 
relationship as de Mutsert et al examined the association of BMI with mortality in the 
hemodialysis population, and the general population, when age and time of follow-up were made 
strictly comparable.  They reported that the association with BMI and mortality was not 
significantly different between the two groups (de Mutsert, 2007).  
Malnutrition is a pro-inflammatory state (Pecoits-Filho, 2002) exposing underweight dialysis 
patients at increased risk of the cardiovascular consequences of inflammation.  Therefore the 
protective benefit of obesity may simply be as a result of a comparable increased risk in the 
malnourished, making the obese patients appear better off.  With respect to malnourishment, 
hypoalbuminaemia has been established as an independent predictor of overall mortality in the 
ESRD population (Foley, 1996).  In the haemodialysis population, each 1g/dL drop in mean 
serum albumin was independently associated with the development of de novo and recurrent 
heart failure, de novo and recurrent ischaemic heart disease, cardiac mortality and overall 
mortality (Foley, 1996).  However, the relationship between hypoalbuminaemia and cardiac 
disease is not fully understood.  Despite lack of clarity as to the exact mechanism of how 
hypoalbuminaemia increases cardiovascular risk, in this study albumin data was collected on a 
cohort of patients to correlate with carotid intimal media thickness measurements. 
 
 
 
 72 
1.7.4  Diabetic control 
Diabetes is an independent risk factor for CAD (Howard, 2002).  Diabetic nephropathy is the 
most common cause of ESRD in the UK (Rayner, 2004).  It is widely accepted that the 
combination of diabetes and ESRD is not a favourable one.   Until recently targeted HbA1C 
levels, in order to have sustained tight glycaemic control, was accepted practice based on results 
from trials in the 1990s (DCCT, 1993; UKPDS, 1998).  But the most recent well-designed RCT 
in the non-ESRD population with type 2 diabetes has failed to demonstrate lower cardiovascular 
events rates in the intensive treatment limb of the study (ACCORD study group, 2011). 
As nephrologists we have learned that we need to exercise caution when extrapolating best 
clinical practice guidelines originating from general population studies, as recently highlighted 
with statin treatment (Fellstrom, 2009).  There is now contemporary data specific to the dialysis 
population that has shown strict glycaemic control may not be as advantageous as previously 
thought to be (Williams, 2010; Shurraw, 2010).  The reasons for this are not entirely clear 
although it is known that renal failure reduces insulin clearance; renal gluconeogenesis is lost 
when patients are on dialysis; and the risk of hypoglycaemia, which is greater in patients with 
ESRD than in general population, seem to play a role (Fortes, 2009; Muhlhauser, 1991). 
Data from Williams et al that included 25000 dialysis patients found that the group with the 
lowest CV mortality were the ESRD patients with HbA1C measurements between 7-9%; it is 
therefore felt to be reasonable practice to not be overly aggressive with diabetes management 
(Williams, 2010). 
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1.7.5 Anaemia 
The established cardiovascular consequences of anaemia include left ventricular hypertrophy and 
left ventricular systolic dysfunction (Greaves, 1994; Levin 1999).  In the ESRD population 
anaemia has also been associated with increased cardiovascular mortality and morbidity 
including stroke (Jurkovitz, 2003; Abramson, 2003; Sarnak, 2002). 
Erythropoietin stimulating agents [ESAs] are extensively used in the CKD and ESRD population 
to improve haematocrit and thereby reduce the need for blood transfusions. However, 
determining haemoglobin targets for patients on ESAs has not been straightforward.  The 
Correction of Haemoglobin and Outcomes in Renal Insufficiency [CHOIR] study randomised 
1432 CKD patients to a target haemoglobin of 13.5 or 11.5g/dL (Singh, 2006).  After 3 years, the 
cardiovascular events were significantly higher in the high haemoglobin group, and there was no 
reported difference in quality of life (Singh, 2006). The Cardiovascular Risk Reduction by Early 
Anaemia Treatment with Epoetin-beta (CREATE) study had similar adverse outcome results in 
the high haemoglobin group (Drueke, 2006).   
Anaemia research has expanded to involve non-ESA therapies that are likely to emerge over the 
next few years.  Hepcidin is a substance produced by the liver in the setting of inflammation, and 
contributes to an iron deficit state via its action in the gastrointestinal tract and via inhibition of 
iron release from macrophages and hepatocytes (Young, 2009).  Hepcidin inhibitors are being 
developed in order to improve red blood cell production in the setting of inflammation (Nemeth, 
2010).  
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Current UK guidelines are a target haemoglobin of 11g/dl, but not to exceed 12g/dl, which is 
aimed at achieving protection against LV hypertrophy, but not inducing a pro-thrombotic state 
which may predispose to cardiovascular events (Locatelli, 2010). 
 
1.7.6 Ethnicity & gender 
There are a number of potentially modifiable risk factors that can be targeted for treatment.  
However, un-modifiable risk factors such as gender and race may be important and also need to 
be considered when carrying out cardiac risk stratification before and after transplantation.  
There are limited data available in the literature on the prevalence of CAD in patients with 
ESRD, and the largest registry review to address the differences in the prevalence of obstructive 
CAD by ethnicity included, but did not focus on, patients with ESRD (Shaw, 2008). 
In the United Kingdom [UK] 8% of the total population (4.6 million people) are from ethnic 
minorities, half of which originate from the Indian subcontinent (National Statistics Website, 
2001). When examining the geographical distribution of the ethnic groups, it is reported that 
45% of the ethnic minority population reside in London
 
(National Statistics Website, 2001).  
Multiple studies of migrant South Asian populations have shown a 3- to 5-fold increase in the 
risk of myocardial infarction and cardiovascular death as compared with other ethnic groups 
(Harding, 2003; McKeigue, 1989).  In addition, South Asians are susceptible to developing 
coronary heart disease often below the age of 40 years in men (Enas, 1996). Unfortunately these 
data do not specifically focus on patients with ESRD. 
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Data from the United States [US] have suggested that among dialysis patients, ethnic minorities 
have superior dialysis outcomes and survival compared to Caucasians (USRDS, 2002; 
Frankenfield, 2003).  In the UK, survival in Indo-Asians and Afro-Caribbean dialysis patients is 
comparable to Caucasian dialysis patients, despite a higher burden of diabetes (Prasad, 2004).  
Unfortunately, Prasad et al did not specifically address cardiac morbidity and mortality (Prasad, 
2004). 
There is evolving knowledge regarding the influence of gender in respect to CAD, and a recent 
suggestion that although women have lower rates of anatomical coronary artery disease, they 
have higher rates of ischaemic episodes and adverse outcomes; the theory is that microvascular 
dysfunction is linked to abnormal coronary reactivity (Shaw, 2009).  Results of local data 
relating to the influence of gender and ethnicity on cardiovascular outcomes in the ERSD 
population can be seen in the results section. 
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1.8 Cardiac assessment prior to transplantation 
In the UK there is no consensus on optimal cardiac work up prior to transplantation.  In the US 
the American Society of Nephrology (ASN) and the American Society of Transplantation (AST) 
advocate myocardial perfusion imaging to assess for functional ischaemia, and after further 
evaluation patients may require revascularization (Kasiske, 2001). In general the lack of 
consistency and evidence base has allowed cardiac assessment prior to transplantation to be 
locally led, and in many cases driven by resources that may contribute to sub-optimal cardiac 
evaluation (Lentine, 2010). For patients with CKD, transplantation offers a greater survival 
advantage over other forms of renal replacement therapy (Meier-Kriesche, 2004). Kidneys from 
living or cadaver donors are a precious resource, and because cardiovascular death is a major 
cause of eventual graft loss (USRDS, 2009), the decision to diagnose and treat CAD before 
transplantation is an important one, particularly because the majority of patients have no cardiac 
history or symptoms. 
In a population without renal failure, there is sufficient evidence to show that coronary artery 
intervention in asymptomatic patients does not improve survival (McFalls, 2004). However, this 
cannot be extrapolated to patients with years of renal failure and the unique vascular 
complications associated with the condition.  In Sections 1.8.1 and 1.8.2 I have discussed the UK 
and USA guidelines for cardiac assessment prior to transplantation that differ significantly.  In 
order to understand the differences the rationale for the guidelines are explored in greater detail.  
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1.8.1 UK Guidelines 
The current Renal Association guidelines on pre-transplant cardiac assessment have suggested, 
“screening tests may be best used to identify high risk patients for exclusion from the transplant 
waiting list” (Dudley, 2011).  The rationale for this guideline is based on a recent prospective 
cohort study performed in a predominantly Caucasian population in Scotland (Patel, 2008).  The 
authors reported that there was no significant survival difference between patients undergoing 
coronary angiography with intervention, coronary angiography without intervention and patients 
who did not undergo coronary angiography (median survival in years 4.0 ± 2.1 vs. 3.9 ± 1.8 vs. 
4.0 ± 1.4, respectively; log-rank test p = 0.67).  Interestingly, the number of patients undergoing 
angiography was small (n=99) and further to this the number of patients undergoing intervention 
was even smaller (n=17).  National guidelines have been written on the basis of this single study, 
in combination with a non-renal population study of asymptomatic patients (McFalls, 2004). 
Given that there was no direct evidence of patient benefit from cardiac screening in the Scottish 
study, the authors have suggested that it may serve as a barrier to being placed on a waiting 
listing.   
An opposing view comes from de Lima (2010); in their study they retrospectively reviewed five 
times the number of patients undergoing coronary angiograms (n=519) than Patel et al, and had 
higher numbers of patients undergoing intervention (n=30).  They concluded that in patients with 
CKD found to have significant CAD on angiography, medical therapy played an important role 
in future cardiac event free survival.  In addition, they reported that failure to perform a coronary 
intervention where indicated increases the risk of future cardiac events and death (de Lima, 
2010). 
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In view of the high risk for cardiovascular disease in renal transplant candidates, it is practice at 
Imperial Healthcare NHS Trust, to have a thorough approach to pre-transplant cardiac 
investigations with the use of invasive cardiac investigations and subsequent revascularization.  
The criteria for performing screening coronary angiography on potential transplant recipients 
includes: all patients over the age of 50 years; all patients with diabetes mellitus; all patients with 
cardiac symptoms or disease (irrespective of age); and all patients with an electrocardiogram 
showing changes suggestive of ischaemia or previous myocardial infarction (this included ST 
segment changes, left bundle branch block and other conduction abnormalities, diagnostic q 
wave changes in two contiguous leads, or deep T wave changes). 
 
1.8.2 US Guidelines 
The AST advocate pre-transplant cardiac assessment to be risk stratification driven, but 
acknowledge that renal failure per se is a cardiovascular risk factor and that all patients should 
receive risk factor modifications (Kassike, 2001).  The AST recommend functional non-invasive 
testing in high risk patients, followed by revascularization in the setting of a positive invasive 
test result (Kassike, 2001).  Of note K/DOQI recommend re-screening of dialysis patients 
according to risk every 1,2 or 3 years (Section 1.4).  Finally, the ACC/AHA provide guidance for 
evaluation prior to non-cardiac surgery, which is not directly relevant to this thesis.  A summary 
is seen in Table 3.   
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Organization and Target Population Recommendations 
American Society of Transplantation  
Kidney Transplant Candidates  
(Kassike, 2001) 
Clinical Practice Guidelines for the Evaluation of Renal 
Transplant Candidates 
 Assess CAD risk factors: age ≥45 years in men, ≥55 years 
in women, cigarette smoking, diabetes, hypertension, 
dyslipidaemia, left ventricular hypertrophy 
 Aggressive risk factor modifications for all candidates 
 “High risk patients”, defined as those with renal disease 
form diabetes, prior ischemia or ≥ 2 risk factors 
 Patients with positive stress tests should be studied by 
angiography for possible revascularization 
 Patients with critical coronary lesions should undergo 
revascularization prior to transplant. 
Kidney Disease Outcomes Quality 
Initiative (K/DOQI)  
Dialysis Patients on the Transplant 
Waitlist 
 (National Kidney Foundation, 2005) 
Clinical Practice Guidelines for Cardiovascular Disease in 
Dialysis Patients 
 Annual performance of non-invasive stress tests for dialysis 
patients on the kidney transplant waiting list who have 
diabetes, known coronary artery disease or ≥ 2 risk factors 
Table 3: Summary of Current Consensus-Based Guidelines for Preoperative Cardiac Evaluation 
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1.9 Coronary Artery Disease Intervention 
The purpose of CAD intervention is to restore blood flow to an ischaemic area of myocardium. 
Revascularization procedures will not alter the pathophysiological processes involved in CAD, 
but serve as a solution to improve blood flow and prevent myocardial infarction, whether by 
surgical means, or percutaneously with the use of stenting. 
The best method of revascularization procedure for patients with ESRD is still to be established, 
mainly due to the lack of randomized control trials that are plentiful in the general population.  
For the few studies reported, the data is limited by small numbers, problems with controlling 
confounding factors, and selection bias in patients who undergo invasive procedures (Logar, 
2003).  However, the literature would support both surgical and percutaneous options as 
effective in symptomatic disease, and until further data emerge, there is little choice but to follow 
standard criteria for this highly unique cohort of patients.  CABG complication rates of up to 
10% are higher in ERSD patients then the general population (Cooper, 2006), however it is still 
the treatment of choice for patients with multi vessel disease and LV dysfunction, with both 
symptomatic and prognostic benefit. 
Manske investigated the strategy of pre-transplant coronary revascularization before renal 
transplantation in diabetics with CKD in the 1990s (Manske, 1992).  This study is still 
extensively quoted, not just for its findings but also for the rarity of the study design; a RCT in 
ESRD patients was, and still is a virtually unheard of occurrence.  In reality this study has major 
inherent weaknesses, namely that the numbers were small, and the then medical treatment 
options have now been superseded (Manske, 1992).  Furthermore, this study does not take into 
account newer revascularization techniques available in the modern era and it included only 
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diabetic patients, and therefore does not provide any guidance as to whether or not non-diabetic 
transplant candidates should undergo intervention to significant coronary artery lesions. 
In the following section I will review the current best evidence base for coronary intervention in 
the ESRD population; the extensive literature for the non-ESRD population is not applicable to 
this study. 
 
1.9.1 Surgical revascularization 
The increased mortality following CABG in the CKD population compared with the non-CKD 
population is well recognized (Cooper 2006; Holzmann, 2005; Lok, 2004).  15,550 patients were 
included in the Northern New England Cardiovascular Disease Study, and subgroup data 
analysis was performed on 279 dialysis patients undergoing CABG (Lui, 2000).  The authors 
reported greater numbers of co-morbidities in the ESRD population compared to the non-CKD 
population and found that patients with ESRD were more likely to encounter in-hospital 
mortality (OR 4.4, CI 3.0-6.4; p<0.001) (Lui, 2000). From the same cohort of patients, 5-year 
survival after CABG in the non-CKD population was 83.5%, compared with 55.5% in the ESRD 
population (Dacey, 2002).  There is data which supports the theory that estimated GFR is an 
independent predictor of mortality in patients undergoing CABG (Hillis, 2006). 
A significantly larger number of 14306 dialysis patients undergoing their first revascularization 
procedure were included in the URSDS data analysis, which reported in hospital death rates in 
patients undergoing CABG at12.5% (Herzog, 1999).   
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1.9.2 Percutaneous Intervention (PCI) 
Much of the original CKD/ESRD and coronary revascularization data was during the era prior to 
stenting, and is now less relevant to modern practice.  From the point of view of CKD patients 
undergoing PCI, the findings are not dissimilar to those undergoing CABG, i.e. there is greater 
mortality and morbidity than in the general population.  One of the reported reasons for this is a 
higher risk of re-stenosis requiring target vessel revascularization in the CKD population (Naidu, 
2003; Ting, 2001). 
Within the CKD population, as drug eluting stent availability has become more pronounced there 
has been a shift in focus within the literature towards DES use, compared to BMS use. A 
subgroup analysis of a randomized control trial comparing slow-release paclitaxel-eluting stents 
compared with bare metal stents demonstrated a reduction in re-stenosis and target vessel 
revascularization (Halkin, 2005).   
In the dialysis population no randomized controlled trial data exists, however there is a meta-
analysis of clinical outcomes for dialysis patients following DES (Abdel-Latif, 2010).  The data 
included 869 patients from 7 different studies, and reported a good safety profile, with a 
significant reduction in target lesion revascularization and target vessel revascularization.  
However, in terms of overall outcome, the use of DES in dialysis patients did not significantly 
reduce death from all causes or myocardial infarction rates.  In conclusion the authors felt that a 
RCT was now required to formally assess the impact of DES in the ESRD population. 
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1.9.3 PCI v CABG 
Interestingly there are more studies in the dialysis population than the CKD population when 
comparing PCI with CABG. In the CKD population, one of the largest studies reported no 
survival benefits for CABG over PCI (Hemmelgarn, 2004).  
Once again the URSDS data provides us with the largest and most up to date cohort studies in 
dialysis patients. Appreciative of the potential benefits of stenting over balloon angioplasty, data 
was re-analysed to compare 4836 dialysis patients who have had balloon angioplasties, 4280 
dialysis patients who were treated with stenting, and 6668 that were treated with CABG. The 
outcomes confirmed the hypothesis that angioplasty alone in the ESRD population is 
complicated by high re-stenosis rates (Schoebel, 1997), and showed that in comparative terms 
stents reduced the re-stenosis rates.  Patients who went down the surgical revascularization route 
had even lower rates of repeat revascularization procedures (Herzog, 2002). 
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1.10 Non-invasive markers of cardiovascular disease 
A significant proportion of both traditional and novel cardiac risk factors will have some bearing 
on the vessel wall itself and examining various features of a vessel wall is therefore an 
opportunity to assess the progressive nature of cardiovascular disease without having to subject 
patients to invasive tests.  A variety of non-invasive tests that correlate with cardiovascular 
outcomes have surfaced over the years and this section focuses on some of those with an 
evidence base to support their use in dialysis patients. Three of the four techniques discussed are 
directly related to characteristics of the vessel wall. 
 At the time of writing, the imaging modalities discussed are currently only being utilised as 
predictive tools when carrying out cardiac risk stratification.  In the future the mechanisms 
linking modifiable factors to these non-invasive tests should provide target points for therapeutic 
intervention resulting in a reduction in cardiovascular mortality. 
 
1.10.1 Carotid intimal media thickness [CIMT] 
The process of CIMT measurements involves using ultrasonography to assess the severity of 
atherosclerosis in the internal carotid artery (O’Leary, 1999). CIMT measurements are taken 
from the edge of the lumen-intima to the border of the media-adventitia in a vessel (Figure 6). It 
is considered standard practice to measure CIMT 1 cm proximal to the carotid bulb in order to 
maintain consistency of the procedure.  The major strengths of CIMT, other than its predictive 
value which is discussed below, is that it is an inexpensive, non-invasive quantitative measure of 
sub-clinical atherosclerosis and is easy and quick to perform serially (O’Leary, 2002).  
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Hypertrophy of the carotid medial layer may also cause increased CIMT and this has given rise 
to the suggestion that carotid plaque may be a more accurate marker of atherosclerotic vascular 
risk (Spence, 2004).  
 
Figure 6: B-mode ultrasound of distal common carotid artery demonstrating measurement of CIMT as distance 
from lumen-intima (leading edge 1) to media-adventitia (leading edge 2). A, Normal CIMT; B, increased CIMT. 
 
CIMT measurements in the general population have been shown to increase with age, correlate 
with prevalent cardiovascular disease and are strong independent predictors of cardiovascular 
events (Burke, 1995; O’Leary 1999; Hodis, 1998). CIMT measurements have also been analysed 
in dialysis patients. Blacher et al demonstrated a definite relationship between increased CIMT 
thickness and increased risk of all cause and cardiovascular mortality (Blacher, 1998). Perhaps 
the most frequently referred to study in the dialysis population was reported by Kato et al which 
found that a 0.1mm increment in CIMT in asymptomatic dialysis patients was associated with a 
41% increase in cardiovascular mortality (Kato, 2003). Preston et al found the CIMT 
measurements in CKD patients were predictive of cardiovascular events, and reported no 
correlation with increased CIMT and traditional risk factors such as smoking or diabetes 
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(Preston, 2005). This lack of correlation with traditional cardiac risk factors was also seen in 
dialysis patients, however CIMT did correlate with age and total cholesterol (Kato, 2003). Other 
findings include a correlation with increased CIMT and cumulative dialysis time, raised serum 
calcium-phosphorus product and CRP (Oh, 2002; Szeto, 2007).  
 
1.10.2  Aortic pulse wave velocity [PWV] 
Aortic PWV can be measured by various imaging modalities including MRI, echo tracking, 
peripheral artery tonometry and pulse recognition algorithms (Deloach, 2008).  Aortic PWV is 
calculated by dividing the distance that a pulse waveform travels within the aorta by the time it 
takes to cover that distance (Safar, 2006) (Figure 7).  PWV measurements have been shown to 
correlate with aortic stiffness that in itself is an independent risk factor for cardiovascular disease 
(Blacher, 1999).  In terms of absolute values, patients with aortic PWV above 10 m/s are 
considered to be in a high risk group for cardiovascular events (Wimmer, 2007). Application of 
aortic PWV measurements in clinical practice is still under consideration, as the “normal” 
reference has only recently been established (Arterial Stiffness Collaboration, 2010).   
In the CKD population, serial aortic PWV measurements are seen to increase proportionally to 
the loss of GFR (Taal, 2007). Ford et al studied 120 patients with CKD III/IV and demonstrated 
that patients with the greatest decline in their GFR (>25% loss of GFR or RRT) during the 12 
month follow-up had higher aortic PWV measurements compared with aortic PWV 
measurements in those patients with a slower decline in GFR (13.9±4.2m/s v12.3 +/- 2.2 m/s, 
p=0.05) (Ford, 2010). 
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Figure 7: Principle of arterial stiffness measurement by pulse wave velocity with the foot-to-foot method with 
L=distance and t=time. 
 
Dialysis patients were involved in some of the early aortic PWV studies, which showed PWV to 
be a risk factor for cardiovascular death and non-fatal cardiac events independent of systolic BP 
(Blacher, 1999; Shoji, 2001).  Guerin et al used aortic PWV to study 150 dialysis patients and 
demonstrated the clinical implications of serial PWV measurements; an increase over time of 
PWV was associated with death, and a decrease in PWV measurements over time reflected 
improvement in blood pressure control (Guerin, 2001).  Aortic PWV may therefore be 
considered a useful marker of treatment efficacy. 
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1.10.3 Calcium Scoring and Electron Beam Computed Tomography [EBCT] 
EBCT is a non-invasive imaging tool, which is used to produce a coronary artery calcium score 
[CAC]. When EBCT was first launched in the 1980s as a potential screening tool to look for 
early CAD in asymptomatic patients, it was hoped that it would revolutionise the market of non-
invasive imaging modalities and promote risk factor modification.  In reality, it wasn’t until the 
1990s that any real interest in CAC scoring developed, and EBCT was re-introduced.  However, 
this time around it was promoted as a potential surrogate marker for cardiovascular mortality 
(Arad, 1996) on the basis of evidence that CAC score correlated both with the degree of 
atherosclerosis on autopsy, and the degree of CAD on conventional coronary angiography 
(Rumberger, 1994; Breen, 1992; Kaufmann, 1995).  Thirty years on researchers have reported 
that the burden of CAC has been shown to be a more accurate predictor of cardiovascular risk 
compared to the Framingham score in asymptomatic patients without kidney disease (Budoff, 
2007). Of note, EBCT systems have widely been replaced with multi-detector CT [MDCT] 
systems, but the majority of the research in this field relates to EBCT. 
One of the reasons such controversy surrounded EBCT in the general population is the lack of 
consistent results in the literature.  Interestingly, there are studies which have been unable to 
demonstrate a relationship between other recognised predictors of cardiovascular risk such as 
CRP or Lipoprotein(a) levels, and CAC scores measured by EBCT (Redberg, 2000; Nishino, 
2000).  One theory for this lack of correlation is that calcification may be a distinct process that 
occurs independently from the inflammatory mechanisms responsible for CAD (Redberg, 2000).  
For dialysis patients the situation with regards to CAC scoring is complex due to the extensive 
calcification which occurs as a by product of poor calcium/phosphate control; in fact one study 
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found evidence of CAC in >83% of the 205 participants (Raggi, 2002), and another study has 
shown that a CAC score greater than 400 was found in 69% of PD patients (Baig, 2009).  When 
comparing coronary angiographic disease severity with CAC score in dialysis patients there was 
not enough evidence to demonstrate an association (Tong, 2008).  This may relate to the site of 
calcification, with the calcification in the non-ESRD patients occurring in the vascular intima, 
compared to calcification in the vascular media (Shroff, 2008).  The current opinion is that the 
diagnostic value of EBCT in the dialysis population is unknown (Greenland, 2007). 
 
1.10.4 Left Ventricular Mass [LVM] 
LVM can be measured with various imaging modalities including 2D echocardiography, 3D 
echocardiography and cardiac MRI.  LVM is calculated from multiplying estimated myocardial 
volume by a theoretical myocardial density of 1.05g/ml, and needs to normalized for body size 
(Chirinos, 2010).  
Given that 2D echocardiography is so readily available and relatively low cost it has become the 
imaging technique most commonly used for measuring LVM.  However, due to the inaccuracies 
of 2D echocardiography in terms of the restricted acoustic window affecting views in some 
individuals, and foreshortening of the ventricle in its long axis, the results generated are often 
underestimates of LVM (Rubin, 2011).  The lack of reproducibility of 2D echo measurements of 
LVM has significant bearing on its use in clinical trials, and has been shown to be inferior to 3D 
echocardiography, with MRI being the gold standard in terms of reproducibility and image 
acquisition (Jacobs, 2006; Myerson, 2002).  The benefit of MRI, in addition to its advantages 
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already described, include the potential for looking for myocardial fibrosis, which has been 
discussed in Section 1.4.2. 
A number of studies have demonstrated that LVM is strongly predictive of cardiovascular 
mortality in patients with hypertension (Koren, 1991), in patients in the general population 
independent of traditional risk factors (Levy, 1990), and in the dialysis population (Silberberg, 
1989; Zoccali, 2001).  LVM is also considered a useful surrogate end point for therapeutic 
interventions as it has been shown to decrease in response to treatment, most notably in the 
Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study (Wachtell, 2007).  
 
 
 
 
 
 
 
 
 
 
 91 
1.11 Summary 
The pathophysiological processes involved in the development of cardiovascular disease in 
patients with all degrees of chronic kidney disease are complex.  As discussed above, patients 
with end stage renal disease have a high prevalence of traditional and non-traditional 
cardiovascular disease risk factors. It is also known that inflammation and endothelial 
dysfunction play major roles in the development atherosclerosis, which can be seen as an 
accelerated process in patients with renal failure.  
Whilst it is appreciated that there is a diverse spectrum of cardiovascular disease that can cause 
significant mortality and morbidity for patients with end stage renal disease, the majority of this 
work focuses on the progression of coronary artery disease diagnosed by coronary angiography.  
However, before recruiting patients to a clinical study that involved performing an invasive 
procedure it was important to be certain that the safety profile of a coronary angiogram is 
acceptable to patients. In this thesis I have addressed one aspect of safety relating to coronary 
angiography, and examined the effect of radio-iodinated contrast on the glomerular filtration rate 
of patients with advanced stages of chronic kidney disease. 
With the position on safety addressed, the work that follows aims to examine various aspects 
relating to the prevention, diagnosis and management of coronary artery disease in patients with 
end stage renal disease. For the general population there are guidelines for managing coronary 
artery disease, however, clear consensus guidelines such as those for the general population are 
lacking for patients with end stage renal disease. A greater understanding of risk factor 
management and optimal treatment strategies for coronary artery disease in this group of patients 
in needed, given the mortality and morbidity that cardiovascular disease presents. 
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In view of the important role of inflammation in coronary artery disease, one of the focuses of 
this work is on the role of chemokines in coronary artery disease in patients with end stage renal 
disease. By measuring CCL15, CCL18 and MCP-1 in asymptomatic patients with interval 
coronary angiograms, this work examines whether an association between certain chemokines 
and progressive coronary artery disease exists.  This work also examines if the selected 
chemokines can predict future cardiac events. In addition, using non-invasive investigations such 
as measuring carotid artery intima media thickness is an appealing option. This work also 
examines the relationship between carotid intimal media thickness and progressive coronary 
artery disease.  
Another focus of this thesis was to develop a greater understanding of ethnicity as a risk factor 
for coronary artery disease in the end stage renal disease population.  The following work 
therefore examines levels of chemokines in different ethnic groups, and examines how ethnicity 
impacts on cardiovascular mortality and morbidity.  Finally, this work aims to examine if any 
therapeutic interventions can reduce the mortality and morbidity associated with coronary artery 
disease for patients with end stage renal disease,  focusing on revascularisation of 
angiographically significant coronary vessel lesions in both symptomatic and asymptomatic 
patients.   
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2.  MATERIALS & METHODS 
2.1 CLINICAL POPULATION 
2.1.1 Overview of the clinical population 
This work was carried out at the Imperial College Renal and Transplant Centre in London which 
serves an ethnically diverse population of approximately 3.5 million patients and performs 
approximately 170 kidney transplants are per annum. 
2.1.2 Description of the clinical population 
2 main population groups were studied. The first patient population group was examined in a 
retrospective study on the effect of contrast on the GFR of patients with advanced CKD (Section 
3.1). This group included all pre-dialysis patients seen in eight West London clinics between 
October 2004 and August 2007, n = 482. Seventy-six potential transplant recipients met the 
criteria for proceeding to CA (see Section 3.1.3), and 406 patients were excluded from the study 
group as they did not meet the criteria for referral for coronary angiography at this institution. 
The second population group was examined for the remainder of the work in this thesis. This 
group included all patients undergoing transplant assessment work up for the first time between 
Jan 2006 and Oct 2009, n=1304. 657 patients had coronary angiograms and 359 patients were 
assessed for inclusion into the chemokine and progression study, with 221 eligible patients 
approached to participate. 80 patients were recruited from those eligible, 70 proceeded with 
coronary angiography and 2 patients were omitted from scoring by the cardiologists. Therefore 
68 patients were included for final analysis. In addition, retrospective data analyses were 
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performed on the 657 patients with coronary angiograms, to examine the clinical outcomes of 
patients undergoing revascularisation and also to examine the influence of gender and ethnicity 
on overall and cardiovascular survival. 
2.1.3 Flow diagram of the clinical populations 
Figure 8a and 8b, show the diagrammatic summary of the 2 patient populations studied  
Figure 8a: Flow diagram to illustrate the patient population for Section 3.1 
482 pre-dialysis patients 
8 Satellite clinics 
Between Oct 2004 - Aug 2007 
76 patients 
Underwent coronary angiography 
Studied for the effect of contrast on GFR 
Section 3.1 
0 patients 
 required dialysis 
immediatley after 
contrast 
13 patients  
started dialysis 
 
40 patients  
remained dialysis 
independant 
22 patients  
pre-emptively 
trnasplantnted 
1 patient  
died 
 
406 patients excluded 
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Figure 8b: Flow diagram to illustrate the clinical population for Sections 3.2, 3.3 and 3.4
1304 patients 
assessed for renal 
transplantation 
Between Jan 2006 - Oct 2009 
657 patients 
Underwent coronary angiography 
657 patients  
retrospectively studied for  
Ethnicity study 
Section 3.4 
 
657 patients  
retrospectively studied for 
 Revascularisation study 
Section 3.3 
 
473 patients 
with angiographically 
non signifincant CAD 
184 patients 
with agiographically 
significant CAD 
164 patients 
 revasculrised 
16 patients  
declined 
revascularisation 
 
359 patients 
assessed for  
Chemokine and progression study 
Section 3.2 
 
138 patients 
 not eligible 
221 patients 
eligible 
80 patients 
recruited 
70 patients 
proceeded 
68 patients  
Angiograms scored by Cardiologists 
10  patients 
did not proceed 
647 patients excluded 
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2.2 SERUM SAMPLES 
10-20ml samples of whole blood were taken from patients and transported on ice to the 
laboratory where they were spun down in the centrifuge to separate serum from packed red cells 
at 3000rpm for 10mins.  Samples were then placed in 2ml vials and stored in -80 degrees Celcius 
(
◦
C) freezer.  Once removed from the -80
◦
C freezer the serum samples were allowed to warm to 
room temperature before incubation with the antibody described in Sections 2.6, 2.7 and 2.8. 
 
2.3 PREPARATION of REAGENTS 
The reagents used for CCL15, CCL18 and MCP-1 ELISAs are listed in Table 5.  
 
2.4 PREPARATION of ANTIBODIES 
Antibodies were obtained from R&D systems.  Preparation of capture, detection and standard 
antibody for CCL15, CCL18 and MCP-1 ELISAs are described in Table 4. All antibody stock 
solutions are aliquoted and stored at -80 
◦
C. 
 
2.5  CALCULATION OF RESULTS 
When calculating the results, an average of the duplicate optical density readings for each 
standard, control, and sample was calculated.  The average background optical density was then 
subtracted. A standard curve was created by plotting the mean corrected optical density for each 
standard on the y-axis against the log (standard concentration) on the x-axis and drawing a best 
fit curve through the points on the graph using Prism 5 software (GraphPad Software, San Diego, 
California, USA). GraphPad was also used to derive the log (sample concentration) from the 
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measured optical density using the standard curve. The sample concentration was then calculated 
from the derived log (sample concentration); if samples had been diluted, the concentration read 
from the standard curve was then multiplied by the dilution factor.  
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2.6 CCL 15 ELISA 
2.6.1 Plate preparation: 
For the CCL15 ELISA, 96 well plates were coated overnight with 100µl per well (µl/w) of anti-
human mouse monoclonal CCL15 capture antibody in PBS (22µl of stock solution diluted in 
11mls PBS to make a solution of 1µg/ml) and kept at 4°C.  The following morning plates were 
washed three times with washing solution (3x360µl) and blocked with blocking solution 
(300µl/well) and covered for 1 hr at room temperature.   
 
2.6.2 Assay Procedure: 
Standards were prepared with 5µl of CCL15 stock solution diluted in 12.5ml of Diluent (to give 
10000pg/ml concentration). 10 x 1.5ml tubes were pre-labelled with 5000, 2500, 1250, 625, 312, 
156, 78, 39, 19 and 0, and 500µl of Diluent were added to each tube. 500µl from standard was 
added to tube 5000 to create a top standard of 5000pg/ml. Serial dilutions were then made to 
create standards of decreasing concentration.  
 
Next the plates were washed with washing solution (3x360ul) and incubated with serum samples 
at 1:20 dilution (100µl/w) and standard (100µl/w) for 2 hrs. All standards and samples to be 
assayed were done in duplicate. The plates were washed again with washing solution (3x360ul), 
and then incubated with 100ul/w CCL15 detection antibody (11ul of stock solution diluted in 
11mls Diluent to make a solution of 50ng/ml) and covered for 2 hrs at room temperature.  
Washing was repeated (3x360ul) and Streptavidine added for 20 mins.  
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Substrate (3,3’,5,5’ tetramethylbenzidine (TMB, Cambridge Bioscience)) solution, which is 
removed from the fridge to reach room temperature 5 mins in advance, and is prepared by 
mixing 5.5ml of Solution A to 5.5ml of Solution B, was added (100ul/w) after washing 
Streptavidine.  Plates were covered and protected from direct sunlight for 5-20mins until the 
5000pg/ml standard became deep blue. The reaction was stopped with stopping solution (50ul/w) 
and the optical density was measured at 450 nm. 
 
 Capture Detection Standard 
CCL15 MAB363 500µg  
Biotinylated goat anti-
human MIP-1ä 
Reconstitute with PBS 1ml to 
make a stock solution of 
500µg/ml 
 
BAF363 50ug 
Biotinylated goat anti-
human MIP-1ä 
Reconstitute with 1ml Tris-
buffered saline pH 7.3(20mM 
Trizma base, 150mM NaCl) 
containing 0.1% BSA to give 
a stock solution of 50µg/ml 
 
363-MG-025  
Recombinant human MIP-
1ä 
Reconstitute with 1ml sterile 
PBS with 0.1% BSA to give a 
stock solution of 25µg/ml 
 
CCL18 500µg MAB394 
Reconstitute with PBS 1ml to 
give a stock concentration of 
500µg/ml 
 
50µg BAF394 
Reconstitute with 1ml Tris-
buffered saline pH 7.3(20mM 
Trizma base, 150mM NaCl) 
containing 0.1% BSA to give 
a stock solution of 50µg/ml 
 
10µg 394-PA 
Reconstitute with 0.4ml 
sterile PBS with 0.1% BSA to 
give a stock solution of 
25µg/ml 
 
MCP-1 500µg MAB679 
Reconstitute with PBS 1ml to 
make a stock solution of 
500µg/ml 
 
50µg BAF279 
Reconstitute with 1ml Tris-
buffered saline pH 7.3(20mM 
Trizma base, 150mM NaCl) 
containing 0.1% BSA to give 
a stock solution of 50µg/ml  
10µg 279-MC 
Reconstitute with 1ml sterile 
PBS with 0.1% BSA to give a 
stock solution of 10µg/ml 
 
Table 4: Details of stock solution preparation and reconstitution protocols 
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Reagent Contents 
PBS Sodium chloride (NaCl) 8.0g/L 
Potassium chloride (KCl) 0.2g/L 
Disodium hydrogen phosphate (Na2HPO4 2H2O ) 1.44g/L 
Potassium dihydrogen phosphate (KH2PO4) 0.2g/L 
Blocking solution PBS 200mls 
Sucrose 10g 
Bovine Serum Albumin (BSA) 4g 
Diluent H20 (Millipore) 500mls 
NaCl 4.4g 
Trisma base F.W.121.1 Sigma T-1503 1.2g 
Hydrogen Chloride (HCL) until pH 7.3 
BSA 0.5g 
Tween 20 0.25mls 
Substrate solution Color Reagent A (H2O2)  
Color Reagent B (Tetramethylbenzidine)  
Streptividine HRP PBS 20mls 
Streptividine 2ul 
Conjugated to horseradish peroxidase 
Stopping solution Sulphuric Acid (H2SO4) 10mls 
Water (H20) 90mls 
Wash Buffer (pH 7.4) Tween 20 (0.05%) 500ul 
PBS 1000mls 
Table 5: Preparation of reagents used for CCL 15, CCL18 and MCP-1 ELISAs 
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2.7 CCL 18 ELISA 
2.7.1 Plate preparation: 
For the CCL18 ELISA, 96 well plates were coated overnight with 100ul/w of anti-human mouse 
monoclonal CCL18 capture antibody (22ul diluted in 11mls PBS to give a concentration of 
1µg/ml) and kept at 4°C.  The following morning plates were washed three times with washing 
solution (3x360ul) and blocked with blocking solution (300ul/w) and covered for 1 hr at room 
temperature.   
 
2.7.2 Assay Procedure: 
Standards were prepared with 5ul of stock CCL18 standard diluted in 12.5ml of Diluent (to give 
10000pg/ml concentration). 10 x 1.5ml tubes were pre-labelled with 5000, 2500, 1250, 625, 312, 
156, 78, 39, 19 and 0, and 500ul of Diluent were added to each tube. 500ul from standard was 
added to tube 5000 to create a top standard of 5000pg/ml. Serial dilutions were then made to 
create standards of decreasing concentration. 
 
Next the plates were washed with washing solution (3x360ul) and incubated with serum samples 
at a dilution of 1:200 (100ul/w) and standards (100ul/w) for 2 hrs. All standards and samples to 
be assayed were done in duplicate. The plates were washed again with washing solution 
(3x360ul), and then incubated with 100ul/w CCL18 detection antibody (22ul stock solution 
diluted in 11mls Diluent to give a concentration of 100ng/ml) and covered for 2 hrs at room 
temperature.  Washing was repeated (3x360ul) and Streptavidine added for 20 mins.  
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Substrate solution (prepared by adding 5.5ml of Solution A to 5.5ml of Solution B) that is 
removed from the fridge to reach room temperature 5 mins in advance was added (100ul/w) after 
washing Streptavidine.  Plates were covered and protected from direct sunlight for 5-20mins 
until the 5000pg/ml standard became deep blue. The reaction was stopped with stopping solution 
(50ul/w) and the optical density was measured at 450 nm. 
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2.8 MCP-1 ELISA 
2.8.1 Plate preparation: 
For the MCP-1 ELISA, well plates were coated overnight with 100ul/w of anti-human mouse 
monoclonal MCP-1 capture antibody (44ul of stock solution diluted in 11mls PBS to give a 
concentration of 2µg/ml) and kept at 4°C.  The following morning plates were washed three 
times with washing solution (3x360ul), blocked with blocking solution (300ul/w) and covered 
for 1 hr at room temperature. 
 
2.8.2 Assay procedure: 
Standards were prepared with 5ul of stock MCP-1 standard diluted in 5000ul of Diluent (to give 
10000pg/ml concentration). 11 x1.5 ml tubes were pre-labelled with 5000, 2500, 1250, 625, 312, 
156, 78, 39, 19, 9 and 0, and 500ul of Diluent were added to each tube. 500ul from standard was 
added to tube 5000, to create a top standard of 5000pg/ml. Serial dilutions were then made to 
create standards of decreasing concentration. The tube labelled “5000” is not used; leaving 10 
tubes labelled 2500 to 0. 
 
Next the plates were washed with washing solution (3x360ul) and incubated with serum samples 
(100ul/w) and standard diluted 1:2 with Diluent (100ul/w) for 2 hrs. All standards and samples to 
be assayed were done in duplicate. The plates were washed again with washing solution 
(3x360ul), and then incubated with 100ul/w MCP-1 detection antibody (22ul of stock solution 
diluted in 11mls Diluent to give a concentration of 100ng/ml) and covered for 2 hrs at room 
temperature.  Washing was repeated (3x360ul) and Streptavidine added for 20 mins.  
 104 
Substrate solution at room temperature (100ul/w) was added after washing Streptavidine.  Plates 
were covered and protected from direct sunlight for 5-20mins until the 2500pg/ml standard 
became deep blue. The reaction was stopped with stopping solution (50ul/w) and the optical 
density was measured at 450 nm.  
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2.9 CIMT Measurements 
Assessments of CIMT were carried out with high resolution B-mode ultrasonography (Toshiba 
Aplio XG ultrasound) system in conjunction with a 7.5MHz linear transducer (Toshiba Medical 
System Corporation, Japan).  This ultrasound system allowed adjustment of the central frequency 
of ultrasound beam, and the highest available frequency setting was selected for the study.  The 
focal zone was set at the depth of the far wall of the CCA. The overall gain was adjusted for each 
subject to give the best visualization of the blood–intima and media–adventitia interfaces. The 
time gain compensation was set linearly from the lower value at superficial tissues depth to the 
higher value at the maximum scanning depth.  
 The patient was asked to lie supine on the examination table for 10 minutes. This allowed the 
CIMT to be measured in resting conditions, avoiding vigorous pulsation of the carotid arteries. 
With the patient’s neck slightly extended and turned away from the side under examination, the 
left and right CCA were examined in longitudinal scans. The CCA segment proximal to the 
carotid bulb was assessed, and the transducer was slightly angled medially or laterally and 
rotated clockwise or counter clockwise until a scan plane, which clearly demonstrated blood–
intima and media–adventitia interfaces on the far wall was obtained. For each CCA, longitudinal 
ultrasound image with optimal visualization of these interfaces was taken. CIMT were measured 
at the far wall of the artery, five measurements were taken at 0.5cm intervals along the common 
carotid artery moving proximally from the bifurcation, on both right and left sides. CIMT was 
defined as the distance between the blood–intima and the media–adventitia interfaces (Salonen 
and Salonen, 1991).  Areas of the CCA with plaque disease were not measured. For each carotid 
artery, the mean value of the CIMT was calculated from the five measurements. 
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A CIMT measurement >1.0mm was considered to be an abnormal finding (Kanters, 1997). 
Specific software has been developed for automatic CIMT measurements that is intended to 
reduce the inter-user variability of direct visualisation, however despite the software being able 
to generate the mean of over 100 reading s in a short time, the results obtained are no more 
accurate than manual measurements (Loizou CP, 2007).  In this study all CIMT measurements 
were performed on a magnified image, using the inbuilt electronic calipers.  All scans were 
performed in the vascular laboratory, 2
nd
 Floor, A block, Hammersmith Hospital. All 
examinations were performed by a single operator (Dr Mo Aslam), who has formal qualifications 
in vascular diagnostic procedures. 
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2.10 Coronary angiography 
Coronary angiograms can be carried out specifically for the assessment of the right side or the 
left side of the heart. Left heart catheterization includes measurement of aortic and left 
ventricular pressures, selective coronary angiography and a left ventricular angiogram. In order 
to perform a left ventriculogram, contrast is injected into the left ventricle allowing visualization 
of the endocardial borders.  If the patient has had prior coronary bypass surgery, angiograms of 
the vascular grafts are also obtained. When assessing pulmonary hypertension a right heart 
catheterization is performed.  For the potential renal transplant recipient patient, practice at 
Imperial Healthcare NHS Trust is to perform only a left heart catheterisation unless there is 
specific indication for a right heart study.  Ventriculograms are avoided where possible to reduce 
the contrast volume and instead of a ventriculogram standard echocardiography is used to assess 
LV function. 
Prior to entering the cardiac catheterization suite, the risks and benefits of the procedure are 
discussed with the patient and written consent obtained.  Practice at Imperial Healthcare NHS 
Trust is to quote a risk of a major complication of 0.1% although the data shown in Table 6 
reports that the actual risk is less than this (Olade, 2012). In the end stage renal failure population 
the risk-benefit balance is not well established, so standard risks are extrapolated with the added 
caveat that patients with diabetes and patients with end stage renal failure have a greater risk of 
vascular complications. Contrast nephropathy has been discussed in an earlier section.  All 
coronary angiograms in this study were performed using (Toshiba INFX radiographic 
equipment), and were carried out in the cardiac day ward at Hammersmith Hospital. The 
angiograms were performed by an operator with formal training in cardiac catheterisation under 
the supervision of Dr Christopher S R Baker (Consultant Cardiologist). 
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Table 6: Complications of cardiac catheterisation, adapted from (Olade, 2012) 
 
 
 
Complication Incidence/comment 
Contrast Allergy Approximately 1% of the population will be allergic to iodinated 
contrast agents. This reaction is an anaphylactoid reaction; it 
occurs as a consequence of direct complement activation.  Patients 
may report urticarial rash, angioedema, bronchospasm and 
hypotension. 
Congestive Cardiac Failure Contrast has an osmotic effect and can trigger an episode of 
congestive heart failure, particularly in patients with marginal LVF. 
Chest Pain The current risk rate for procedure-related myocardial infarction is 
<0.03%. The vasodilator effect of the contrast can trigger mild 
chest discomfort and occasionally myocardial ischemia with ST-
segment changes may occur.  
Arrhythmia Arrhythmias can vary from minor abnormalities such as atrial or 
ventricular premature beats, and non-sustained runs of 
supraventricular tachycardia. Ventricular tachycardia or 
fibrillation is a rare (incidence of 0.4%) and requires prompt 
defibrillation. Arrhythmias may be provoked by the catheter itself or 
by the injection of contrast directly into a coronary artery. 
Bradycardia tends to occur following injection of high osmolar 
contrast into the right coronary artery. 
Vascular damage Vascular damage is one of the most frequently occurring 
complications of CA. At the site of insertion, the vessel can be 
damage by acute thrombosis with or without distal embolization.  It 
is also possible to cause vessel dissection, formation of a pseudo 
aneurysm, and retroperitoneal bleeding.  A late complication is 
formation of arterio-venous fistula. 
Infection The American College of Cardiology/American Heart Association 
reports a greater risk for infection from the brachial approach 
compared to the femoral approach (0.62% v 0.06%).  
Stroke The procedure-related stroke rate is currently approximately 
0.06%.  The symptoms may occur hours after the procedure. High-
osmolar contrast agents in the carotid arteries may cause transient 
neurological deficits. 
Death Incidence of procedure related death is 0.08%.  A high-risk 
subgroup included NYHA Class IV, Age >60, CKD, Diabetes, PVD, 
CVD, valvular heart disease. 
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Throughout the procedure basic observations of blood pressure, pulse and oxygen saturations are 
recorded.  The patient is positioned supine on the table.  An image intensifier and camera are 
sited over the patient’s chest with the x-ray source tube directly below the patient. The camera 
can be manoeuvred to create various views.  In this study biplane angiography was the preferred 
method of angiography.  With biplane imaging two X-ray tubes are used to acquire two 
simultaneous image projections with a single contrast injection. Biplane angiography is the 
preferred option for patients with renal failure, as its major advantages include firstly producing 
images from 2 view points, which enables the operator to gain more information on complex 
coronary anatomy, and secondly a reduction in the overall contrast volume used and radiation 
exposure for the patients (Sterner, 2001). 
The access site in the majority of cases is via the femoral artery approach in the groin. It is also 
possible to perform the study via the brachial or radial artery in the upper limb in circumstances 
such as poor peripheral access. The access site is cleaned with antibacterial solution and covered 
with surgical drapes. The groin is then infiltrated with 1% lidocaine solution. The common 
femoral artery puncture was first utilized by Judkins, and is often referred to as the Judkins 
technique.  A curved tip guidewire is inserted via an introducer needle in the femoral artery and 
guided to the ascending aorta using fluoroscopy. Puncturing the artery too low and accessing the 
arterial system via a bifurcation branch of the common femoral artery may increase 
complications of pseudo-aneurysm and femoral artery thrombosis. A puncture involving the 
bifurcation increases the risk of requirement for surgical repair and finally, retroperitoneal 
bleeding can complicate a high approach, because it becomes difficult to achieve adequate 
compression when there is no bony structure behind the point of access.  
 
 110 
A vascular access sheath is placed into the artery over the guidewire, and the size of the sheath 
depends on the size of the catheter used. Through the sheath and over the guidewire, a Judkins 
catheter, usually between 5-7 French gauge is directed, with the use of video fluoroscopy to the 
ostium of the coronary artery. Once in position, 1-2mls of contrast is injected via the catheter to 
cause opacification of the coronary arteries. At this stage equipment positioning is established to 
obtain optimal views.  Pressure is measured at the tip of the catheter to ensure that the catheter 
tip is not against the wall of the artery.  If the procedure were to continue at high pressure, there 
is an increased risk of vessel dissection when the contrasted is forced into the artery. Angiograms 
are obtained while injecting an iodinated contrast material through the catheter.  
 
2.10.1 SYNTAX Score 
The SYNTAX score became accepted as an effective coronary artery disease scoring tool, 
following the SYNTAX trial (Sianos, 2005) which enlisted patients with complex CAD 
including LMS and 3VD and examined the outcome data following both revascularization 
percutaneously with DES and revascularization surgically with coronary artery by pass grafting.  
The higher the SYNTAX scores the greater the complexity of CAD, and in the SYNTAX trial 
the scores were divided into a low (score <18), intermediate (score 18-27) and high (score >27) 
risk categories. The SYNTAX trial demonstrated there was a significant difference in mortality 
in patients with a high SYNTAX score depending on the revascularization technique used; 
CABG surgery was shown to be superior to PCI in patients with SYNTAX scores >32.  It also 
showed that PCI was equivalent to CABG in patients with low or intermediate SYNTAX scores 
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(Sianos, 2005). These results suggested that the SYNTAX score might be employed to assist 
with choosing the most appropriate revascularization strategy.  
 
Figure 9: The coronary tree is divided into 16 segments according to the AHA classification 
 
The SYNTAX score has since been validated in subsequent studies which recruited moderate 
numbers of patients including the ARTS II trail (Serruys, 2010) which had 607 patients 
undergoing revascularisation, and a study of 255 patients all with LMS disease undergoing PCI 
(Capodanno, 2009), and was again shown to be predictive of cardiac events and cardiac 
mortality. 
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Various features of the coronary vasculature on angiography are graded when formulating a 
SYNTAX score, which were based on a number of elements from other studies including the 
AHA classification of coronary artery tree segments modified for the ARTS study (Serruys, 
1999), the Leaman score (Leaman, 1981), the ACC/AHA lesion classification system, the total 
occlusion classification system, a combination of the Duke and International Classification for 
Patient Safety (ICPS) classification system for bifurcation lesions and a consensus opinion from 
a number of world experts in the field of cardiology.  
The coronary tree is divided into 16 segments according to the AHA classification (Figure 9), 
and the SYNTAX score is the sum of the points allocated to each individual lesion identified in 
the coronary tree. Essentially the SYNTAX score covers the number of lesions, the location of 
the lesion, the presentation of total occlusion, bifurcations, aorto-ostial stenosis, tortuosity, lesion 
length, calcification, thrombus and diffuse disease.  Allocation of points can be seen summarized 
in Table 7 and 8 below. 
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Segment No Right Dominance Left Dominance 
1 RCA proximal 
2 RCA mid 
3 RCA Distal 
1 
1 
1 
0 
0 
0 
4 Posterior descending 1 n/a 
16 Posterolateral branch from RCA 
 16a Posterolateral branch from RCA 
 16b Posterolateral branch from RCA 
 16c Posterolateral branch from RCA 
0.5 
0.5 
0.5 
0.5 
n/a 
n/a 
n/a 
n/a 
5 Left main 5 6 
6 LAD proximal 
7 LAD mid 
8 LAD apical 
3.5 
2.5 
1 
3.5 
2.5 
1 
9 First diagonal 
9a   First diagonal 
1 
1 
1 
1 
10 Second diagonal 
10a Second diagonal 
0.5 
0.5 
0.5 
0.5 
11 Proximal circumflex artery 1.5 2.5 
12 Intermediate artery 
12a Obtuse marginal 
12b Obtuse marginal 
1 
1 
1 
1 
1 
1 
13 Distal circumflex artery 0.5 1.5 
14 Left posterolateral artery 
14a Left posterolateral artery 
14b Left posterolateral artery 
0.5 
0.5 
0.5 
1 
1 
1 
15 Posterior descending n/a 1 
Table 7:  SYNTAX score: Segment weighting factors 
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Characteristic Score 
Diameter reduction* 
Total occlusion 
Significant reduction 
 
X5 
X2 
Total Occlusions (TO) 
>3 months or unknown 
Blunt stump 
Bridging 
1
st
 segment visible beyond TO 
Side branch (SB)  
SB Yes <1.5mm** 
SB Both < and > 1.5mm 
 
+1 
+1 
+1 
+1 
 
+1 
+1 
Trifurcations 
1 diseased segment 
2 diseased segments 
3 diseased segments 
4 diseased segments 
 
+3 
+4 
+5 
+6 
Bifurcations 
Type A, B, C 
Type D, E, F, G 
Angulation <70% 
 
+1 
+2 
+1 
Other 
Aorto ostial stenosis 
Severe tortuosity 
Length >20mm 
Heavy calcification 
Thrombus 
Diffuse disease 
 
+1 
+2 
+2 
+2 
+1 
+1 per segment 
X: Multiplication. +: Addition. *In the SYNTAX algorithm there is no question for 
% luminal diameter reduction.  The lesions are considered significant (50-99%) 
luminal diameter reduction or occlusive.  ** If all the side branches are <1.5mm in 
diameter, no points are added since the lesion is considered as a bifurcation and 
will be scored as such. 
Table 8: SYNTAX score: Lesions adverse characteristic scoring 
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2.11 Ethics 
Ethical approval was formally granted in Jan 2009 (REC reference 08/H0711/111) by the 
Charing Cross Research Ethics Committee (Room 4W/12, 4th Floor Charing Cross Hospital, 
Fulham Palace Road, London, W6 8RF). The ethics application and letter of approval is included 
in Appendix 1. 
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2.12 Statistical analysis 
For the data examining the non-invasive markers of atherosclerosis, all data were normally 
distributed and expressed as means ± SDs except where stated, which includes the chemokine 
data expressed as mean (SEM).  Regression with interpolation was used to determine chemokine 
levels from ELISA results.  Unpaired t test for continuous variable samples was used to test for 
significant differences. P value less than 0·050 were considered significant. When examining 
two variables the non-parametric Spearman correlation coefficient was used and results 
displayed both in numerical and graphic format.  Statistical analysis was conducted using Prism 
5 (GraphPad Software, San Diego, California, USA).  
For the data examining the effect of elective coronary angiography on glomerular filtration rate 
in patients with advanced chronic kidney disease, dialysis- and transplant-free survival was 
analysed using the Kaplan Meier analysis performed using SPSS Version 16.0. Dialysis-free 
survival is censored for transplantation or death. All numeric values are expressed as mean ± 1 
SD unless stated otherwise. MDRD GFR pre and post-angiography and contrast volumes in the 
setting of biplane versus monoplane angiography were analysed using the paired t test. Results 
with a P value less than 0.05 were considered significant. 
For the data examining cardiac survival after pre-emptive coronary angiography in transplant 
patients and those awaiting transplantation, continuous variables are expressed as means ± SDs 
except where stated. The differences between groups were analysed using chi-squared tests and 
ANOVA as appropriate. Event-free survival was estimated by the Kaplan-Meier method, with 
the effect of angiographic finding on outcome assessed using the Weibull proportional hazards 
model. Results with a P value less than 0.05 were considered significant. Statistical analyses 
were performed using Stata version 10 (StataCorp LP, College Station, TX). 
 117 
For the data examining the influence of ethnicity and gender on the severity of coronary artery 
disease in potential renal transplant recipients, continuous variables are expressed as means ± 
SDs except where stated.  The differences between groups were analysed using chi-squared tests 
and ANOVA as appropriate with Fisher’s test used for analysing groups with small numbers. 
Event-free survival and overall survival was estimated by the Kaplan-Meier method using the 
log-rank (Mantel-Cox) test to compare differences between groups. A Cox regression analysis 
was used to calculate Exp(B) when comparing unmatched groups. Results with a P value less 
than 0.05 were considered significant. Statistical analysis was conducted using Prism 5 
(GraphPad Software, San Diego, California, USA).  
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3 RESULTS  
3.1 Effect of Elective Coronary Angiography on GFR in Patients with Advanced CKD 
3.1.1 Objectives 
The purpose of this study was to establish the risk of contrast nephropathy to patients with 
advanced CKD (stages IV or V) who undergo elective and timely screening coronary 
angiography, and to determine whether or not pre-emptive transplantation is achievable. 
 
3.1.2 Patient Population 
This retrospective analysis included all pre-dialysis patients seen in eight West London clinics 
between October 2004 and August 2007, n =482. This patient population group has been 
outlined in the Sections 2.1.1 and 2.1.2. Seventy-six potential transplant recipients met the 
criteria for proceeding to CA (see Section 3.1.3), which was performed at two hospital sites 
within the same institution. Patients on dialysis undergoing cardiac assessment before 
transplantation were excluded. All patients were seen by a consultant cardiologist before 
angiography and the risks of the procedure, including contrast induced nephropathy (CIN), were 
explained. More than one cardiologist was involved, but practice was consistent according to 
local protocol and national guidelines. 
 
3.1.3 Screening Criteria 
Criteria at this institution for performing screening coronary angiography (CA) on potential 
transplant recipients include all patients over the age of 50 years (yrs), all patients with diabetes 
mellitus, all patients with cardiac symptoms or disease (irrespective of age), and all patients with 
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an electrocardiogram showing changes suggestive of ischemia or previous myocardial infarction; 
this included ST segment changes, left bundle branch block and other conduction abnormalities, 
diagnostic q wave changes in two contiguous leads, or  deep T wave changes. All patients in this 
study were seen by one of two consultant cardiologists in a dedicated cardio-renal clinic before 
angiography.  
 
3.1.4 Reno-protection 
Reno-protection in the form of adequate hydration, 0.9% saline 500mls at least 2 h before and 2 
h after the procedure, and oral N-Acetylcysteine 600mg twice daily at day -1, 0, and +1 was 
administered in all cases. All potentially nephrotoxic drugs were withheld 24 h before the 
angiogram, and recommenced 48 h later, if not contraindicated. Seventy-four of 76 (97.4%) 
patients received Visipaque® contrast media, the remaining two of 76 (2.6%) received 
Omnipaque® contrast media. 
 
3.1.5 Statistical Analyses 
Simplified Modification of Diet in Renal Disease (MDRD) GFR results were generated from 
serum creatinine at time points pre- and post-coronary angiography and slopes were derived 
from mean values.  Data on weight change during the follow up were not included, and it is 
acknowledged that this imposes limitations when interpreting serial eGFR data using the MDRD 
GFR method in this setting. 
Serum creatinine measurements were made on each visit to the clinic; frequency of visits varied 
between 2 to 12 wk depending on patient’s symptoms and the rate of progression of his or her 
CKD. Values were recorded if within 28d of 12, 9, 6, and 3 mo before and after the date of the 
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angiogram; if out with 28 days, no value was entered for analysis. By nature of this retrospective 
analysis of real-life care for patients who were not in a trial protocol, there were missing data 
points as a result of non-attendance in clinic at appropriate time point. For -12, -9, -6, -3, 0, +3, 
+6, +9, +12 month points data were absent in 17 of 76, ten of 76, five of 76, two of 76, 0 of 76, 
four of 68, five of 56, five of 40, and six of 38 patients at risk, respectively. Patients were also 
advised to have their serum creatinine checked once between 3 to 7 days after their angiogram; 
seven of 76 patients failed to attend for this investigation. 
 
3.1.6 Definitions 
A history of myocardial infarction (MI) was defined as present if the patient had 
electrocardiogram evidence of ST-elevation, MI previously, or if the patient had a documented 
acute presentation with cardiac symptoms, with associated troponin rise according to the 
reference range in the biochemistry laboratory at that time. A history of smoking was defined as 
present if the patient was a current smoker or if the patient was an ex-smoker of less than 5 yr. 
Flow-limiting CAD was defined as >50% stenosis of one or more dominant coronary vessels. 
Any atheromatous lesion <50% not requiring intervention was defined as non-flow limiting. 
Endpoints included remaining pre-dialysis, undergoing transplantation, commencing dialysis, 
and death. 
 
3.1.7 Demographics 
The clinical and demographic characteristics of the patients who met the criteria for proceeding 
to CA are outlined in Table 9. The male: female ratio was approximately 3:2, with a mean age of 
56.33±9.59 yr. The population was predominantly Caucasian, although 17 of 76 (22.4%) were 
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Indo-Asian, reflecting the diverse ethnicity of the population in West London. Thirty-three of 76 
(43.4%) of the patients were diabetic, with diabetic nephropathy being the most common cause 
of CKD in this group of patients. Only two of 76 (2.6%) had a history of previous MI. All 
patients were followed up for 12 mo following angiography, unless they reached a defined 
endpoint resulting in a mean follow up of 8.71 ± 4.0 mo. 
 
Demographics n=76 
Men 
Women 
49 (64.5%) 
27 (35.5%) 
Mean Age (years) 56.33 ± 9.59 
Caucasian 
South Asian 
Other ethnicity 
52 (68.4%) 
17 (22.4%) 
7   (9.2%) 
Diabetes  
Diabetic Nephropathy as cause of CKD 
Mean total cholesterol (mmol/l) 
History of previous MI  
History of smoking  
33 (43.4%) 
28 (36.8%) 
3.92±0.99 
2 (2.6%) 
17(22.4%) 
Flow-limiting coronary artery disease  
Non-flow limiting coronary artery disease 53 of 76 
23 (30.3%) 
53 (69.7%) 
Mean follow up (months)   8.71±4.0 
MI= Myocardial Infarction; SBP=Systolic blood pressure; DBP=Diastolic blood pressure 
Table 9: The clinical and demographic characteristics of the patients 
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3.1.8 Treatment 
 
Treatment Details Number 
Lipid lowering therapy 
 
Statin 
Fibrate 
Ezetimibe 
SHARP trial 
Total 
61/76 (80.3%) 
1/76 (1.3%) 
2/76 (2.6%) 
1/76 (1.3%) 
65/76 (85.5%) 
Angiography Monoplane 
Biplane 
30/76 (39.5%) 
46/76 (60.5%) 
Mean contrast volume (mls)  55.74 ± 50.18 
Revascularisation procedure Percutaneous [staged] 
Surgical 
Total 
11/76 (14.5%) 
10/76 (13.2%) 
23/76 (30.3%) 
CABG= Coronary artery by-pass graft 
Table 10: The treatment details 
 
Sixty-five of 76 (85.5%) patients received some form of lipid-lowering therapy; the majority of 
patients received statin monotherapy (80.3%). One of 76 (1.3%) patients was enrolled in the 
SHARP trial, and was blinded to treatment with either statin±ezetimibe, or statin alone. Thirty of 
76 (39.5%) of patients had monoplane angiography, with a mean contrast dose of 69.1mls, and 
46 of 76 (60.5%) patients had biplane angiography, with a mean contrast dose of 47.8mls (t test, 
P =0.07). All 23 patients with flow-limiting disease underwent revascularization; 10 of 23 
(43.5%) patients required coronary artery bypass grafting and 13 of 23 (56.5%) required 
percutaneous intervention. Eleven of 13 (84.6%) patients undergoing percutaneous 
revascularization had a staged procedure. The two patients that did not undergo staged 
procedures received a moderate contrast volume, between 60 to 80mls. Table 10 summarizes the 
treatment details. 
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3.1.9 eGFR Pre- and Post-angiography  
 
Figure 10: Modification of Diet in Renal Disease (MDRD) eGFR before and after coronary angiography 
 
 
 
Mean MDRD GFR at angiography was 12.46±3.41ml/min. Figure 10 demonstrates the trend in 
MDRD GFR, which was not significantly different 6 mo pre- and post-angiography (slope 
change in MDRD GFR -0.21 ±0.27 versus -0.21±0.30 ml/ min/mo [t test, P=0.42]).  
This figure also demonstrates the temporary decline in MDRD eGFR following administration of 
contrast media from a mean MDRD GFR of 12.46±3.41ml/min to a mean MDRD GFR of 
11.49±3.34ml/min.  At the next time point analysis of 3 mo, the mean MDRD GFR had 
improved back to 11.77±3.35ml/min. 
Of additional note the use of statins did not significantly impact the degree of rise in serum 
creatinine at 1 wk post-angiography (t test, P =0.51). 
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3.1.10 Contrast Volumes 
 
Figure 11: Change in serum creatinine up to 1 wk after contrast administration 
The mean contrast volume administered was 55.74±50.18mls. Figure 11 demonstrates the 
relationship between contrast volume and difference in serum creatinine from baseline up to 1 
wk after contrast. There was a significant relationship between increasing contrast volume and 
rise in creatinine at 1 wk (R=0.423). Unconventionally, one patient received a large 400ml 
volume of contrast for an aortogram due to concern about a possible aortic dissection, and this 
patient has not been included in this sub-analysis. This patient had a significant decline in renal 
function, but despite a period of anuria was managed without the need for dialysis. In a number 
of patients (n= 18) an improvement in serum creatinine was noted at 1 wk post-contrast, which 
may be explained by the reno-protection protocol, which included pre-hydration and withholding 
of potentially nephrotoxic drugs. This improvement was not sustained and the slope of GFR in 
these patients reverted to the pre-contrast slope in the proceeding months after angiography.  
Biplane angiography was used in 46 of 76 (60.5%) patients and was associated with a reduction 
in contrast volume, although not statistically significant (t test, p = 0.07). 
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3.1.11 Contrast induced Nephropathy 
If CIN is defined as a rise in serum creatinine ≥10% above baseline within 1 wk of contrast 
administration, only six of 17 (35.3%) patients had contrast nephropathy with the smallest dose 
of contrast (20 to 39ml), compared with four of four (100%) patients with the highest doses of 
contrast (>100mls). Overall, 18 of 69 patients had CIN, of which four of 18 (22.2%) patients 
with a mean MDRD GFR of 12.05 ± 1.75 ml/min started dialysis during the 12 mo follow up; 
patients without CIN had a similar outcome with eight of 51 (15.7%) patients with a mean 
MDRD GFR of 10.34 ± 2.07ml/min started on dialysis. Those patients who remained dialysis 
independent had a better baseline MDRD GFR 13.35 ±3.39 ml/min in the group who got CIN, 
and 14.03 ±3.85 ml/min in the group that did not get CIN. 
 
3.1.12 Dialysis-Free Survival 
Thirteen of 76 (17.1%) patients started dialysis during the follow-up period. No patients required 
dialysis treatment immediately post-contrast administration and only one patient commenced 
dialysis within 3 mo of undergoing coronary angiography. Figure 12 demonstrates cumulative 
dialysis-free survival, which was 89.1% at 6-mo post-coronary angiography. Forty of 76 (53.3%) 
patients remained dialysis independent and one of 76 (1.3%) patients died from trauma awaiting 
transplantation. More diabetic patients started dialysis within the period of study, but cumulative 
dialysis-free survival following angiography to 12-mo was not statistically different in diabetics 
versus non-diabetics (Log rank p =0.09). 
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Figure 12: Kaplan-Meier analysis demonstrating cumulative dialysis free survival 
 
3.1.13 Time to Transplantation 
 
Figure 13: Kaplan-Meier analysis demonstrating time to transplantation 
Of the 76 patients that had coronary angiography, 25 of 76 (32.9%) patients underwent 
transplantation, with 22 of 25 (88.0%) transplants being performed before the need for dialysis. 
Of these patients receiving pre-emptive transplantation, 18 of 22 received live donor transplants, 
two of 22 received a deceased donor kidney transplant, and two of 22 received a simultaneous 
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pancreas kidney transplant. Nine of 22 patients were transplanted within 3 mo of coronary 
angiography. The renal function for these pre-emptively transplanted patients before they exited 
the study (as a result of transplantation), was not declining more or less abruptly than the rest of 
the cohort. Figure 13 demonstrates cumulative patient survival without transplantation, which 
was 64.5% at 12 months. 
 
3.1.14 Conclusion 
These data suggest that CA did not accelerate decline in renal function for patients with 
advanced CKD. A transient decline in GFR was demonstrated in the first week following CA but 
this was entirely reversible. Potential transplant recipients should not be put off coronary 
angiography until established on renal replacement therapy, as this only heightens their 
cardiovascular burden, which may be halted or slowed down by successful kidney 
transplantation (Meier-Kriesche, 2004).  
These results are of relevance to all clinicians involved with patients requiring cardiac 
catheterization in the setting of advanced CKD. If the procedure is performed appropriately with 
small volumes of contrast, biplane angiography using N-Acetylcysteine, and adequate hydration 
around the time of the procedure, then the risk of contrast exposure can be minimized in this 
population. 
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3.2 Non-invasive markers of progressive atherosclerosis 
3.2.1 Objectives 
The primary objective of this study was to establish if selected non-invasive markers of 
inflammation and atherosclerosis correlate accurately with coronary angiographic findings.  The 
non-invasive markers to be examined in this study were MCP-1, CCL15, CCL18 and CIMT 
measurements as described in earlier Sections 1.3.1, 1.3.2, 1.3.3 and 1.10.1. The secondary 
objective of this study was to investigate if the findings of these non-invasive tests were 
predictive of major adverse cardiac events. 
 
3.2.2 Patient population 
Since January 2006 a local database created by the department of cardiology, has recorded all 
coronary angiograms performed at the Hammersmith site of Imperial College Healthcare NHS 
Trust.  Any patient with either CKD IV/V or ESRD having an angiogram as part of their 
transplant assessment is labelled and easily identifiable. This patient population group has been 
outlined in the Sections 2.1.1 and 2.1.3.   
Approximately 150 coronary angiograms per annum are performed as part of pre-transplant 
cardiac assessment at this institution. Baseline data on patients undergoing screening coronary 
angiograms for transplant work up were entered onto a confidential research database, and 
formed the basis of this prospective study.  
 
3.2.3 Patient recruitment 
Patients were approached sequentially, from the date of their baseline CA and invited to enrol in 
the study once a minimum of 3 yrs had elapsed since their baseline screening CA.  Once 
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recruited, patients were offered a surveillance CA, and at the time of the surveillance CA serum 
samples for chemokine analysis were taken, and CIMT measurements were performed. Inclusion 
and exclusion criteria are outlined in Table 11. These criteria were intended to minimise 
potential risk to patients. It was also intended to select patients with similar backgrounds i.e. 
patients transplanted overseas would have been exposed to immunosuppressive therapies that 
would not be standard practice in at Imperial Healthcare NHS Trust. Pancreas alone recipients, 
who by nature of their transplant requirements would not have CKD IV or V were therefore 
excluded. 
 
Inclusion Criteria Exclusion criteria 
Age >18 yr Unable to provide consent 
3yr from initial screening angiogram Overseas transplant recipients 
 Potential Pancreas alone recipients 
 Life expectancy <18 months 
 No longer active on transplant waiting list 
 Contrast Allergy 
 Patient received a transplant since initial screening 
angiogram, but allograft function suboptimal  (Cr >250) 
 Patient has undergone an indicative coronary angiogram 
in interim time period 
Table 11: Inclusion criteria for recruitment 
3.2.4  Reno-protection 
Patients not on renal replacement therapy had angiotensin-converting enzyme inhibitors(ACEIs), 
angiotensin receptor blockers (ARBs), and diuretics stopped for the procedure unless clinically 
contraindicated. All of the patients had oral N-Acetylcysteine (600 mg twice daily on days -1, 0, 
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and +1), and biplane angiography with Visipaque® contrast was used. Adequate hydration was 
achieved with the use of intravenous saline from arrival until discharge if patients had no clinical 
signs of fluid overload.  Patients on dialysis who were fluid restricted did not undergo any reno-
protective measures. 
 
3.2.5  Definitions 
Patient were defined as having significant CAD if they had a >75% stenosis of one or more 
coronary vessels (Kern, 2006), >50% LMS disease (Eagle, 2004), or an equivocal lesion with 
flow limitation as described above. These lesions were significant enough that revascularisation 
was performed as a consequence. Patients with non-significant disease were then categorised 
according to their SYNTAX score with either Score 0 or Score ≥1.  It is important to note that a 
SYNTAX score 0 did not imply “pristine” coronary arteries. The SYNTAX score may be 0 when 
a coronary artery stenosis is present but <50% (see Table 7 and 8).   
A cardiac event was defined as either death caused by cardiac disease, ventricular fibrillation, or 
pulseless electrical activity cardiac arrest with no identifiable reversible cause, non-ST elevation 
and ST elevation myocardial infarction (MI), or a primary cardiac arrhythmia.  Patients were 
considered “symptomatic” if they had known ischemic heart disease or if they had reported 
cardiac chest pain; patients with breathlessness alone, which included breathlessness on exertion, 
were not considered symptomatic because the cause of breathlessness in a patient with ESRD is 
not likely to be cardiac specific. Hypercholesterolemia was defined as present if the patients had 
been prescribed cholesterol-lowering agents or they had a total cholesterol of >5.0 mmol/L. 
Hypertension was defined as present if the patient had been prescribed BP-lowering agents or if 
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they had a systolic BP of >140 mmHg and/or a diastolic BP of >90 mmHg. Ischemic heart 
disease was defined as present if the patient had evidence of previous intervention on CA, a 
previous episode of ACS, or stable angina. 
 
3.2.6 Clinical characteristics and patient demographics 
The clinical and demographic characteristics of the patients who were recruited for surveillance 
CA are outlined in Table 12. The male:female ratio was approximately 3:2, with a mean age of 
56.62 ± 8.12 yrs. The population was predominantly South Asian (45.6%) and Caucasian 
(41.2%).  
Patient details n=68 
Men 
Women 
47 (68.6%) 
21 (31.4%) 
Mean Age (yrs)  56.62 ± 8.12 
Caucasian 
South Asian 
Afro-Caribbean  
Other ethnicity 
28 (41.2%) 
31 (45.6%) 
6 (8.8%) 
3 (4.4%)  
Diabetes  
Hypertension  
Hypercholesterolemia  
Ischemic heart disease  
Previous CABG 
32 (47.1%) 
66 (97.1%) 
56 (82.4%) 
12 (17.6%) 
6 (8.8%) 
Live donor  
Deceased donor  
Awaiting transplant 
20 (29.4%) 
21 (30.9%) 
27 (39.7%) 
Time to repeat angiogram (yrs) 3.60 ± 0.55 
Follow up (months) 60.28 ± 7.16  
Table 12: Clinical and demographic data 
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Thirty-two of 68 (47.1%) of the patients were diabetic. Only twelve of 68 (17.6%) had a history 
of previous MI or previous coronary revascularisation. As dictated by the inclusion criteria, all 
repeat CA were carried out after a minimum of 3 yrs had elapsed from the time zero (baseline) 
angiogram, with a mean of 3.60 ± 0.55yrs. Patients were followed up for a mean of 60.28 ± 7.16 
months from their baseline angiogram; no patients were lost to follow up. 
 
3.2.7 Patient outcomes 
Of the 68 patients recruited, 6 patients had had previous CABG surgery (Table 13). SYNTAX 
scoring cannot be applied to patients who have undergone CABG surgery.  For this reason these 
6 patients were excluded from the analysis of baseline CA results that are summarised in Table 
13 as a SYNTAX score could not be assigned to them. Forty-two of 62 (67.7%) of patients had a 
SYNTAX score of 0 (SYNTAX 0).  Nineteen of 42 (45.2%) of these patients from the SYNTAX 
0 group were diabetic. Thirty-three of 42 (78.5%) patients with SYNTAX scores of 0 on initial 
screening had unchanged SYNTAX scores on surveillance at 3 years, i.e. SYNTAX score 
remained 0.  For those fifteen of 62 (24.2%) patients with significant CAD, ten of 15 (66.7%) 
were diabetic.  All these patients underwent revascularisation, six of 15 (40%) had CABG 
surgery and nine of 15 (60%) had percutaneous revascularisation. 1 cardiac event occurred in 
this group at time 1-mo after CA; this individual suffered an episode of sustained VT with 
associated Troponin rise.   
At surveillance angiography, 3 of 56 (5.4%) patients had progressive CAD that met criteria for 
revascularisation. Observation of the patients in this cohort continued to 60.28 ± 7.16 months 
after baseline angiography.   
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Baseline 
Angiogram 
Non-significant CAD 
(see definition 3.1.6) 
Significant CAD 
(see definition 3.1.6) 
SYNTAX Score 0 ≥1 n/a 
Number 42/62* (67.7%) 5/62* (8.1%) 15/62*(24.2%) 
Diabetic 
Non-Diabetic 
19/42 (45.2%) 
23/42 (54.8%) 
3/5 (60%) 
2/5 (40%) 
10/15 (66.7%) 
5/15(33.3%) 
Intervention 0 0 15 (100.0%) 
CABG 
PCI 
0 
0 
0 
0 
6 
9 
Cardiac events 0 0 1 
*Patients with CABG in the past excluded (see text) 
Table 13: Findings at baseline angiography 
 
During the period following surveillance angiography, 3 further cardiac events occurred at time 
t=2-mo, 18-mo and 19-mo after surveillance angiogram.  The patient who suffered a cardiac 
event at 2-mo after surveillance CA had an NSTEMI. This individual was a transplanted patient, 
who was awaiting a staged procedure to intervene on his in stent re-stenosis in order to reduce 
the risk of contrast nephropathy; unfortunately the procedure was delayed and in retrospect may 
have been prevented. The original stenting procedure predated the baseline angiogram.  Of the 
other 2 patients who suffered cardiac events, both were on dialysis, one had been revascularised 
after baseline angiogram with PCI (cardiac events at time 18-mo and 19-mo). 
 It is important to note that the 9 patients who had undergone percutaneous revascularisation 
following their baseline angiogram had evidence on surveillance angiography, that their treated 
lesions were stable. As mentioned, one revascularised patient had an event at 19-mo following 
surveillance angiogram. Four of 68 (5.9%) patients died during this study; none were attributable 
to cardiac causes.  It is also acknowledged that patients undergoing indicative angiograms were 
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not recruited into this study. This group of patients are highly relevant and need to be included in 
future analysis, if we are to gain greater understanding into the risk factors for progressive CAD 
in this population. 
 
3.2.8 Chemokines and baseline angiogram findings 
Chemokine data was collected on thirty-nine of 68 (57.4%) patients recruited for the study. 
Assay techniques were performed using the techniques described in Sections 2.6, 276 and 2.8.  
Table 14 and Figure 14 shows the levels of chemokines MCP-1, CCL15 and CCL18 in patients 
who had a SYNTAX score of 0 on baseline angiography (n=23), and those who had evidence of 
more advanced CAD (n=16). Of the 3 chemokines, CCL15 levels were higher in those patients 
with advanced CAD on baseline angiogram (p=0.028).  The blood tests for chemokine assay 
were taken at the time of surveillance coronary angiography.  This was due to the recruitment 
procedure for the study, therefore there were no baseline serum samples for chemokine analysis. 
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Figure 14: Chemokines and baseline angiography findings 
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Chemokine  Syntax = 0 
 
Syntax ≥1 
 or CABG 
T-test 
MCP-1 
(pg/ml) 
Mean 
SEM 
N 
234.4 
23.7 
20 
290.1 
34.2 
16 
p= 0.178 
CCL15 
(ng/ml) 
Mean 
SEM 
N 
19.4 
1.9 
22 
29.5 
4.4 
16 
p=0.028 
CCL18 
(ng/ml) 
Mean 
SEM 
N 
38.2 
3.9 
23 
47.4 
5.3 
15 
p=0.159 
Table 14: Chemokine levels according to baseline angiography findings 
 
3.2.9 Chemokines and progressive CAD 
Chemokine  No 
progression 
 
Progression T-test 
MCP-1 
(pg/ml) 
Mean 
SEM 
N 
207.2 
27.5 
13 
300.4 
37.5 
15 
p=0.062 
CCL15 
(ng/ml) 
Mean 
SEM 
N 
16.7 
1.8 
15 
29.3 
4.3 
15 
p=0.012 
CCL18 
(ng/ml) 
Mean 
SEM 
N 
32.1 
4.9 
15 
53.4 
3.3 
15 
p=0.0013 
Table 15: Chemokine levels according to those patients with progressive versus stable CAD 
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Figure 15: Chemokine levels according to those patients with progressive versus stable CAD 
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Figure 15 shows the levels of chemokines MCP-1, CCL15 and CCL18 in patients who had 
evidence of progression of CAD on SYNTAX score, and in those patients who had stable 
disease. Table 15 shows that for all 3 chemokines, the mean (SEM) was higher in those with 
progressive CAD.   Although there was considerable overlap in the levels of the chemokines 
between the 2 groups, the group with the highest levels of chemokines were at increased risk of 
progressive CAD. For MCP-1, CCL15 and CCL18 p-values calculated using an unpaired t test 
were p=0.06, p=0.012 and p=0.0013 respectively. 
 
3.2.10 Chemokines and future cardiac events 
Chemokine  No cardiac 
event 
 
Cardiac event T-test 
MCP-1 
(pg/ml) 
Mean 
SEM 
N 
259 
22 
32 
257 
33 
4 
 
p=0.976 
CCL15 
(ng/ml) 
Mean 
SEM 
N 
23.4 
2.4 
35 
26.1 
5.3 
4 
 
p=0.723 
CCL18 
(ng/ml) 
Mean 
SEM 
N 
39.1 
3.2 
34 
64.9 
5.4 
4 
p=0.01 
Table 16: Chemokine levels and future cardiac events 
Table 16 shows the levels of chemokines MCP-1, CCL15 and CCL18 in patients who had a 
cardiac event after their surveillance coronary angiograms. The results show that patients who 
suffered a cardiac event had higher levels of CCL18 at the time of their surveillance angiogram, 
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compared to patients who did not suffer a cardiac event (p=0.01). MCP-1 and CCL15 did not 
show the same correlation. With further validation, CCL18 may be a useful measure of future 
cardiac events. One possible theory for this finding is that CCL18 is released by or is found at 
increased levels in relation to, vulnerable plaque. 
3.2.11 Chemokines and ethnicity 
Chemokine  South Asian 
 
Caucasian T-test 
MCP-1 
(pg/ml) 
Mean 
SEM 
N 
306 
25.3 
21 
200 
31.4 
12 
 
p=0.01 
CCL15 
(ng/ml) 
Mean 
SEM 
N 
30.7 
3.1 
22 
14.2 
1.6 
13 
 
p=0.0005 
CCL18 
(ng/ml) 
Mean 
SEM 
N 
48.3 
3.8 
22 
33.2 
5.4 
13 
p=0.02 
Table 17: Chemokine levels and ethnicity 
Table 17 shows the levels of chemokines MCP-1, CCL15 and CCL18 in patients of South Asian 
and Caucasian ethnicity. The results show that patients of South Asian ethnicity had higher 
levels of MCP-1, CCL15 and CCL18 at the time of their surveillance angiogram, compared to 
patients of Caucasian ethnicity (p=0.01, p=0.0005 and p=0.02 respectively). The influence of 
ethnicity on cardiovascular disease has been examined in the literature, and both altered 
inflammatory biomarkers and adipokine production (or action) have been implicated as playing a 
role in the heightened vascular risk observed in the South Asian ethnic group (Gupta, 2006). 
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3.2.12 Chemokines and CIMT 
The relationship between chemokines and other markers or factors associated with 
cardiovascular risk in the ESRD population was also examined.  This included serum albumin, 
CRP, Troponin, Age, Ca/P04 product, diabetes, anaemia, cholesterol, bicarbonate, urate and 
CIMT. The correlation table is demonstrated in the Figure 16, and Table 18 shows the results of 
the Spearman correlation coefficients. Of note CIMT correlated with Age, Albumin (pre 
angiogram), MCP-1 and CCL15, but not CCL18 (p=0.069). As CIMT is an established marker 
of cardiovascular mortality in the ESRD, it interesting to note the positive relationship with 
CIMT and MCP-1 and CCL15.  
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Figure 16: Correlation table of factors including Age, Albumin, MCP-1, CCL15, CCL18 & CIMT 
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Correlations 
 Age Apre MCP-1 CCL15 CCL18 CIMT 
Spearman's 
rho 
Age 
Correlation Coefficient 1.000 -0.071 0.136 0.203 0.259 0.392
*
 
Sig. (2-tailed) . 0.557 0.428 0.216 0.116 0.022 
N 70 70 36 39 38 34 
Apre 
Correlation Coefficient -0.071 1.000 0.041 -0.264 -0.141 -0.396
*
 
Sig. (2-tailed) 0.557 . 0.814 0.104 0.398 0.020 
N 70 70 36 39 38 34 
MCP-1 
Correlation Coefficient 0.136 0.041 1.000 0.523
**
 0.431
**
 0.619
**
 
Sig. (2-tailed) 0.428 0.814 . 0.001 0.010 0.002 
N 36 36 36 36 35 22 
CCL15 
Correlation Coefficient 0.203 -0.264 0.523
**
 1.000 0.476
**
 0.593
**
 
Sig. (2-tailed) 0.216 0.104 0.001 . 0.003 0.003 
N 39 39 36 39 38 23 
CCL18 
Correlation Coefficient 0.259 -0.141 0.431
**
 0.476
**
 1.000 0.385 
Sig. (2-tailed) 0.116 0.398 0.010 0.003 . 0.069 
N 38 38 35 38 38 23 
CIMT 
Correlation Coefficient 0.392
*
 -0.396
*
 0.619
**
 0.593
**
 0.385 1.000 
Sig. (2-tailed) 0.022 0.020 0.002 0.003 0.069 . 
N 34 34 22 23 23 34 
*Correlation is significant at the 0.05 level (2-tailed) 
**Correlation is significant at the 0.01 level (2-tailed) 
Table 18: Spearman Correlation Coefficient
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3.2.13 Conclusion 
These data have demonstrated that patients with angiographically progressive CAD have higher 
serum chemokine levels in the form of MCP-1, CCL15 and CCL18 when compared to a similar 
cohort of patients who do not have progressive CAD.  As these chemokines are felt to be 
biomarkers of inflammation, this would support the existing evidence that atherosclerosis is an 
inflammatory process.  CCL18 levels were found in higher levels in patients who went on to 
have a cardiac event, compared to those who did not have a cardiac event. With further 
validation CCL18 may be useful in identifying patients at risk of future cardiac events before 
they occur. Also of interest is the finding that South Asian ethnicity is associated with higher 
levels of all 3 chemokines in this study when compared with patients of Caucasian ethnicity.  
The effect of ethnicity on cardiac outcome in the ESRD population is explored in Section 3.4. 
This data has also shown that only a small number of patients with a baseline CA SYNTAX 
score of 0 had evidence of progressive CAD on SYNTAX score. In addition, none of the patients 
who underwent revascularisation after baseline angiogram, had any evidence of progressive 
CAD.  The small number of patients (n=3) with progressive CAD requiring intervention were all 
from category with a SYNTAX ≥1. Those patients who had cardiac events during the follow up 
after surveillance angiogram were also from the SYNTAX ≥ 1 category (n=3). One potential 
focus of our attention in the future may be this small but select group of patients.   
In summary, the results of this pilot study draws into question the recommendations surrounding 
the frequency of rescreening patients who remain untransplanted. The data would indicate that if 
the original SYNTAX score was 0 then the risk of developing significant coronary disease at 3 
years was low. In contrast there may be an indication for repeat screening in other groups.  
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3.3 Pre-emptive coronary angiography & intervention improves cardiac survival in 
transplant patients and those awaiting transplantation.    
3.3.1 Objectives 
In view of the high risk for cardiovascular disease in renal transplant candidates, pre-transplant 
practice at Imperial College Healthcare NHS Trust involves an aggressive approach to invasive 
cardiac investigations and subsequent revascularization. The purpose of this study was to 
establish whether ESRD patients awaiting renal transplantation benefit from pre-emptive 
coronary angiography and intervention. 
 
3.3.2 Patient population 
1304 patients were assessed for transplantation between January 2006 and October 2009, with 
657 of 1304 (50.3%) undergoing screening angiography. No patients were excluded from 
angiography unless self directed. The same screening criteria as described in Section 3.1.3 were 
utilised for this study. 
 
3.3.3 Definitions 
Significant CAD was defined as >75% stenosis of one or more coronary vessels (Kern, 2006), 
>50% LMS disease (Eagle, 2004), or an equivocal lesion with flow limitation as described 
above. Patients were given a diagnosis of “normal” coronary arteries only if their coronary 
vessels were “pristine” on angiography. Those patients with mild to moderate CAD included 
patients with mild atheroma or minor plaque disease, as well as those with more advanced 
lesions that were not severe enough to be defined as “significant.”  
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A cardiac event was defined as described in Section 3.1.6. Similarly hypercholesterolaemia, 
hypertension, and the definition of “symptomatic” are described in Section 3.1.6. To further 
clarify “cardiac death,” patients had to have suffered either MI or a primary arrhythmia or have 
given a clear history of cardiac chest pain in the hours to days leading up to their subsequent 
death. Deaths out of hospital without post-mortem evidence of MI were classified as unknown. A 
history of smoking was defined, as present if the patient was either an ex-smoker or a current 
smoker. 
 
3.3.4 Renoprotection & optimisation of cardiac disease and risk factors 
Patients not on renal replacement therapy had ACEIs, ARBs and diuretics stopped for the 
procedure unless clinically contraindicated. All of the patients had oral N-Acetylcysteine (600 
mg twice daily on days -1, 0, and +1), and biplane angiography with Visipaque® contrast was 
used. Adequate hydration was achieved with the use of intravenous saline from arrival until 
discharge if patients had no clinical signs of fluid overload. Left ventricular assessment was 
performed by echocardiography rather than left ventriculography to reduce contrast dose. For 
those patients with CKD stage IV/V (not on dialysis) and angiographically significant CAD, 
intervention was staged to minimize the volume of contrast administered in a single dose. 
Patients on dialysis who were fluid restricted did not undergo any reno-protective measures.  
Intervention was at the discretion of a single consultant cardiologist, and in the absence of 
symptoms the decision to intervene was guided by the angiographic severity of the lesion. If the 
lesion was felt to be equivocal, evidence of flow limitation of each lesion was sought with 
pressure wire assessment, DSE or myocardial perfusion scanning. Hypercholesterolaemia and 
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hypertension were aggressively managed with the use of statins (target cholesterol ≤4.0 mmol/L) 
and ARBs or ACEIs (target BP ≤140/90 mmHg) as first-line therapy. 
 
3.3.5 Demographics  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19: Demographics and clinical characteristics 
 
 
 
2006-2009 n=657 
Men 
Women 
427 (64.9%) 
230 (35.1%) 
Mean Age (years) 56.55 ± 9.94 
Caucasian 
South Asian 
Afro-Caribbean  
Other ethnicity 
273 (41.6%) 
240 (36.5%) 
84 (12.8%) 
60 (9.1%) 
Diabetes  
Hypertension  
Hypercholesterolemia  
Ischemic heart disease  
Smoker  
310 (47.2%) 
612 (93.2%) 
520 (79.1%) 
116 (17.6%) 
191/536 (35.6%) 
Live donor  
Deceased donor  
122 (49.4%) 
58 (51.6%) 
Dialysis  
Pre-dialysis  
476 (72.5%) 
181 (27.5%) 
Activated on waiting list  
Not activated on waiting list  
573 (87.2%) 
84 (12.8%) 
Mean follow-up (months)  30.09 ± 11. 
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Demographic and clinical characteristics are summarised in Table 19.  Of the cohort studied, 573 
of 657 (87.2%) patients were considered fit for transplantation after coronary angiography, and 
247 of 573 (43.1%) patients were transplanted; 122 of 247 transplants (49.9%) were from a live 
donor. The mean time from cardiac referral to coronary angiography was 3.42±3.0 months, and 
that from diagnostic angiography to intervention where indicated was 3.06±2.82 months. The 
period between diagnostic and interventional angiogram resulted from a combination of planned 
staged procedures in patients with residual renal function and also occurred when patients with 
equivocal lesions underwent further non-invasive physiologic investigations. 
 
3.3.6 Exclusion from Transplantation 
After CA, 84 of 657 (12.8%) patients were not put forward for transplantation. The reasons for 
exclusion from the waiting list are outlined in Table 20. Eight patients were excluded from the 
waiting list because of morbid obesity, including three female patients with a body mass index 
(BMI) of >35 and five male patients with a BMI of >40. Seven patients were excluded from the 
waiting list because of infection; these infections included staphylococcal discitis (one patient), 
sternal wound dehiscence (one patient), osteomyelitis (three patients), and tuberculosis (two 
patients). With respect to the cardiac reasons for not wait listing patients, the cardiologists were 
unable to fully revascularise three of 184 (1.6%) patients, 16 of 184 (8.7%) declined 
intervention, and eight of 657 (1.2%) patients were not activated because of severe left 
ventricular (LV) dysfunction, defined as EF of <30%. Unfortunately, the three patients whose 
revascularization procedure was either abandoned or considered incomplete all died, at 0.36, 
18.1, and 21.6 mo after CA. 
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2006-2009 n=84 
Cardiac 
Unable to fully revascularize  
Patient declined intervention 
Severe left ventricular (LV) dysfunction EF < 30% 
 
3 
16 
8 
Non-Cardiac 
Active lupus  
Cerebrovascular  
Encapsulating sclerosing peritonitis  
Gastrointestinal or hepatological  
Gynaecological  
Haematological  
Infection  
Malignancy  
Morbid obesity  
Peripheral vascular disease  
Respiratory  
 
1 
3 
3 
3 
2 
2 
7 
8 
8 
4 
3 
Other 
Non-compliance  
Patient choice  
 
3 
10 
 EF = Ejection Fraction 
Table 20: Exclusion from transplantation 
 
 
3.3.7 Waiting List Status 
20 of 573 (3.5%) patients who were active on the transplant waiting list died during follow-up. 
Survival in patients wait listed was 98.9% and 95.3%, respectively, at 1 and 3 years. 40 of 84 
(47.6%) patients who were excluded from the transplant waiting list died during follow-up. 
Survival in patients not wait listed was 83.2% and 45.7%, respectively, at 1 and 3 years. The 
high mortality rate in the latter group may be attributed to a number of factors; however, the 
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most likely explanation is that the process of pre-transplant assessment is rigorous enough to 
identify and exclude those patients unlikely to survive because of significant co-morbidities, both 
cardiac and non-cardiac. Table 21 outlines the cause of death in patients inactive on the wait list 
and in those patients revascularized and transplanted or revascularized and awaiting deceased 
donor transplants. 
 
 Patients Inactive on 
Wait List (n=84) 
Patients Revascularized and 
Active on Wait List (n=88) 
Patients Revascularized and 
Transplanted (n=51) 
Cerebrovascular 8 (9.5%) 2(22.7%) 1(1.9%) 
Cardiac 12 (14.3%) 1(11.4%) 1(1.9%) 
Gastrointestinal 1 (1.2%) 1 (11.3%) 0 
Hepatic failure 1 (1.2%) 0 1 (1.9%) 
Infection 4 (4.8%) 2 (22.7%) 0 
Ischaemic bowel 0 0 1(1.9%) 
Malignancy 5 (5.9%) 0 0 
Unknown* 6 (7.1%) 2 (22.7%) 0 
Total 40 (47.6%) 8 (9.1%) 5 (9.5%) 
RRT= Renal replacement therapy; *Out of hospital death 
Table 21: Cause of death 
 
3.3.8 Medical Therapy 
Medical treatment for CAD was recommended where indicated by the cardiologist, and 
commenced by the renal physicians responsible for the patients’ long-term care. Our local 
protocol is not to standardize the use of beta-blockers, because peri-operatively beta-blockers, as 
might be used in other surgeries, limit the ability to use inotropes to increase renal perfusion 
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pressure. In this study, 464 of 657 (70.6%) patients were on either an ACEI or ARB or both, and 
520 of 637 (79.1%) patients were on statins.  
 
 
 
 Normal Coronary 
Arteries 
n =125/756 (19.1%) 
Mild to Moderate 
Atheromatous Disease 
n = 348/657(52.9%) 
Angiographically 
Significant Disease 
n=184/657(28.0%) 
Symptomatic 
Asymptomatic 
0 
125 (100%) 
77 (22.1%) 
271 (77.9%) 
81 (44.0%) 
103 (54.0%) 
Diabetic 
Non-diabetic 
34 (27.2%) 
91 (72.8%) 
152(43.7%) 
196 (56.3%) 
123(66.8%) 
61 (33.2%) 
Intervention advised 
Intervention declined 
0 
0 
0 
0 
184 (100%) 
16 (8.7%) 
CABG 
PCI 
0 
0 
0 
0 
51 (27.7%) 
117 (63.6%) 
Deaths (all cause) 5 24 36 
CABG= Coronary artery bypass graft; PCI= Percutaneous coronary intervention. 
Table 22: Coronary angiographic findings 
 
 
 Hazard Ratio 95% CI 
Cardiac event 
Intervention 
Normal  
Declined intervention 
Non-obstructive CAD 
 
1 
0.1 
6.7 
0.4 
 
 
0.03 to 0.56 
2.91 to 15.33 
0.21 to 0.81 
Patient Survival 
Intervention 
Normal  
Declined intervention 
Non-obstructive CAD 
 
1 
0.25 
6.0 
0.47 
 
 
0.10 to 0.65 
2.91 to 12.57 
0.27 to 0.81 
 CI=Confidence Interval; CAD=Coronary artery disease 
Table 23: Patient death and cardiac events according to coronary artery disease severity 
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3.3.9 Coronary Revascularization 
The CA findings are outlined in Table 22. 184 of 657 (28.0%) patients were offered coronary 
intervention, and 168 of 184 (91.3%) of these patients underwent intervention. 93 of 168 (55.4%) 
patients were asymptomatic or had no previous history of CAD. 49 equivocal lesions were 
identified; 18 of 49 patients had negative DSE studies and underwent no further assessment, 17 
of 49 had negative DSE studies but positive FFR studies and as a result underwent intervention, 
and 14 of 49 patients had positive DSE studies and therefore underwent intervention. Our past 
experience has led us to interpret negative DSE studies with caution, because false negatives are 
common in patients with ESRD (Preston, 2006). 117 of 184 (63.5%) patients had percutaneous 
coronary intervention with deployment of drug-eluting stents in 97 of 117 (82.9%) patients. Bare 
metal stents were used in 20 of 117 (17.1%) patients, when they expressed a wish to proceed to 
transplantation without delay. 51 of 184 (27.7%) patients underwent CABG surgery. No serious 
adverse events occurred as a consequence of elective CA in this cohort of patients. Those 
patients who received Clopidogrel® were made active on the waiting list 4 to 6 months after 
their procedure, unless they received a bare metal stent, when they were able to proceed within 5 
weeks of angiography. When transplantation occurred within 1 year of the patient’s percutaneous 
coronary intervention, surgery was performed under cover of platelet transfusion.  
There was a 100% survival associated with the 51 patients who underwent CABG; however, the 
following severe adverse events were reported: bilateral pnuemothoraces requiring chest drains 
(one patient), haemofiltration for acute kidney injury in patients not established on dialysis 
(eleven patients), sternal wound dehiscence (one patient), and tracheostomy for prolonged 
respiratory wean (two patients). All of the patients not on dialysis pre-CABG who required 
haemofiltration recovered independent renal function. Data on minor or late presentation adverse 
 152 
events such as a psuedoaneursym or groin haematoma were not readily available, as patients 
often present to their local hospitals following discharge; the lack of the information on the full 
profile of adverse events is acknowledged as a limitation of this study.  
Figure 21 shows the overall survival in this group. The patients who declined intervention had 
75.0% and 37.1% survival at 1 and 3 years, respectively, with 10 of 16 deaths; six of the 10 
deaths were due to cardiac causes. The cardiac risk factors and co-morbidities in the patients who 
declined intervention were similar to those who underwent intervention as advised; of note six of 
16 patients were symptomatic yet still declined intervention.  
The association of revascularization category on cardiac outcome and survival during follow-up 
were determined by fitting a Weibull proportional hazards model as outlined in Table 23. 
Compared with those undergoing revascularization, cardiac event and death rates were 
significantly greater in those who were offered but declined intervention (hazard ratio [HR] 6.7, 
P<0.001; and HR 6.0, P<0.001 respectively) and significantly less frequent in those with low 
risk angiographic findings that were therefore not offered intervention (HR 0.4, P <0.01; and HR 
0.47, P <0.005, respectively). 
 
3.3.10 Patient and cardiac event–free survival after transplantation and in patients 
awaiting transplantation 
Of the 168 patients who underwent intervention, 51 (30.4%) patients have been successfully 
transplanted since their cardiac revascularization. Overall patient survival was 100% and 97.2%, 
and cardiac event–free survival was of 98.0% and 88.4% at 1 and 3 years, respectively, as shown 
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in Figure 20. Of the remaining 117 (69.6%) patients who underwent intervention, 88 (75.2%) 
were activated on the waiting list for deceased donor transplantation. Overall patient survival 
was 94.9% and 80.7%, and cardiac event–free survival was 94.0% and 90.0% at 1 and 3 years, 
respectively. Table 24 summarizes overall and cardiac survival with further division according to 
whether patients were symptomatic or asymptomatic, intervened on or not intervened on, and 
transplanted or not transplanted. There were 30 deaths with a functioning graft recorded out of 
662 patients transplanted between January 2006 and October 2009. One patient (3.3%) died from 
a cardiac cause. 20 deaths occurred in 324 patients active on the wait list in this study group, and 
one death (5%) was due to a cardiac cause. 
 
3.3.11 Extended follow up data on cardiac morbidity and mortality 
Data was re-analysed with the benefit of extended follow up to 46.70 ± 15.56 mo, during which 
time there were a total of 89 cardiac events and 111 deaths. The survival data is summarized in 
Figures 17 and 18 showing that although those patients who were revascularized (1) had poorer 
outcomes than those who did not require revascularization (0), both groups had a steady decline 
in both overall and cardiac event free survival, and again highlights the poor outcome in patients 
who declined intervention [Logrank (Mantel-cox)=0.000]. 
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Figure 17: Kaplan-Meier analysis of overall survival according to intervention category, 
with risk table 
 
 
 
 
 
 
Figure 18: Kaplan-Meier analysis of cardiac event free survival according to intervention category, 
with risk table. 
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 155 
3.3.12 Extended follow up data on survival benefit of transplantation 
Further Kaplan-Meier analysis of cardiac survival and overall survival in this cohort of patients 
with extended follow up to 46.70 ± 15.56 mo is shown in Figure 19. Patients were grouped 
according to whether they were transplanted, wait listed but remained on dialysis or not wait 
listed.  This demonstrates the beneficial effect of transplantation, not just on cardiac morbidity 
but on all cause mortality, which is consistent with UK and USRDS registry data.  
 
 
 
  
Figure 19: Kaplan-Meier analysis of overall survival according to transplantation category, 
with at risk table
0 20 40 60 80
0
20
40
60
80
100
Time from angiogram [months]
P
e
rc
e
n
t 
s
u
rv
iv
a
l
Transplanted
Awaiting Transplant
Not on wait list
Log rank [Mantel-cox] p=<0.0001
Number at risk      
Transplanted 294 293 288 278 278 
Awaiting Transplant 279 270 251 234 233 
Not wait listed 84 62 43 36 36 
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3.3.13 Discussion 
This is the largest reported study of cardiac screening on the basis of coronary angiography 
before renal transplantation. Significant CAD was identified in 184 of 657 (28.3%) angiograms, 
and 168 of 657 (25.6%) patients in this study underwent coronary revascularization after their 
cardiac assessment; no other single centre observational studies have published data with an 
intervention rate comparable to this (Lentine, 2008; Kasiske, 2005; Lewis, 1999; Patel, 2003).  
UK Registry data report 16% of all deaths with a functioning graft are due to cardiac causes (UK 
Renal Registry 10
th
 Annual Report, 2007), and the US Renal Data System reports that 30% of 
deaths with a functioning graft are due to cardiac causes (USRDS, 2008).  Only 3.3% of the 
patients in this study with functioning grafts died of a cardiac cause, and it is notable that only 
5% of the patients on the waiting list in this study died of cardiac causes during this period. 
In the general population without renal failure there is no convincing evidence that either 
anatomical or functional testing is of prognostic value in patients who do not have any cardiac 
symptoms (Boden, 2007; McFalls, 2004; Schouten, 2009). However, other than the Manske et al 
study discussed in Section1.9 (Manske, 1992) there is no other RCT that has addressed the 
asymptomatic renal failure patient with a view to the prognostic benefit of coronary 
revascularisation. There are 2 other recent studies that would support an aggressive 
revascularisation strategy in order to improve clinical outcome. The first is a study of 259 
haemodialysis patients who had coronary angiography; 137 had significant lesions. Patients in 
this study were informed of the benefits and risks of PCI and made the decision jointly with the 
physicians as to whether to proceed (88 patients) or not (49 patients). Both all cause and cardiac 
5-year survival rates were strikingly higher in the PCI group than the medication-only group, and 
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although this was not a RCT, the survival benefit was so large it was unlikely to be as a sole 
consequence of referral bias (Yasuda, 2006). The other study of interest examined 1460 patients, 
of whom 357 had coronary angiography, and 212 had obstructive disease. Those with medically 
managed CAD had a significantly higher rate of death at the end of the 5 year period compared 
to those who received PCI (aHR 3.792: CI 95% 1.32-10.89, p=0.0013) or those who received 
CABG (aHR 6.691: CI 95% 1.20-37.32) (Kahn, 2011). 
 
3.3.14 Conclusion 
These data are of relevance to all clinicians involved with pre-transplant assessment when they 
are considering the risks and benefits of invasive cardiac investigation and treatment. This 
cardiac assessment and intervention protocol used during the pre-transplant period may be 
considered aggressive, but the aim is to have fully optimized patients’ cardiac status in 
preparation for transplantation. Although coronary intervention strategies in this group remain 
unclear, we advocate revascularization for potential transplant recipients with flow-limiting 
coronary artery lesions irrespective of symptoms. This study has demonstrated that this approach 
is associated with low cardiac morbidity and mortality for those patients transplanted as well as 
for those patients who remain on dialysis awaiting a deceased donor organ. 
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Table 24: Patient and cardiac event–free survival according to symptoms, intervention, and transplant status 
 
Group Subgroup 
analysis 
Overall Survival 
1 Year after 
Angiogram 
Overall Survival 
3 Years after 
Angiogram 
Cardiac event 
free Survival 
1 Year after 
Angiogram 
Cardiac event 
free Survival 
3 Years after 
Angiogram 
Entire Cohort Symptomatic 
Asymptomatic 
93.8% 
96.5%  
77.8% 
83.5%  
93.8% 
95.3%  
84.7% 
86.8% 
Entire Cohort* Intervention 
No intervention 
96.5% 
97.8%  
83.5% 
91.5% 
95.3% 
98.9%  
86.8% 
95.1% 
Waitlisted patients Received TXP 
Awaiting TXP 
100% 
94.9% 
97.2% 
80.7% 
98.0% 
94.0% 
88.4% 
90.0% 
TXP=Transplant; *Excluding patients who declined intervention. 
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Figure 20: Cardiac event–free survival in patients who have had coronary  Figure 21: Patient survival by intervention group  
        revascularization, with risk table. 
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3.4 Does ethnicity and gender influence severity of coronary artery disease and cardiac 
survival in potential renal transplant recipients undergoing coronary angiography? 
 
3.4.1 Background 
There are a number of potentially modifiable risk factors that can be targeted for treatment of 
CAD.  However un-modifiable risk factors such as gender and race may be important, and also 
need to be considered when carrying out cardiac risk stratification before and after 
transplantation.  There are limited data available in the literature addressing how ethnicity 
influences the prevalence of obstructive CAD in patients with ESRD. The largest registry study 
to date included, but did not focus on patients with ESRD
 
(Shaw, 2008).  
 
3.4.2 Objectives 
The purpose of this study was to identify if any subgroups of patients from a West London 
cohort exists with relatively few traditional cardiac risk factors, whose gender and ethnicity may 
influence their cardiac status. 
 
3.4.3 Patient population 
The same patient population and screening criteria as described in Section 3.3.2 was utilised for 
this study. 
 
3.4.4 Definitions 
The same definitions as described in Section 3.3.3 were utilised for this study. 
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3.4.5 Renoprotection & optimisation of cardiac disease and risk factors 
The same renoprotection and optimisation of cardiac disease and risk factors as described in 
Section 3.3.4 were applicable to this study cohort. 
 
3.4.6 Classification of ethnic group 
Recording of ethnicity was derived from the electronic ethnicity coding in the renal unit records 
uploaded by nursing staff, and correlated the coding with the hospital patient administration 
systems, which uses national coding systems based on patient self-reported ethnicity.  In keeping 
with Census 2001 ethnic classification (NATIONAL STATISTICSWEB SITE, Census 2001), 
patients were categorised into the following ethnic groups Caucasian, South Asian (Indian, 
Bangladeshi, Pakistani), Afro-Caribbean (Black African and Caribbean), and other (Pan Asian, 
and Middle Eastern). 
 
3.4.7 Demographics 
 The population of patients in West London is ethnically diverse; only 273/657 [41.5%] patients 
were of Caucasian ethnicity in this study (Table 25).  240/657 [36.5%] patients were South 
Asian, 84/657 [12.8%] were Afro-Caribbean and 60/657 [9.2%] were classified as “Other” 
ethnicity. 55.4% of the South Asian patients in this study had a diagnosis of Diabetes, compared 
with 43.2% of the Caucasian patients, 44.0% of the Afro-Caribbean patients and 36.7% of the 
Other ethnicity patients [p=0.01]. A history of smoking was reportedly greatest in the Caucasian 
group [p=0.000]; 41.8% of Caucasian patients were classified as either a current or ex-smoker.  
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Table 25: Patient characteristics and demographics according to ethnic group  
Table 26: Coronary angiographic findings according to ethnicity and gender 
 South Asian 
[n=240] 
Caucasian 
[n=273] 
Afro Caribbean 
[n=84] 
Other 
[n=60] 
P value 
Age [years] 
Gender M:F 
56.86+/-9.17 
161:79 
55.98+/-10.95 
175:98 
57.04 +/- 10.06 
48:36 
57.2+/-7.79 
43:17 
0.999 
0.260 
Smoker 
Diabetes 
Hypertension 
Hypercholesterolaemia 
44 
133 
221 
191 
114 
118 
252 
215 
22 
37 
80 
65 
11 
22 
59 
49 
0.000 
0.010 
0.280 
0.931 
Normal coronaries 
Moderate CAD 
Significant CAD 
43 
127 
70 
50 
142 
81 
20 
45 
19 
12 
34 
14 
0.667 
0.932 
0.495 
No intervention 
PCI 
Surgical revascularisation 
Declined intervention 
170 
48 
14 
8 
192 
46 
29 
6 
65 
15 
3 
1 
46 
8 
5 
1 
0.495 
0.619 
0.088 
0.665 
Ethnicity CAD Male Female P 
Caucasian  
 
N 
Normal 
Mid-Moderate 
Significant 
175 
21 
98 
56 
98 
29 
45 
24 
 
0.0005 
0.1297 
0.2137 
South Asian  
 
N 
Normal 
Mid-Moderate 
Significant 
161 
22 
85 
54 
79 
21 
41 
17 
 
0.0194 
1.0000 
0.0706 
Afro-Caribbean  
 
 
N 
Normal 
Mid-Moderate 
Significant 
48 
10 
25 
13 
36 
10 
20 
6 
 
0.6055 
0.8267 
0.3015 
Other Ethnicity 
 
N 
Normal 
Mid-Moderate 
Significant 
43 
6 
25 
12 
17 
6 
9 
2 
 
0.0806 
0.7772 
0.3103 
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Table 26 shows that females were more likely to have normal coronaries than their male 
counterparts if they were Caucasian [p=0.0005(Fisher’s test)] or South Asian [p=0.0194], but 
this relationship was not demonstrated for all ethnic groups. In this study, follow up of data was 
extended to 46.70 ± 15.56 months. 
 
3.4.8 Influence of gender, ethnicity and other cardiovascular risk parameters 
In this cohort of patients with ERSD, there was no survival influence with respect to female 
gender, despite the finding of less CAD in Caucasian and South Asian women.  In addition there 
was no survival difference according to ethnic group.  Cox regression analysis demonstrates that 
the only predictive factors in this cohort of patients for all cause mortality are age, cardiac 
symptoms and diabetes, as shown in Table 27. The factor with the greatest magnitude of effect 
on outcome is the presence of cardiac symptoms or previous history of CAD [Exp(B)=2.599].  
Table 27: Cox regression analysis showing predictive factors for all cause mortality 
 
 
 
 B SE Wald Df Sig Exp(B) 
Gender -0.081 0.185 0.194 1 0.660 0.922 
South Asian 0.319 0.342 0.871 1 0.351 1.376 
Afro-Caribbean  0.220 0.382 0.332 1 0.564 1.246 
Caucasian  0.443 0.343 1.670 1 0.196 1.558 
Age 0.025 0.009 7.807 1 0.005 1.025 
Cardiac symptoms 0.955 0.172 30.686 1 0.000 2.599 
Diabetes 0.433 0.172 6.362 1 0.012 1.543 
Revascularisation -1.846 0.338 29.806 1 0.000 0.158 
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3.4.9 Discussion 
In Section 3.2.11, the chemokine analysis performed demonstrated higher levels of MCP-1, 
CCL15 and CCL18 in patients of South Asian ethnicity when compared with Caucasian patients, 
consistent with established data on the potential role of inflammation in atherosclerosis in the 
South Asian ethnic group (Anand, 2004; Raji, 2004; Snehalatha, 2003).   Although we 
commonly see higher rates of diabetes in patients from the Indian subcontinent, it appears to be 
the diabetes per se and not the ethnicity, which affects patient outcome in this ESRD population 
studied.  Likewise, whilst we see CAD less frequently in females with ESRD, from our analysis 
female gender does not appear to confer any cardio-protective benefit.  
Therefore currently there is little evidence with regard to specific preventative or treatment 
strategies for South Asians (Gupta, 2006) or male patients. The INTERHEART study carried out 
in 52 countries showed that 9 risk factors accounted for >90% of the populations attributable risk 
of MI in all ethnic groups (Yusuf, 2004). These risk factors included smoking, raised 
apolipoprotein B/apolipoprotein A ratio, hypertension, diabetes, abdominal obesity, and 
psychosocial stress (Yusuf, 2004).  Clinicians should be aware of these factors and screen those 
at risk both South Asian and other ethnic populations alike. 
In this study that looked at an ESRD population, patients of South Asian ethnicity had higher 
chemokine levels than patients of Caucasian origin, and it would therefore be expected that 
South Asian patients would fare badly overall. Yet for some reason this study showed that 
patients of South Asian ethnicity on dialysis did not have significantly lower overall or 
cardiovascular survival, but it is not clear why this is the case. 
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3.4.10 Conclusion 
Neither ethnicity nor gender significantly influenced cardiovascular outcome in this data 
analysis. In this study the main factors that influenced cardiac mortality and overall morbidity 
were age, cardiac symptoms and diabetes. It is therefore essential to consider all of these factors 
as part of cardiac risk stratification, whether in the setting of pre transplant work up, or when 
addressing risk factor management and intervention in a dialysis patient not listed for 
transplantation.  
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4. DISCUSSION 
 
As highlighted in the introduction, cardiovascular morbidity and mortality is of great concern for 
patients with all degrees of renal failure, and remains an issue even after successful kidney 
transplantation.  Consequently there exists a continuing need for therapeutic strategies aimed at 
reducing cardiovascular events for patients with renal disease in order to reduce hospitalization 
and improve survival.  Furthermore, targeting cardiovascular disease successfully will allow a 
reduction in loss of functioning allografts due to cardiovascular death. 
This work has emphasized some of the potential pathophysiological processes that contribute to 
the significant cardiovascular burden to this population.  This includes inflammation and 
endothelial dysfunction in the setting of atherosclerosis and risk factors both unique and 
prevalent in patients with end stage kidney disease.  The literature supports the alarming findings 
of coronary artery disease in relatively young patients with renal failure (Sarnak, 2003), and for 
sometime this has been a target for prevention and intervention. Although the majority of this 
work centres on the diagnosis and management of coronary artery disease, it is now widely 
accepted amongst cardiologists and nephrologists that the burden of cardiovascular disease for 
patients with end stage renal disease is not just a problem of coronary artery disease.  It is multi-
factorial with myocardial fibrosis, myocardial stunning, congestive cardiac failure and electrolyte 
abnormalities all contributory as discussed. 
Over the past decade clinical and experimental studies have reinforced the key role that 
inflammation has in a variety of cardiovascular diseases.  This work has demonstrated a 
relationship between 2 chemokines, namely MCP-1 and CCL15 with an established marker of 
atherosclerosis in the form of CIMT.  MCP-1 has been implicated as fundamental not only in the 
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early stages of atherosclerosis, but also has a role in arterial injury due to it’s direct effect on 
stimulating smooth muscle cells, and in arteriogenesis due to it’s direct effect on 
monocytes/macrophages and contributory collateral vessel formation.  Expression of CCL15 has 
been found not only at the mRNA level in human atherosclerotic lesions, but also in circulating 
levels in patients with atherosclerosis, when compared to patients with no atherosclerosis (Yu, 
2004).   However, unlike MCP-1, data on levels of CCL15 in relation to CIMT measurements 
are not readily available in the literature.  It is still unclear as to whether or not chemokines have 
site specificity i.e. coronary versus carotid versus peripheral arteries (Tengui, 2006).  
Also of note this work has shown a lack of correlation between CIMT and CCL18.  Hagg et al 
performed immuno-histochemical examination of diseased carotid arteries and showed that the 
CCL18 protein was localized to a subset of macrophages in the carotid plaques (Hagg et al, 
2009). The same investigators also compared serum levels of CCL18 from subjects with 
symptomatic carotid artery disease with control subjects and found no differences in serum 
levels of CCL18 between the two groups.  Further functional studies of CCL18 are potentially 
limited as no agonist receptor for CCL18 has been identified, although CCL18 has been shown 
to have antagonist effects on chemokine CC motif receptor 3 [Nibbs, 2000]. 
CIMT has been validated as a marker of atherosclerosis and is predictive of cardiac mortality in 
an ESRD population (Blacher 1998, Kato 2003).  It is relevant to note that recently the AHA has 
refuted CIMT as a screening tool for atherosclerosis.  The reasons for questioning the role of 
CIMT as a marker of atherosclerosis are many.  Recent evidence suggests that plaque 
measurements rather than CIMT measurement may be a more sensitive and representative 
indicator of the atherosclerotic burden (Mathiesen, 2011;Finn, 2009; Johnsen, 2007).  Costanzo 
et al also raise concerns about referring to CIMT as a surrogate end point, as according to the 
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definition of surrogate end point there needs to be a clear association between intervention 
induced changes in the surrogate end point and changes in the clinical end point that is felt to be 
lacking for CIMT (Prentice, 1989; Costanzo, 2011).  The assumption that carotid wall injuries 
are representative of the status of the whole arterial bed in the body, including the coronary tree, 
has been disproved in post mortem and clinical studies (Pasterkamp, 1997; de Groot, 2008; 
Lorenz 2010).  The role of CIMT measurements in cardiovascular risk stratification is an 
attractive one given the non-invasive nature of the test.  However, it is limited by the technical 
aspects impacting on reproducibility, in particular with relation to inter-observer and intra-
observer variability.  This is almost certainly an area set to improve due to technical 
improvements, standardization and training.  In addition to the technical limitations described, 
my data was also limited by the small sample size.  
This work has also shown a relationship between progressive coronary artery disease and the 
panel of chemokines used.  Kraaijeveld et al found that CCL18 levels were temporarily raised in 
patients with episodes of severe cardiac ischaemia, but there is otherwise limited published data 
on the potential role of CCL18 as a predictor of cardiovascular events (Kraaijeveld, 2007).  
MCP-1 and CCL15 have been more frequently studied, with particular focus on MCP-1 in terms 
of large cohort studies (de Lemos, 2003; Deo, 2004).   
This work in addition to the other studies already described (de Lemos, 2003; Deo, 2004; 
Kraaijeveld, 2007) may have highlighted a possible role for chemokines in both predicting 
cardiac events (in the setting of plaque rupture) and in predicting chronic progression of CAD. 
By investigating cytokines to establish if they have a similar role in both early and late 
atherosclerosis, we may gain greater understanding for their role as a biomarker. The potential 
role of biomarkers for predicting CV events is an interesting concept.  Risk algorithms have been 
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available for some decades, with the Framingham Score being the most commonly utilised in the 
current era.  However there are at risk patients not readily picked up by the Framingham Score, 
and being able to identify these patients would improve patient treatment and outcome.  Ideally a 
biomarker needs to be applicable to patients who are disease naive, as well as those with 
established disease, and applying its use in monitoring therapeutic intervention is fundamental.  
Some chemokines have had disappointing results as biomarkers of cardiovascular disease as they 
have a role in only one pathway of a multiple pathway disease process.  However this may not be 
the case for all inflammatory biomarkers.  For example, CRP is an established biomarker in 
cardiovascular disease, and does not play a key pathogenic role in atherosclerosis, but instead 
reflects upstream inflammatory activity (Aukrust, 2007) At present the consensus is that the role 
of chemokines as clinical biomarkers is unclear and further large prospective studies are 
required; in addition a reliable, rapid and cost effective assay is required. 
This pilot study has also drawn into question the recommendations surrounding the frequency of 
re-screening patients who remain untransplanted. This data would indicate that if the original 
SYNTAX score was 0 then the risk of developing significant coronary disease at 3 years was 
low. In contrast there may be an indication for repeat screening in other groups. 
In terms of the study design examining chemokine levels in relationship to various 
cardiovascular parameters, this data could have been strengthened by comparing time zero 
chemokine levels with the levels acquired from samples taken at the time of the surveillance 
angiogram.  Likewise, with the CIMT measurements there should ideally have been a time zero 
reading.  In addition, the study should have excluded patients who had undergone CABG, as the 
SYNTAX score was not applicable in terms of disease progression.  Inclusion of patients who 
had undergone CABG was on the basis of the original study design, which intended to use QCA 
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to assess disease progression.  41/68 (60.3%) patients in the cohort were transplanted during the 
follow up period, 24/68 (35.3%) were transplanted before their surveillance angiogram and 7 
patients transplanted before their surveillance angiogram had chemokine analysis performed. 
This is of relevance when interpreting the chemokine data as renal function may be a 
confounding factor. 
The results from the study of contrast on GFR in patients with advanced CKD in the setting of 
elective coronary angiography demonstrated a better safety profile for coronary angiography 
than previously shown.  It is possible that the practice of preventing contrast nephropathy from 
coronary angiography has improved in the modern era with the use of adequate hydration, N-
Acetylcysteine, smaller volumes of non-ionic contrasts, biplane imaging techniques, staged 
procedures in cases requiring intervention, and careful post-angiography monitoring (Pucelikova, 
2008).  Results from this study confirm this.  These findings suggest that any potential transplant 
recipients should not have coronary angiography deferred until established on renal replacement 
therapy, as this only heightens their cardiovascular burden that may be halted or slowed by 
successful kidney transplantation (Meier-Kriesche, 2004).  The results have to be interpreted 
with consideration for the fact that this was a retrospective analysis and no control existed; 
however the data came form a cohort of pre-dialysis patients screened in a consistent fashion. 
Data on dialysis-free survival is uncontroversial, but by nature of its design, there were a small 
number of missing data for serum creatinine in patients at risk for each time point.  These have 
been clearly outlined in the results section and must be taken into account. Pragmatically, by 
virtue of their coronary angiography, 22/38 patients had pre-emptive transplantation, the most 
ideal treatment for their already advanced renal disease. As a result of this study we have been 
able to draw some useful conclusions that may influence potential transplant-recipient screening 
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practice within transplant units and enable the facilitation of a safe and prompt pre-emptive 
transplantation program. 
The results from examining outcomes of an aggressive coronary artery disease screening 
program have been described and show a favourable outcome.   The major limitation of these 
results is that it is observational data, and because there is no comparison group, it is not possible 
to advocate one line of therapy over another, only to comment on the low rates of cardiac events 
and cardiac deaths within this group.  Also noteworthy is the ethnic diversity of the patients in 
this study, which consisted of a significant number of South Asians (36.5%) and cannot therefore 
be applied to predominantly Caucasian or Afro-Caribbean populations.  
The major strength of this study lies in the large number of patients undergoing angiography and, 
where indicated, coronary revascularization.  In addition, there is consistency of clinical practice 
with a clear protocol for referral, and a single cardiologist making the decision with regards to 
intervention. Coronary angiography and intervention before transplantation can be achieved in 
<6 months, and the cardiac assessment process is best done via a dedicated cardio-renal clinic. 
Recent research has suggested that females have less anatomically abnormal CAD than men 
(Shaw, 2006; Bairey Merz, 2006).  Despite this they have more symptoms and more ischaemia 
and adverse outcomes than men, and it is has been suggested that microvascular dysfunction is 
linked to abnormal coronary reactivity (Shaw, 2009), and that the pathophysiology of CAD in 
women is a differing process to males, with more plaque erosion and distal microembolisation 
(Shaw, 2008).  Our data suggest that Caucasian and South Asian females were more likely than 
their male counterparts to have normal coronary anatomy, but this was not applicable across all 
ethnic groups, and gender did not significantly impact on cardiac event rates.  One theory to 
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explain the equalization of cardiac outcomes between the genders is in reference to CRP.  It is 
known that women in the general population have a greater mean CRP compared with men, and 
this is consistent with the 2 to 50-fold increase of inflammatory mediated autoimmune disease in 
women compared to men (Burke, 1998; Burke, 2003).  As CRP is commonly elevated across the 
dialysis population, this may explain why the risk difference for IHD in women compared with 
men is lost once patients are on dialysis.  
It has been hypothesised that South Asian ethnicity may be associated with poorer cardiovascular 
outcomes than other ethnic groups, but in this study it was not the case.  In fact, there may be a 
factor unique to South Asians that increases their survival on dialysis that has not yet been 
established.  This retrospective study examining the influence of gender and ethnicity on 
cardiovascular outcomes in the end stage renal failure population has several limitations, 
however, studies of this nature in the transplant population are limited.  As with any study that 
focuses on cause of death, there will always be difficulties with accurately reporting cardiac 
death, and often out of hospital deaths will be recorded as unknown, resulting in the possibility 
that cardiac death is under reported.  In addition, the cohort of patients being studied included 
patients with CKD IV and V who were not on dialysis and therefore Kt/V data was not included, 
which is also an important marker of survival (Eknoyan, 2002). 
In summary this work has provided increased insight into which patients with end stage renal 
disease are at greatest risk of cardiovascular mortality and morbidity. Potential areas of related 
research are described in the following section.  
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5. FUTURE WORK 
 
5.1 Laboratory research 
Further laboratory work should include chemokine analysis in a large prospective cohort of 
ESRD patients, to examine if chemokine levels are predictive of future cardiac events.  The 
chemokine analysis should include a wider panel of chemokines, and potentially extend to 
include analysis of atherosclerotic plaques.  In order to achieve a greater understanding of the 
potential role of chemokines as biomarkers of CAD it is important to analysis chemokine levels 
over time, as well as at the time of cardiovascular end points. 
 
5.2 Clinical research 
Further clinical research should consider the randomisation of asymptomatic patients to CAD 
intervention or observation.  This needs to be large scale and multi-centred in order to 
satisfactorily assess for any survival difference between the two groups, as well as provide data 
on cost effectiveness.  More work also needs to be carried out to establish optimal investigations 
for cardiovascular disease surveillance.  I would also like to carry out a pilot study to establish 
the effect of PCI on myocardial stunning, with pre-intervention and post-intervention 
echocardiography.  Finally, by combining laboratory and clinical research, I would like to utilise 
the identified highly predictive parameters of cardiovascular disease in patients with renal 
failure, in order to establish a risk stratification score and management algorithm to aid clinicians 
when assessing patients prior to transplantation, and allow aggressive risk factor management for 
those at greatest risk. 
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